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Summary 
 
Muscle excitation-contraction coupling (ECC) is a fundamental physiological process 
by which electrically-evoked sarcoplasmic reticulum (SR) Ca2+ release triggers 
cardiomyocyte contraction. Human ryanodine receptor 2 (RyR2) is an ion channel 
present in the SR membrane of cardiac myocytes, responsible for mediating calcium 
efflux. Cardiac myosin binding protein-C (cMyBP-C) is a modular protein anchored to 
the thick filament through its C-terminal region, whereas the N-terminal region of 
cMyBP-C is thought to regulate myocardial contractility by modifying actin-myosin 
association. Here, we present several lines of evidence indicating potential 
RyR2:cMyBP-C interaction, which could provide a novel retrograde regulation of SR 
Ca2+ release by the sarcomere. 
Firstly, co-immunoprecipitation (co-IP) experiments indicated that the detected 
putative association between RyR2 and cMyBP-C can be applicable to large 
mammalian species as well as to recombinant human proteins heterologously 
expressed in a mammalian cell line, with RyR2 N-terminus and cMyBP-C C-terminus 
being responsible for the binding. A 3D co-localisation immunocytochemistry study 
supported the possibility for the proteins to be readily available for protein-protein 
interaction, with recombinant human RyR2 and cMyBP-C shown to co-localise in 
HEK293 cells.  
Secondly, with the aid of two complementary techniques, namely co-IP and yeast 2-
hybrid (Y2H), we showed that RyR2 residues 1-906 comprise the main cMyBP-C 
site, with residues 1-346 (corresponding to subdomain A and B of RyR2 NTD) and 
654-906 (domain SPRY1 and P1) being important determinants for the binding with 
cMyBP-C C-terminus. Further mapping studies implied that cMyBP-C residues 820-
972 and 1061-1274 are involved in the interaction with RyR2 N-terminus, with 
cMyBP-C Fn domain/s proposed to be directly responsible for the binding. 
Additionally, parallel experiments with the skeletal muscle RyR1 demonstrated that 
the corresponding N-terminus region (RyR2 1-906 amino acids) of mammalian 
isoform RyR1 can also interact with MyBP-C, which could indicate that the detected 
association can also be relevant in the regulation of ECC in skeletal muscle.  
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Thirdly, we pursued the possible functional significance of RyR2:cMyBP-C 
interaction. The results from single cell Ca2+ imaging indicated that cMyBP-C 
interaction with RyR2 may have an inhibitory effect on Ca2+ release channel function, 
with cMyBP-C binding diminishing RyR2 channel activity. In particular, HEK293 cells 
co-expressing RyR2 and cMyBP-C had a reduced frequency of spontaneous 
intracellular calcium oscillations compared to cells expressing only RyR2. 
Lastly, further co-IP data demonstrated that cMyBP-C:RyR2 binding is not affected 
by four different RyR2 single point mutation variants (S166C, R176Q, R420Q and 
L433P) associated with different pathological phenotypes. Thus, while a physical and 
functional association between RyR2 and cMyBP-C was shown to possibly regulate 
normal cardiac physiology, it is unlikely to be involved in RyR2-related cardiac 
disease. In order to unravel the pathological significance of the detected cMyBP-
C:RyR2 association, more studies are needed to understand what role cMyBP-C 
plays in RyR2 channel dysfunction that could potentially affect muscle 
contraction/relaxation. 
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1 General introduction 
 
1.1 Cardiac calcium signalling and contraction 
Ionised calcium (Ca2+) is a highly versatile intracellular signalling molecule, 
responsible for regulating a wide range of different cellular processes, including 
muscle contraction, neurotransmission, fertilisation, proliferation and apoptosis 
(Clapham 2007). To control so many diverse functions, the Ca2+-signalling systems 
exhibit high degree of versatility in terms of Ca2+ signals’ frequency, amplitude and 
spatio-temporal patterning, thus operating in a wide dynamic range from localised 
rapid brief bursts of Ca2+ to longer-lasting, global Ca2+ transients in the form of 
repetitive waves. Despite its importance in the cell function, sustained or high 
concentrations of Ca2+ are known to be cytotoxic, and for this reason Ca2+ fluxes 
must be tightly regulated. To assure that, the complexity of Ca2+ signals is aided by a 
subset of molecules and protein complexes that acts in a coordinated manner, 
allowing to regulate intracellular Ca2+ release and sequestration (Berridge et al. 2003; 
Berridge 2006). 
 
1.1.1 Excitation-Contraction Coupling (ECC) 
In the cardiac muscle, Ca2+ is an essential messenger directly transducing the 
electrical depolarisation stimulus into mechanical contraction of the heart, in a 
process termed Excitation-Contraction Coupling (ECC, see Figure 1.1)(Bers 2002). 
Cardiac Ca2+ signalling has been most extensively studied in cardiomyocytes isolated 
from the ventricles. It is well established that Ca2+ transients in mammalian 
ventricular myocytes take the form of homogenous whole-cell increases (Bers 2008). 
When the heart is at rest (diastole), intracellular Ca2+ is sequestered into the 
sarcoplasmic reticulum (SR), which is the major internal Ca2+ store of the 
cardiomyocytes. During systole, the cardiac ECC is initiated by the electrical 
excitation (originating from the sinoatrial node) of the myocyte sarcolemma, and 
concomitant change in the cardiomyocyte plasma membrane potential causing 
depolarisation (from ~-80 mV to ~+40 mV) in form of an action potential (AP) (Bers 
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2002). The propagation of AP depolarizes plasma membrane of cardiomyocyte and 
subsequently causes coordinated opening of the voltage-gated calcium channels 
(VGCCs) present on the sarcolemma. Their opening allows Ca2+ to enter the cardiac 
myocyte cytoplasm, increasing the local intracellular Ca2+ ([Ca2+]i) from a resting level 
of ~100 nM to 10µM  within tens of microseconds (Fearnley et al. 2011). 
Cardiomyocytes exhibit two classes of VGCCs, namely L-type (LTCC) and T-type 
calcium channels. The latter are activated by low voltage and expressed mainly in 
conducting and pacemaker cells and at negligible levels in ventricular myocytes, 
whereas LTCCs are characterized by higher voltage activation profile and are the 
main contributors in the regulation of both AP (by providing an inward Ca2+ current) 
and ECC (by triggering the release of calcium from SR) (Bers 2008).  
The mammalian ventricular cardiomyocytes are characterized by the presence of an 
extensive network of the transverse-axial tubule system (TATS), which plays a crucial 
role in the process of ECC and Ca2+ release from SR (Ferrantini et al. 2013). TATS 
are deep physical invaginations of the surface membrane that branch within the cell 
to form a complex network with predominantly transverse elements (T-tubules) that 
occur at each Z-line, but also longitudinal (axial) components running from one Z-line 
Figure 1.1 Schematic showing the major elements of ECC. Main panel: (1) AP travels along 
sarcolemma and (2) activates LTCC, which results in Ca2+ influx into the cytoplasm. This in turn (3) 
activates RyR2 and Ca2+ release from SR (4); the increase in cytoplasmic Ca2+ enables (5) acto-
myosin cross-bridge formation and muscle contraction. During diastole, (6) Ca2+ returns to resting 
levels by SERCA-mediated pumping of Ca2+ back into SR and Ca2+ extrusion via NCX; (Small 
panel) the temporal relationship of cardiac AP (black) and the Ca2+ transient (red) and muscle 
contraction (blue) during the single ECC event. Adapted from (Bers 2002). 
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to the next (Ferrantini et al. 2013). The regions of close apposition of the T-tubules 
and the junctional SR (termed dyads) bring the LTCCs in close proximity (~15 nm) to 
clusters of Ca2+ release channels (ryanodine receptors type 2, RyR2) on the 
junctional SR membrane (Asghari et al. 2009). In this way, the formed RyR2:LTCC 
structures, known as junctions or couplons, are found in close proximity to the Z-
lines, usually <250 nm (Jayasinghe et al. 2009). The architecture of the dyadic 
microdomains (also referred to as dyadic clefts) allows for the local increases in Ca2+ 
by influx of extracellular Ca2+ through the LTCCs, leading to increase of Ca2+ 
concertation within the cleft. In adult mammalian cardiac muscle, this initial rise of 
[Ca2+]i is not substantial enough to trigger contraction but is sufficient to open RyR2 
channels, leading to efflux of Ca2+ from the SR (Asghari et al. 2009). The activation of 
RyR2 clusters increases the concentration of Ca2+ in the dyadic cleft (>100 μM), 
which diffuses a through the cytoplasm, causing a global rise in intracellular Ca2+ (up 
to ~1 μM), constituting a Ca2+ transient (Bers 2008; Ferrantini et al. 2013). The 
phenomenon of global Ca2+ release from the SR stores in response to the relatively 
small influx of extracellular Ca2+ through the LTCCs is known as Ca2+-induced Ca2+-
release (CICR) (Berridge 2006).  
Figure 1.2 Schematic representation actin-myosin interaction triggered by Ca2+ binding. Depicted 
are the main components of the thick (lower bracket) filament and thin (upper bracket) filament of 
the sarcomere. The parallel arrays of myosin-containing thick filaments overlap with actin-
containing thin filaments (actin polymers and troponin (Tn) complex/tropomyosin (Tm) units). The 
Tn complex is composed of three subunits: troponin C (TnC), troponin I (TnI) and troponin T 
(TnT). Muscle myosin contains two heavy chains (MYH) and four light chains, with two of the light 
chains belong to the essential light chain (ELC) family, and the other two are regulatory light 
chains (RLC). The N-terminal region of each MHC and two light chains make up the myosin head 
domain (the S1 fragment), and other portion of the rod is referred to as S2 and connects the 
myosin heads to the thick filament core. During the diastole, Tn-complex sterically obstructs 
binding sites for S1 myosin on the thin filament; Ca2+ binding to the TnC, causes an allosteric 
change in associated TnI, which allows Tn-complex to move, unblocking the binding sites on the 
actin. This allows myosin to interact with actin, enhancing Ca2+ binding and cross-bridge formation 
at neighbouring sites and thus resulting in systolic contraction. Adapted from (Bers 2008). 
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The RyR2-mediated global Ca2+ increase during systole engages the contractile 
machinery of the cardiomyocytes to drive ventricular contraction mediated by the 
sarcomere, the smallest contractile unit (Gautel and Djinovic-Carugo 2016). The 
sarcomere is defined as the region of myofilament structures between two Z-lines, 
with the distance between Z-lines (the sarcomere length) being ~2 μm in human 
hearts (Subramanian et al. 2001). SR released Ca2+ binds to troponin C (TnC) and 
causes a conformational change in an associated inhibitory subunit troponin I (TnI). 
This allows the S1 globular myosin heads to interact with actin. The contractile force 
is generated by repetitive acto-myosin cross-bridge cycling, which causes the relative 
sliding of thick and thin filaments past one another, leading to shortening of the 
sarcomere. During this process, ATP hydrolysis is required, which provides energy 
for the movement (Clark et al. 2002) (Figure 1.2). The synchronized Ca2+ release 
during each membrane excitation allows co-ordinated contraction among the many 
sarcomere units within each working ventricular myocyte. Thus CICR reflects the 
spatial and temporal summation of signals from many Ca2+ release sites, thus allows 
for synchronized myofilament contraction within and among millions of working 
ventricular myocytes. Ultimately, the whole heart muscle will contract and generate 
the maximal contractile force with the least energy cost (Bers 2008). 
The cardiomyocytes need to relax after a contraction phase so the ventricular 
chambers can be refilled and be prepared for the next contraction (Opie 2004). 
During diastole, the positive feedback cycle of CICR is broken due to depletion of SR 
Ca2+ content, which causes the closure of RyR2 channels and termination of Ca2+ 
release. Relaxation of the muscle is achieved by rapid removal of Ca2+ from the 
cytosol in preparation of the next wave of membrane depolarisation. This process of 
depletion of [Ca2+]i to diastolic levels (~100 nM) is carried out by four types of 
transporters: (1) SR Ca2+-ATPase pump (SERCA), (2) Na+-Ca2+ exchanger (NCX), 
(3) Plasma membrane Ca2+-ATPase (PMCA) and (4) mitochondrial Ca2+-uptake 
(Bers 2002). The major contribution in Ca2+ removal in human cardiomyocytes is 
~70% by SERCA and ~28% by NCX, while the other two transporters play a minor 
role (~1% each), a pattern also observed in other species such as dog, guinea pig 
and rabbit. In mouse and rat, the ratio is ~92% and ~7% for SERCA and NCX, 
respectively (Fearnley et al. 2011). The global decline of [Ca2+]i leads to the 
dissociation of Ca2+ from TnC and cross-bridge detachment as the thick and thin 
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filaments slide back to their original positions, causing myocyte to relax (Fearnley et 
al. 2011; Eisner et al. 2013). Thus, the three distinct events can limit the rate of 
cardiac muscle relaxation: (1) the rate of intracellular Ca2+ decline, the rate of thin-
filament de-activation and the kinetics of cross-bridge cycling (reviewed by 
(Biesiadecki et al. 2014)). 
 
1.1.2 ß-adrenergic regulation of ECC. 
During times of emotional stress and/or exercise, increase of cardiac output is 
required to meet higher physiological demands of the body (Opie 2004). Rapid 
change in the heart rate (chronotropy), force of contraction (inotropy) and relaxation 
(lusitropy) is achieved by catecholamine activation of ß-adrenergic response (ß-AR), 
which leads to intracellular production of cyclic AMP and subsequent activation of 
protein kinase A (PKA) (Scoote and Williams 2004). Cyclic AMP-mediated PKA 
phosphorylation is central to the regulation of ECC as part of the fight-or-flight 
response, leading to increase both Ca2+ levels within the SR, and produce larger and 
faster Ca2+ transients (Bers 2002). The main functional targets of PKA include: (1) 
LTCC (causes an increase in Ca2+ influx from the extracellular space), (2) 
phospholamban (PLB, which relieves SERCA inhibition and accelerates Ca2+ re-
uptake into the SR, increasing the Ca2+ load), (3) NCX (resulting in activation of the 
exchanger and enhanced extrusion of Ca2+), and (4) TnI (enhances dissociation of 
Ca2+ from myofilaments, thus allows for faster relaxation), (5) RyR2 (see Section 
1.2.3.5) and also (6) cardiac myosin binding protein C (cMyBP-C, see Section 
1.3.4.1) (Bers 2002; Eisner et al. 2013). It is however important to note that whilst 
PKA-mediated phosphorylation can improve contractile function, during prolonged 
activation it may disturb the physiological relationship between heart rate and 
myocardial performance, leading to cardiovascular disease and ultimately heart 
failure (Fearnley et al. 2011). 
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1.2 Ryanodine Receptor (RyR) 
RyRs are the largest known Ca2+ channels in the human body and were initially 
observed in skeletal muscle electron micrographs as large, electron-dense bridging 
structures, situated between T-tubules and the junctional SR (Franzini-Armstrong et 
al. 1999). The RyR name originates form the ability of the channel to bind the plant 
alkaloid ryanodine, which interacts with RyR at its open state with high affinity and 
specificity. Ryanodine is found naturally in the roots and stems of members of the 
genus Ryania, and has proven to be a vital tool for RyR channel identification and 
isolation (Inui et al. 1987). Ryanodine locks the channel in a permanently-open 
subconductance state at low nanomolar concentrations, and blocks it entirely at 
higher micromolar concentrations, thus allowing it to act as a marker of channel 
activation.  
 
1.2.1 Molecular characterization  
Ryanodine receptors are homotetrameric Ca2+ release channels that traverse the SR 
membrane, and consist of four identical ~565 kDa subunits (protomers), creating a 
centrally located pore (Lanner et al. 2010). There are three known mammalian 
isoforms of RyR: RyR1, RyR2 and RyR3, whereas an alternative terminology is 
based on the location of their primary identification. RyR1, also known as skeletal 
isoform, is the most thoroughly examined isoform due to its high expression levels. It 
was cloned from mammalian skeletal muscle (Takeshima et al. 1989), while RyR2 
(cardiac isoform) was originally cloned from rabbit cardiac muscle (Otsu et al. 1990). 
Both of these isoforms are also expressed in a variety of other tissues: RyR1 is 
expressed at lower levels in vascular smooth muscle (Neylon et al. 1995), Purkinje 
cells, cerebellum, testis, ovaries, adrenal glands, spleen, stomach and kidney 
(Giannini and Sorrentino 1995), while RyR2 is the predominant isoform in cardiac 
muscle (Otsu et al. 1990), but can be found at high levels in brain, in cerebellum and 
cerebral cortex (Lai et al. 1992), but also at low levels in lungs, stomach, kidney, 
adrenal glands, ovaries and thymus (Giannini et al. 1995). A third isoform, RyR3, was 
initially identified in rabbit brain (Hakamata et al. 1992), but later was found to be 
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expressed in various tissues including abdomen, slow twitch skeletal muscle and 
diaphragm (Giannini and Sorrentino 1995).   
Genes of the three mammalian isoforms are located on different chromosomes, 
mapped to chromosomal locus 19q13.2, 1q43 and 15q13.3-4 for human RyR1, RyR2 
and RyR3, respectively (Mattei et al. 1994). RyR isoforms share high peptide 
sequence homology (~65%), with the three major regions of diversity: D1 (residues 
4210-4562 for cardiac sequence), D2 (RyR2 residues 1353-1397) and D3 (1852-
1890 of RyR2 amino acids) (Lanner et al. 2010). Those regions have been proposed 
to be responsible for the functional differences between RyR isoforms. For example, 
region D2, completely absent in RyR3, in RyR1 is critical for the mechanical 
interaction with LTCC (Perez et al. 2003) and mutations in D1 alter Ca2+ and caffeine 
sensitivity (Du et al. 2000). It also has been shown that D3 may contain Ca2+ 
inactivation sites in RyR1 (Hayek et al. 1999). The highest degree of RyRs sequence 
identity is located in the extreme pore-forming C-terminus, which is essential for the 
channel oligomerisation into functional tetramers (Gao et al. 1997). RyR diversity is 
further extended by the presence of alternatively spliced variants of each isoform, 
which exhibit tissue- and developmental-stage specific distribution (Futatsugi et al. 
1995; Marziali et al. 1996; Tunwell et al. 1996), also linked to pathological conditions 
(George et al. 2007; Kimura et al. 2007). 
For a long time, the massive size of the receptor and its dynamic nature constituted a 
major challenge in determining its structure, with the computational analysis of the 
channel’s primary sequence revealing several functional motifs seen in other proteins 
(Lanner et al. 2010). Detailed crystal structures were available only for few short 
domains, including the N-terminal fragments (Amador et al. 2009; Lobo and Van 
Petegem 2009; Kimlicka et al. 2013; Borko et al. 2014), the phosphorylation domain 
of RyR (Sharma et al. 2012; Yuchi et al. 2012) and FKBP12 binding region  (Yuchi et 
al. 2015) (see Section 1.2.3.4). However, recent advances in single-particle cryo-EM 
have led for the first time to detailed visualization of the structural organization of 
RyR1 at the closed state, solved independently by the three labs at near-atomic 
resolution, ranging from 3.8 Å (Yan et al. 2015), 4.8 Å (Zalk et al. 2015) to 6.1 Å 
(Efremov et al. 2015). The latter has also provided the putative 8.5 Å open-form 
structure at 10 mM Ca2+, but since RyR1 displays a bell-shaped Ca2+-response curve 
with partial channel activation at micromolar [Ca2+]i and closed state in the presence 
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of 10 mM Ca2+ concertation (Bezprozvanny et al. 1991), the relevance of obtained 
structure to the physiological open-form channel awaits further investigation. 
Together, these studies have offered insights into the global architecture and 
conformational variations in the closed state of RyR1 at unprecedented scale, as well 
as the details of binding sites for a multitude of intracellular molecules responsible for 
modulating RyR activity, which was impossible in previous cryo-EM reconstructions 
at ≥10Å resolution (Samso et al. 2005; Serysheva et al. 2008). RyR1 was used for 
most cryo-EM studies due to its great abundance on the SR in skeletal muscle and 
its relatively easy purification when compared to other RyR isoforms. 
The overall RyR structure is often described as a mushroom-like, with 
~280×280×120 Å cytoplasmic cap (~80% of the entire protein) formed by the large N-
terminal portion protruding into the cytosol. It provides about 500,000 Å2 exposed 
surface area, which serves as a scaffold for an interaction with accessory proteins, 
ions and other regulatory molecules (see Section 1.2.3). The C-terminal part of the 
protein comprises a ~120×120×60 Å transmembrane stem (~20% of the entire 
protein) forming the transmembrane region (Van Petegem 2015). The structural 
architecture of RyR1 subunit can be further divided into large N-terminal cytoplasmic 
moiety and a C-terminal transmembrane-forming domain. The specific domain 
labelling differs in the terminology between the three published papers, however the 
general structure of the channel is similar. The distinct domains established by (Yan 
et al. 2015) are highlighted in Figure 1.3. The N-terminal domain (NTD) is formed by 
three subdomains, A, B, and C, with the latter composed of 5 additional α-helices 
compared to that in the previously published crystal structure (Tung et al. 2010). The 
subdomains A and B are rich in β-strands (folded into 2 β-trefoil subdomains), 
whereas C consists exclusively of 12 α-helices conforming to the first armadillo 
repeats (handle and helical domain), thus for instance (Zalk et al. 2015) labelled it as 
a separate solenoid domain, whereas (Efremov et al. 2015) assigned it directly to the 
first solenoid domain. The NTD is followed by a number of peripheral domains 
including three SPRY domains (SPRY1, SPRY2, and SPRY3), the first repeat 
domains (P1 or R1/2) and handle domain. It is of particular note that the three SPRY 
domains and P1 domain (or R1/2) appear to be intertwined (Figure 1.3, C) (Yuchi et 
al. 2015). Further, the subsequent helical (where second P2, or R3/4, repeat domain 
is located) and central α-solenoid domain act as a scaffold and links the N-terminal 
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domains to the transmembrane region. The direct interactions between the central 
and channel pore-forming domain are thought to primarily regulate the 
conformational changes necessary for RyR opening and closing (Yan et al., 2015). 
Importantly, the central domain was predicted to contain the interaction sites for the 
ligand binding of channel modulators such as calmodulin (CaM, Section 1.2.3.2) and 
FKBPs (Section 1.2.3.4), further highlighting its importance to the regulatory role in 
channel function. The transmembrane domain was found to include six 
transmembrane helices (S1-S6) reminiscent of the voltage-gated ion channel 
superfamily (Efremov et al. 2015; Yan et al. 2015; Zalk et al. 2015), which forms the 
channel selectivity filter of ~10 Å in length, allowing rapid Ca2+ transport across the 
SR membrane (Zalk et al. 2015). As proposed by (Yan et al. 2015), interactions 
between the central region and the S6 transmembrane helix appear to be stabilized 
via a zinc-finger motif, with allosteric regulation of the RyR activation gate predicted 
to be determined by structural transitions of these domains and the four protomers’ 
S6 helices forming a channel pore that conducts Ca2+ flow. 
 
1.2.2 Distribution of RyR2 in the cardiomyocyte 
Section 1.1 outlined the generally accepted view of RyR2 clusters location in the 
ventricular myocyte’s dyad and their role in ECC. Besides the junctional SR, RyR2s 
are also found in the corbular SR (extra-junctional SR), positioned along the Z-line 
(<500 nm), functioning as a secondary amplification system to Ca2+ diffusion from 
sarcolemmal dyads (Scriven et al. 2013). Based on this RyR2 distribution, early 
mathematical models of propagating Ca2+ waves spreading in directions both 
perpendicular to and parallel with Z-line channels suggested that the resultant 
spatiotemporal Ca2+ gradients should lead to non-uniform and inefficient activation of 
contraction. This phenomenon, dubbed ‘the calcium paradox’, was theoretically 
corrected by introduction of additional Ca2+ release units through the length of the 
sarcomere, at a 20% density to that of RyR2s found on the Z-lines (Subramanian et 
al. 2001). Based on findings from super-resolution imaging (Baddeley et al. 2009; 
Jayasinghe et al. 2012; Hou et al. 2015), EM tomography (Hayashi et al. 2009; 
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Asghari et al. 2014) and 3D reconstruction studies (Scriven et al. 2013; Rajagopal et 
al. 2015), it has been estimated that receptors form non-uniform arrays, with 
thechannels adopting multiple arrangements of 50-100 RyR2s within each cluster, as 
well as single, isolated tetramers. Importantly, these new data highlighted the 
existence of functional RyR2 outside of the dyads, with substantial populations of 
non-junctional RyR2s found to be either interspersed between the Z-disks (Salnikov 
et al. 2009) or present in the axial tubular system (Asghari et al. 2009) and/or on the 
periphery immediately under the sarcolemma but absent in the cell interior (Chen-Izu 
et al. 2006; Lukyanenko et al. 2007; Hiess et al. 2015). Notably, it has been 
suggested that up to fifth of the total RyR2 population can be localized outside the Z-
line (Shacklock et al. 1995; Lukyanenko et al. 2007; Asghari et al. 2009; Jayasinghe 
Figure 1.3 Overall structure and domain organization of the rabbit RyR1 at 3.8 Å. (A) The top view 
shows the large cytoplasmic domain and its previously assigned sub-regions (black circles). The 
corners, known as ‘clamps’ are connected through the ‘handle’ domain that surrounds the ‘central 
rim’ domain around the central cavity. Single RyR1 subunit is shown in orange, with the 
corresponding color-coded N-terminal domains from another subdomain as shown in (C). (B)The 
side view shows the transmembrane domain (brown) which is embedded in the SR membrane and 
is connected to the large cytoplasmic domain through the ‘column’. (C) Left: a schematic 
illustration of domain organization in single RyR1 subunit; Right:  the amino acids coordinates of 
each domain. Images created using The PyMOL Molecular Graphic Software (based on ((Yan et 
al. 2015), accession number 3J8H). 
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et al. 2009), in line with the previous mathematical estimation (Subramanian et al. 
2001). 
In addition to these locations, RyR2 have also been reported at low levels in the SR 
around intermyofibrillar and perinuclear mitochondria (Lukyanenko et al. 2007) and in 
SR proximal to the nuclear envelope (Escobar et al. 2011; Ljubojevic et al. 2014). It 
has been proposed that these RyR2s could contribute to mitochondrial and nuclear 
signalling, as well as to Ca2+-dependent gene regulation (Lukyanenko et al. 2007; 
Ljubojevic et al. 2014; Bround et al. 2016). It should be also noted that the RyR2 
distribution is markedly different in adult atrial and neonatal cardiac myocytes, where 
due to lack of TATS, RyR2s are located at the cell periphery immediately under the 
sarcolemma, which makes these two cell types display different Ca2+ patterns in 
response to depolarisation compared to ventricular myocytes (Bootman et al. 2006).  
 
1.2.3 Regulation of RyR2 
The importance of RyR2 is shown by gene knock-out (KO) studies, where lack of 
protein causes early embryonic lethality, with visible degeneration of cardiac muscle 
and impaired Ca2+ homeostasis, including slowed rate of spontaneous diastolic 
depolarization and an absence of Ca2+ sparks. (Takeshima et al. 1998; Yang et al. 
2002; Bround et al. 2013). RyR2 is known to act as a scaffold for a multitude of 
regulatory accessory proteins to form a macromolecular complex which enhance the 
versatility of the regulation of CICR. For example, RyR2 is directly regulated by Ca2+, 
Mg2+ and ATP, which are its physiological ligands, as well as by other proteins 
(Lanner et al. 2010; Van Petegem 2015). To evaluate the functional effect of these 
regulators, a variety of model systems has been developed over the years, mostly in 
vivo. Despite the fact that the functions of the individual accessory proteins are 
known, the effect of their complex interplay in the massive array of RyR2s 
macromolecular complexes in situ is still not well understood, especially in 
pathophysiological conditions. 
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1.2.3.1 Calcium, magnesium and ATP 
Ca2+ is by far the most potent and versatile effector of RyR function as it can bind to 
both cytosolic and luminal sides to activate or inactivate the channel, in an isoform-
dependent manner (Lanner et al. 2010). RyR1 is known to display a bell-shaped 
dependence on cytosolic Ca2+ concentration with activatory micromolar and an 
inhibitory effect at milimolar (>1 mM [Ca2+]i) levels (Bezprozvanny et al. 1991), which 
is thought to be caused by cooperation between a high-affinity activating and an 
inhibitory low-affinity calcium binding sites. On the other hand, RyR2 and RyR3 were 
shown to have a decreased sensitivity to milimolar Ca2+ inhibition and also displayed 
a more potent response to Ca2+ activation, i.e. RyR1 can be activated by ATP even at 
very low nanomolar Ca2+ concentrations, but for the maximal activation it requires 
combination of both milimolar Ca2+ and ATP (Meissner 1984). Importantly, in skeletal 
muscle, RyR1 is physically coupled to LTCC, such that an AP-induced 
conformational change in the latter directly opens RyR1 channel even in the absence 
of Ca2+ influx (Beam et al. 1992). Nevertheless, for RyR2, the primary physiological 
trigger during the process of CICR is cytosolic Ca2+. Under diastolic conditions (<100 
nM [Ca2+]i), the rate of spontaneous activation of RyR2 clusters is negligible, with 
channel being activated at systole by low micromolar concentrations (1-10 µM [Ca2+]i) 
and inactivated at milimolar concentrations (>10 mM) of [Ca2+]i (Meissner and 
Henderson 1987). Conversely, several mechanisms of luminal Ca2+ regulation of 
RyR activity have been proposed, with one attributing it to direct effect through 
luminal facing regulatory sites (Ching et al. 2000), whereas another envisages Ca2+ 
permeation to cytoplasmic sites (Laver et al. 2008) or through the ‘luminal Ca2+ 
sensor’ mediated by calsequestrin/junctin/triadin interaction with RyR luminal side 
(Gyorke et al. 2004) (see Section 1.2.3.3). How exactly cytoplasmic and luminal Ca2+ 
interplay regulates channel activity is still not well understood, but at least four Ca2+-
sensing sites (located in both the cytoplasmic and luminal regions, each displaying 
particular affinity towards different [Ca2+]i levels) of single RyR2 protomer have been 
proposed (Laver 2010). The exact identities of these regulatory binding sites remain 
to be confirmed (Van Petegem 2015), but several reports have indicated the 
predicted EF hands motifs (residues 4071-4132) in the C-terminal area as possible 
Ca2+ sensors (Li and Chen 2001; Fessenden et al. 2004; Xiong et al. 2006). 
However, the recent work of (Guo et al. 2016) indicated that although the EF-hand 
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domain (residues 4036–4082) is not required for RyR2 activation by cytosolic Ca2+, it 
plays an important role in luminal Ca2+activation and store-overload-induced Ca2+ 
release (SOICR).  
Mg2+ is a physiological inhibitor of RyR and plays a role in shaping the cytoplasmic 
and luminal Ca2+ dependencies of channel activity by either competing with high-
affinity Ca2+ activating sites or by binding to less selective inhibitory, low-affinity Ca2+ 
sites (Meissner and Henderson 1987; Laver et al. 1997). In cardiac muscle, the free 
Mg2+ concentration in the cytoplasm and SR are thought to be ∼1mM and not to 
change rapidly during EC coupling (Zahradnikova et al. 2003; Laver 2010). It has 
been proposed that when cytosolic [Ca2+]i is at resting levels (during diastole) and the 
SR store is depleted of Ca2+, Mg2+ may also occupy both luminal and cytoplasmic 
activation sites and thus rendering RyR2 inactive. This model further suggests that 
once the SERCA pump sequesters Ca2+ back into the SR and luminal Ca2+ is 
increased, Ca2+ displaces Mg2+ at the luminal site, relieving channel inhibition and 
allowing further RyR2 channel activation at the cytoplasmic site (Laver 2010). 
Notably, there is different Mg2+ effect between RyR isoforms, with RyR1 displaying 
stronger Mg2+ inhibition compared to the other two isoforms (Lanner et al. 2010). It 
has also been shown that RyR2 exhibits a species-specific profile of regulation by 
Ca²⁺ and Mg²⁺, with human RyR2 having low sensitivity to cytoplasmic Mg2+ inhibition 
at 100 nM [Ca2+]i, and rat RyR2 being 10 times more sensitive to luminal Mg2+ than 
human (Walweel et al. 2014).  
Several adenine nucleotides were found to activate RyR, among them ATP being the 
most efficacious (Meissner 1984). The cytoplasm of resting cardiac muscle contains 
approximately 3-5 mM ATP (Zahradnikova et al. 2003), which under physiological 
conditions predominantly exists as a complex with Mg2+. Thus, it is possible that RyR 
is regulated by the Mg2+/ATP complex, rather than free ATP. Nevertheless, ATP has 
been shown to have a potent effect on RyR1 function and a relatively modest impact 
on RyR2 (Laver 2010), with an ATP binding pocket proposed by (Popova et al. 2012) 
to be next to the C-terminal disease hotspot region in RyR1. 
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1.2.3.2 EF-hand proteins: Calmodulin, Sorcin and S100A1 
In addition to direct Ca2+ sensing, several EF-hand-containing proteins can further 
fine-tune the response of RyRs to changing [Ca2+]i levels. The most widely studied is 
CaM, a 17 kDa protein (containing four EF hands in two domains) expressed 
ubiquitously in all eukaryotic cells. It binds directly to RyRs, but the functional effect 
depends on both Ca2+ concertation and on the exact RyR isoform. It was shown that 
both forms (apo- and Ca2+ bound CaM) can associate with RyR1, with the primary 
binding site mapped to residues 3600-3637 (Moore et al. 1999) and an additional site 
located within residues 1975-1999 (Zhang et al. 2003). For RyR2, the corresponding 
sequence (residues 3583-3603) was found to be entirely responsible for binding with 
C-terminal lobe of both apo- and Ca2+ bound CaM, with the second RyR1 type-
specific site proposed to being the cause for the differential functional CaM regulation 
of two isoforms (Yamaguchi et al. 2003). It was shown that CaM binding displays 
biphasic effect on RyR1 and RyR3: inhibitory at high micromolar calcium and 
activating at lower concentrations (Ikemoto et al. 1995; Chen et al. 1997). In rat 
cardiac myocytes the cellular concentration of CaM is around 2-6 μM, with CaM 
bound to more than 70% of RyR2 with a high affinity and shown to inhibit the channel 
at all Ca2+ concentrations (Fruen et al. 2003). The importance of this modulation is 
underscored by the fact that mutations in CaM can also give rise to ventricular 
tachycardia and sudden cardiac death, which was linked also to RyR channel’s 
dysfunction itself (Hwang et al. 2014; Sondergaard et al. 2015; Vassilakopoulou et al. 
2015).  
Another RyR modulator is sorcin, a 22 kDa Ca2+ binding protein with five EF hands, 
known to form dimers and tetramers in a Ca2+-dependent manner. It has been shown 
that sorcin is abundantly expressed in the heart, where it co-localizes to T-tubules 
and has an isoform-specific impact on RyR channel function. Its exact binding site is 
unknown, but it has been reported to associate with RyR2 at high Ca2+ 
concentrations causing complete inhibition of channel activity (Farrell et al. 2003), 
while it has mild stimulatory effect on RyR1 (Lokuta et al. 1997). Because sorcin 
binds also to LTCC and is predicted to interact with other proteins involved in Ca2+ 
signalling, the exact understanding of its effects on RyR activity in vivo remains 
challenging. 
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S100A1 is also an EF-hand-containing protein, from the S100 protein family. It forms 
homodimers, with each subunit containing a high-affinity and a low-affinity EF hand. It 
promotes opening of both RyR1 (Treves et al. 1997) and RyR2 (Most et al. 2003). It 
has been proposed that the Ca2+ bound S100A1 engages the same binding site as 
Ca2+/CaM, implying that there is competition between S100A1 and CaM (Wright et al. 
2008), thus it is possible that the primary mechanism of RyR regulation by S100A1 is 
the removal of Ca2+/CaM inhibition. In agreement with this model, a study by 
(Yamaguchi et al. 2011) has shown that mutation within CaM binding domain 
abolishes binding of both CaM and S100A1. 
 
1.2.3.3 SR proteins: calsequestrin, triadin and junctin 
The luminal accessory protein calsequestrin (CSQ) exists as a mixture of monomers 
and multimers in the SR where it acts as the principal Ca2+ buffer. It has a low affinity 
and high capacity for Ca2+ binding, with polymerisation of CSQ thought to confer its 
high Ca2+ binding capacity (Park et al. 2004). CSQ regulates SR Ca2+ release by 
acting as stores of releasable Ca2+ that can promote myocyte contraction. In addition 
to serving as a Ca2+ buffer, CSQ can directly regulate RyR2 activity via protein-
protein interactions that involve the anchoring proteins triadin and junctin (Lanner et 
al. 2010). The current accepted model of RyR2 regulation by SR luminal proteins 
suggests that while junctin has the ability to bind directly to the luminal and/or 
transmembrane regions of RyR2, together with triadin they act as the anchoring 
proteins to position CSQ near the channel (Zhang et al. 1997; Gyorke et al. 2004). 
Further, the CSQ/junctin/triadin complex has been proposed to act as luminal Ca2+ 
sensor responsible for termination of Ca2+ release, where the CSQ-mediated 
inhibition of RyR2 function involves binding to triadin/junctin once SR Ca2+ 
concentration drops below a threshold level (Gyorke and Terentyev 2008). The 
importance of the regulatory role of this complex is further highlighted in pathological 
conditions, where perturbed luminal Ca2+ sensing due to mutations in the CSQ gene 
can lead to a life-threatening form of ventricular tachycardia (Song et al. 2007; 
Terentyev et al. 2008). 
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1.2.3.4 FK506-Binding Proteins  
FK506-Binding Proteins (FKBPs, also known as calstabins) are immunophilins 
expressed in most tissues that bind the immunosuppressant drugs FK506 and 
rapamycin. They display peptidylpropyl-cis-trans-isomerase activity thought to be 
important in protein folding, however this enzymatic activity does not contribute to 
their role in RyR modulation (Marks 1996). Two isoforms of FKBP are known to 
interact with RyR with high affinity: FKBP12 and FKBP12.6 (12 and 12.6 kDa, 
respectively) and were shown to co-purify readily with RyRs in a 4:1 stoichiometry 
(one FKBP per RyR subunit) (Jayaraman et al. 1992). Notably, recent RyR cryo-EM 
and obtained crystal structure of SPRY1 domain imply that FKBP12/12.6 docks 
between subdomains SPRY1 and P1 in the clamp region of the channel (Yan et al. 
2015; Yuchi et al. 2015).  
RyR1 binds both FKBP12.6 and FKBP12, with the latter being the predominant 
isoform bound to RyR1 due to its abundance in the skeletal muscle (Timerman et al. 
1996; Chelu et al. 2004). Interestingly, RyR2 exhibits much higher affinity for 
FKBP12.6 than FKBP12, but FKBP12 is the predominant isoform in complex with 
RyR2, whereas FKBP12.6 occupancy is sub-stoichiometric (Zissimopoulos et al. 
2012), with only <20% of RyR2 shown to be bound to this protein in ventricular 
myocytes (Guo et al. 2010). It has been hypothesised that the binding of FKBP 
isoforms to RyR2 channels inhibit Ca2+ release activity by stabilising the channels 
closed state and also proposed to underlie receptor dysfunction observed in 
arrhythmia-associated mutations and heart failure (Marx et al. 2001; Chelu et al. 
2004). (Marx et al. 2000) demonstrated at the single channel level that FKBP12.6-
deficient RyR2 channels exhibited pronounced subconductance states and enhanced 
activity. Consistent with this study, FKBP12.6 KO mice displayed an enhanced 
predisposition to heart failure and sudden cardiac death, tested using a pre-designed 
exercise program (Wehrens et al. 2003). However, both occurrence and the role of 
FKBP12.6 dissociation due to increased phosphorylation has been contested by 
other studies (Stange et al. 2003; Jiang et al. 2005; Liu et al. 2006; Zissimopoulos et 
al. 2009). The role of FKBP in channel modulation was further examined by (Xiao et 
al. 2007) with the aid of three independent techniques, i.e. single channel recordings, 
ryanodine binding and Ca2+ imaging. The authors concluded that the loss of 
FKBP12.6 does not alter channel function. More importantly, the same group also 
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showed that FKBP12.6-null mice do not exhibit enhanced susceptibility to stress-
induced arrhythmia further questioning the hypothesis of FKBP-mediated channel 
dysfunction. Providing a possible explanation for these discrepancies, (Galfre et al. 
2012) demonstrated in a more recent single channel investigation that FKBP12, 
which is largely overlooked in cardiac cells in terms of function, activated RyR2 
channels at very low concentrations, whilst FKBP12.6 did not. The FKBP12.6 isoform 
did however antagonise the effects imparted by FKBP12 (lowering channel Po), 
which led to the idea that (1) dual regulation between both isoforms may be important 
for channel function and (2) that an alteration in the ratio of FKBP12/FKBP12.6 can 
contribute to the defective Ca2+ handling seen in heart failure (Galfré et al., 2012). 
 
1.2.3.5 Post-translational modifications: phosphorylation and oxidation. 
Phosphorylation is an important mechanism by which RyR mediated SR Ca2+ release 
is fine-tuned within myocytes, with PKA (Takasago et al. 1989) and Ca2+/CaM 
dependent protein kinase II (CaMKII) (Hohenegger and Suko 1993) shown to 
mediate RyR2 phosphorylation. S2808 was the first human RyR2 residue identified 
as a phosphorylation site and proposed to be the target of PKA, causing 
destabilisation of the closed state of the channel following dissociation of FKBP12.6, 
resulting in a ‘leaky’ channel and pro-arrhythmic phenotype (Marx et al. 2000; 
Wehrens et al. 2003; Li et al. 2013). However, this has been disputed other groups 
(Stange et al. 2003; MacDonnell et al. 2008), which have shown that PKA 
phosphorylation at S2808 does not have a major role in β-AR regulation of cardiac 
function. In agreement with those studies, another site, S2030, but not S2808, has 
been identified as the primary PKA phosphorylation site (Xiao et al. 2005; Xiao et al. 
2006), but this also failed to be detected by others (Li et al. 2013). Interestingly, 
S2808 has also been shown to be a substrate for CaMKII mediated phosphorylation 
(Witcher et al. 1991). Notably, decrease of phosphorylation at another CaMKII 
specific site, S2815, was proposed to underlie an impaired heart function (Wehrens 
et al. 2004). With regards to the role of phosphatases, protein phosphatase 1 (PP1) 
and protein phosphatase 2 (PP2) were shown to be responsible for RyR2 
dephosphorylation, but confounding reports demonstrated that PP-mediated 
dephosphorylation either enhances RyR2 activity (Terentyev et al. 2003), whilst 
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others reported the opposite (Li et al. 2013). In conclusion, although the target sites 
for phosphatases/kinases are controversial and their interactions complex, it is clear 
that the phosphorylation status of RyR2 has notable effects on Ca2+ release activity 
and offers a versatile control over ECC (Dobrev and Wehrens 2014).  
In addition to phosphorylation, RyR2 also has been shown to be regulated at the 
post-translational level by protein oxidation. Alteration in redox state has been show 
to increase RyR activity (Stoyanovsky et al. 1997; Eager and Dulhunty 1998), with 
approximately 100 cysteine residues per subunit to be available for modifications (Xu 
et al. 1998). It has been proposed that whereas reversible S-nitrosylation seems to 
control the basal redox state of the channel and its adaptive process in the initial 
stages of heart failure, oxidation is a pathological condition found in advanced heart 
disease, responsible for defective inter-domain interaction of the RyR (Yano et al. 
2005).  
 
1.2.4 RyR pathophysiology in skeletal and cardiac muscle disorders 
Given the important role of RyR in SR Ca2+ release, it’s not surprising that functional 
alterations of RyR can seriously perturb the process of EC coupling leading to 
various life-threating human disorders. RyR1 mutations have been shown to have 
direct causative role in several skeletal muscle disorders, including malignant 
hyperthermia (MH) (MacLennan et al. 1990) and central core disease (CCD) (Zhang 
et al. 1993), while mutations in RyR2 gene are directly linked to catecholaminergic 
polymorphic ventricular tachycardia (CPVT) (Priori et al. 2001) and arrhythmogenic 
right ventricular dysplasia (ARVD). Further, recent studies have reported alterations 
of the expression and the function of RyR in human brains affected with Alzheimer 
disease (Del Prete et al. 2014) as well as cardiomyocytes in patients with Diabetes 
(Pereira et al. 2014) .  
MH is a pharmacogenetic disorder of skeletal muscle, inherited in an autosomal 
dominant fashion, in which sustained muscle contractions with attendant 
hypermetabolic response and elevation in body temperature are triggered by 
commonly used inhalational anaesthetics (i.e. halothane) and skeletal muscle 
relaxants (i.e. succinylcholine) (Rosenberg et al. 2015). The first mutation associated 
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with the disease was identified in the N-terminal part of RyR1 protein (Gillard et al. 
1991), but until now over 400 RyR1 variants have been linked to the MH phenotype. 
Notably, some mutations in the skeletal muscle LTCC can also cause this disorder 
(Monnier et al. 1997).  
CCD is a morphologically distinct, autosomal dominant myopathy characterized by 
progressive muscle weakness and the presence of metabolically inactive tissue (or 
cores) in the centre of muscle fibres. These cores lack mitochondria, and the 
myofibrillar organization is disrupted. The common phenotype of CCD includes 
muscle atrophy, floppy infant syndrome, and skeletal muscle deformities (Jungbluth 
2007). It was established early on that there is a connection between CCD and MH 
susceptibility (Zhang et al. 1993), and some RyR1 mutations have been found to 
cause both (Robinson et al. 2002). The majority of CCD mutations tend to cluster in 
the pore-forming region (Monnier et al. 2001; Tilgen et al. 2001). Another sub-type of 
CCD myopathy is multiminicore disease (MmD), inherited in recessive manner, 
manifested by the presence of multiple minicores with highly variable phenotype 
(Zorzato et al. 2007). Although MmD is mainly associated with mutations in RyR1, 
mutations in selenoprotein N1 (Ferreiro et al. 2002) and variants of α-actin have also 
been found to underlie MmD (Kaindl et al. 2004). 
CPVT is an autosomal dominant disease which usually manifests itself at a very 
young age, with either syncope or sudden cardiac death as the first symptom. The 
affected individuals develop cardiac arrhythmias that are triggered by either physical 
exercise and/or emotional stress, typically without any detectable morphological 
abnormalities of the myocardium (van der Werf and Wilde 2013). CPVT is caused 
mostly by mutations in RyR2 (Priori et al. 2001), but variants of its auxiliary proteins, 
CSQ (Lahat et al. 2001), triadin (Roux-Buisson et al. 2012) and CaM (Nyegaard et al. 
2012) have also been linked to the disease. Notably, RyR2 mutations have also been 
associated with ARVD, a similar condition under which the right ventricular muscle is 
gradually replaced by fibro-fatty deposits as a result of progressive cardiomyocyte 
inflammation and apoptosis (Dokuparti et al. 2005). In general, both CPVT and ARVD 
mutations confer gain-of-function phenotypes, causing uncontrolled release of SR 
Ca2+ during cardiac diastole leading to delayed after-depolarisations and cardiac 
arrhythmia (Jiang et al. 2002), thus it has been suggested that they correspond to 
variable phenotypic expression of the same disease (d'Amati et al. 2005). In some 
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cases, the same mutation can present different severity of symptoms or even remain 
completely asymptomatic, indicating involvement of several factors contributing 
towards the disease (Priori et al. 2002). As such, roles of PKA and CaMKII 
phosphorylation and FKBP12.6 dissociation have been suggested as the main cause 
(Marx et al. 2000; Wehrens et al. 2003), while others proposed a change in RyR2 
subunit composition (Milting et al. 2006) and increased RyR2 sensitivity to SR Ca2+ 
overload (Jiang et al. 2005). Importantly, impaired inactivation by Ca2+ has also been 
reported for some mutated channels (Thomas et al. 2005), with the reduction in 
sensitivity to Ca2+ mediated inhibition suggested to be a common defect in RyR2 
mutations linked to arrhythmias and dilated cardiomyopathy (DCM, for overview of 
cardiomyopathies see Section 1.3.5) (Tang et al. 2012). Indeed, a recent multiscale 
DCM genotyping study by (Haas et al. 2014) has shown for the first time RyR2 
mutations can be readily found in patients with DCM, with arrhythmogenic phenotype 
present in up to one-third of DCM cases (Spezzacatene et al. 2015). Interestingly, 
RyR2 gene mutations have also been proposed a role in the molecular pathogenesis 
of hypertrophic cardiomyopathy (HCM) (Xu et al. 2015). For example, the T1107M 
RyR2 mutation has been linked to HCM (Noboru F et al. 2006; Chiu et al. 2010), as 
well as CPVT (Medeiros-Domingo et al. 2009). It is unclear how a single variant could 
result in two different phenotypes, but functional experiments have clearly shown it to 
confer a rare loss-of-function phenotype with early termination of Ca2+ release (Tang 
et al. 2012).  
 
1.3 The myosin binding protein-C (MyBP-C) 
Sarcomere shortening is mechanically driven by the Ca2+-dependent sliding of 
parallel arrays of actin-containing thin filaments past thick myosin filaments. 
Regulation of myocyte shortening involves controlling the thin and thick filament 
cross-bridge formation which ultimately affects the force and frequency of 
contraction. Besides actin and myosin, a whole host of accessory proteins is present 
in the myofilament involved in assembly, maintenance of structural integrity and 
coordination of sarcomere shortening (Clark et al. 2002). One of these regulators is 
the thick filament-associated protein, the myosin binding protein-C (MyBP-C). After 
its first description in skeletal muscle (Offer et al. 1973), MyBP-C was thought to play 
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a principally structural role in the assembly and the stabilization of the sarcomere. 
However, in recent years the picture that has emerged is one in which MyBP-C is a 
key effector of contraction in physiology and disease, that is mediated by 
phosphorylation, ablation or mutation of the protein (Moss et al. 2015). 
 
1.3.1 Molecular characterization 
There are three isoforms of MyBP-C encoded by different genes and classified as 
fast skeletal, slow skeletal, and cardiac (fMyBP-C, sMyBP-C and cMyBP-C, located 
on chromosome 12, 19 and 11, respectively), which all share a highly homologous 
modular architecture despite the overall peptide sequence identity of about 50-55% 
(Weber et al. 1993; Yasuda et al. 1995). Both skeletal muscle isoforms contain 10 
globular domains ~10 kDa each, designated C1-C10, seven of which are 
immunoglobulin-like domains (Ig) I-set and the remaining three being fibronectin-like 
(Fn) type 3 domains (Yasuda et al. 1995; Otey et al. 2009) (Figure 1.4). Because of 
that, MyBP-C belongs to the Ig superfamily, which are cell-surface and soluble 
proteins involved in the recognition, binding and adhesion process of the cell 
membrane. The cardiac isoform is the largest isoform (1274 amino acids, ~140.8 
kDa) due to additional number of insertions between and inside of the C domains: 
28-amino acids insertion within the C5 domain and the additional cardiac specific Ig 
domain localized at the extreme N terminus, named C0 (Yasuda et al. 1995). Further, 
all isoforms have a proline- and alanine-rich (P/A) linker found at the extreme N-
terminus or between C0 and C1, in the skeletal isoforms or in the cardiac isoform, 
respectively. Importantly, there is a conserved MyBP-C-specific domain (M-domain) 
between C1 and C2 in all isoforms, which in cMyBP-C contains specific 
phosphorylation sites (Gautel et al. 1995). It was shown that purified MyBP-C exists 
as a single, flexible polypeptide chain, with an extended length of 50 nm (Furst et al. 
1992) although biochemical and small angle X-scattering studies indicated that the 
protein possesses an ability to dimerize reversibly (Offer et al. 1973; Jeffries et al. 
2011). Further, in electron microscopy images, MyBP-C molecules display a range of 
different forms, from elongated rod-shaped, angled V-shaped and tightly curved U-
shaped (Swan and Fischman 1986). To date, high resolution structure of neither full-
length MyBP-C isoform is available. However, based on crystallographic structure of 
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Ig domain C1 (Govada et al. 2008) and NMR data for the C1 (Ababou et al. 2008), 
C2 (Ababou et al. 2007), and C5 (Idowu et al. 2003), MyBP-C Ig domains show a 
similar overall β sandwich organization, with each composed of a two β sheets 
containing three to four β strands held together by a disulphide bond (Otey et al. 
2009), with the Fn domains predicted to be similar to the Ig domain fold (Oakley et al. 
2004). On the other hand, there are discrepancies in the literature regarding the 
conformation of the M-domain. Recent M-motif NMR data obtained by (Howarth et al. 
2012) implies that this domain has a unique structure, with a largely disordered N-
terminal portion containing three known phosphorylation sites and a more ordered 
and folded C-terminal region, in line with AFM data (Karsai et al. 2011). This 
contrasts to previously proposed compact β-sheet composition of M-domain and 
general similarity to Ig fold (Jeffries et al. 2008). 
 
1.3.2 MyBP-C binding partners 
Cardiac MyBP-C interacts with several sarcomeric components via different domains 
(Figure 1.4). The major interactions important for anchoring cMyBP-C in the 
sarcomere are mediated by its binding with titin and/or light meromyosin portion 
(LMM) of the myosin rod. These occur within the C8-C10 and C10 modules of 
cMyBP-C, respectively, with inclusion of C7 to C9 increasing the binding affinity 
(Freiburg and Gautel 1996; Alyonycheva et al. 1997; Asghari et al. 2014). 
Figure 1.4 Schematic representation of the domain organization of cardiac MyBP-C. Brackets above 
indicate cMyBP-C regions reported to interact with the other sarcomeric components, labels below 
show domains responsible for dimerization of cMyBP-C. Adapted from (Sadayappan and de Tombe 
2012). 
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Henceforth, complete association of cMyBP-C with thick filament requires the 
presence of domain C7 (Gilbert et al. 1996; Gilbert et al. 1999). At the other end of 
the molecule, cMyBP-C interacts also with the S2 head region of the myosin heavy 
chain. The binding site is located at the C1-C2 region (Gruen and Gautel 1999; 
Shannon et al. 2003). Further, another association between the cardiac C0 domain 
and the regulatory light chain (RLC) has also been reported (Salnikov et al. 2009), 
while a study by (Previs et al. 2015) demonstrated that domains C0-C3 are involved 
in Tm binding and activation of cross-bridge cycling (see Section 1.3.4 for overview 
of cMyBP-C role in the contraction). 
Apart from being the thick filament associated protein, cMyBP-C also interacts with 
actin. Initially it was shown that this interaction is mediated by cMyBP-C N-terminal 
portion including C0, C1 domains and the P/A region. In total, three regions of 
cMyBP-C  bind with actin, however the relative binding affinity of C0 domain with 
actin was less comparing to C1-C2 (Kubalova et al. 2005). The interesting property of 
the M-domain is that it has the ability to reach both myosin and actin depending on its 
phosphorylation state (see Section 1.3.4.1) (Kubalova et al. 2005). Further, the 
research using laser trap assay demonstrated that the first 17 residues of M-domain 
are sufficient to interact with actin and affect actin-myosin motion generation (Baker 
et al. 2015). Sequence specific species differences in the P/A linker of cMyBP-C are 
also known to modulate acto-myosin interactions (Shaffer et al. 2010). Surprisingly, 
and in contrast to these findings, it was reported that cMyBP-C interacts with actin via 
a single site between C6-C10 domains, whereas C0, C1, M-domain, C0-C4 and C0-
C5 domains are just weak binding sites (Zissimopoulos et al. 2006), but this 
observation was not supported by others. In conclusion, actin and cMyBP-C 
interaction does exist although it is not clear which binding region is critical for 
modulation in vivo. As studies using cMyBP-C fragments in vitro may be considered 
non-physiological, systematic mutation studies are required in vivo to determine 
precise actin-binding properties of cMyBP-C (Mead-Savery et al. 2009).  
 
1.3.3 MyBP-C location in the sarcomere 
MyBP-Cs are located to a specific sub-zone of the myosin filament A-band, the 
cross-bridge region C zone. They occupy a number of transverse stripes (1-7 or 1-9 
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in skeletal muscle and 1-9 in cardiac), in which MyBP-Cs are spaced in regular 
intervals of 43 nm, with each stripe composed of two to four MyBP-C molecules 
(Bennett et al. 1986). The fast and slow skeletal muscle isoforms are known to be 
abundant in both smooth and striated muscle (Dhoot et al. 1985), and can coexist in 
variable ratios leading to diverse arrangements of the sarcomere stripes (Reinach et 
al. 1983). On the other hand, cMyBP-C is exclusively expressed in the atrium and 
ventricle of heart of mammalian heart throughout development (Gautel et al. 1995), 
and it cannot be trans-complemented by skeletal MyBP-Cs (Gautel et al. 1998). The 
detailed cMyBP-C protein arrangement in the sarcomere is not fully elucidated, but to 
date, two models have been proposed. Results form in vitro Y2H binding studies 
(Flashman et al. 2008) led to proposition of the trimeric collar model, in which C-
terminal C5-C8 domains form the collar-like structure around the thick filament with 
the N-terminal domains extended perpendicular to the thin filament core (El-
Armouche et al. 2007; van Dijk et al. 2009). On the other hand, 3D X-ray modelling 
(Yao et al. 1998) and recent EM microscopy results (Lee et al. 2015) support the rod 
model of the longitudinal arrangement of C8-C10 domains of cMyBP-C. Importantly, 
both models account for the apparent elasticity of N-terminal cMyBP-C suggested by 
NMR structural studies (Howarth et al. 2012) where individual C0-C3 domains are 
like elongated rod particles, sufficient to reach the thin filament. In conclusion, the 
most likely arrangement of cMyBP-C is one in which three C-terminal domains run 
along the thick filament surface, while the rest of the molecule flexibly extends out 
and may interact with the neighboring thin/thick filament (Figure 1.5). 
 
1.3.4  Role and modulation of cMyBP-C 
The functional implications of cMyBP-C were first reported by (Hofmann et al. 1991), 
where removal of the protein from the sarcomere resulted in enhanced shortening 
velocity and displayed increased Ca2+ sensitivity of force. It suggested that cMyBP-C 
acts as internal tether and inhibitor of acto-myosin cross-bridge kinetics, which 
ultimately depresses contraction in muscle. Importantly, extraction of the protein from 
the myofibril had no effect on the gross structure of the sarcomere, which was in line 
with apparent normal shape or size of single cardiac myocytes observed in cMyBP-C 
KO mice studies (Harris et al. 2002; Carrier et al. 2004). However, despite that the 
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KO mice were viable, ultrastructural examination revealed a loss of lateral alignment 
of adjacent myofibrils with their Z-lines misaligned, resulting in hypertrophy and 
reduced diastolic and systolic function.  
 
1.3.4.1 cMyBP-C phosphorylation 
Several studies have suggested that the interactions of cMyBP-C with its binding 
partners vary with its phosphorylation status of the M-domain. Up to four sites have 
been identified for both the human and murine cMyBP-C isoforms (S275, S284, 
S304, S311 and S273, S282, S302, S307, respectively), which are targeted by 
protein kinases in a hierarchical order of events starting with S282 enabling 
phosphorylation of the others (Gautel et al. 1995). It has been shown that cMyBP-C 
phosphorylation occurs (1) in response to ß-AR stimulation via PKA, (2) by increase 
in intracellular Ca2+ levels via CaMKII, (3) by protein kinase C (PKC) in a Ca2+-
independent manner (Gautel et al. 1995; Mohamed et al. 1998), (4) by protein kinase 
D (PKD) (Bardswell et al. 2010) and (5) by p90 ribosomal S6 kinase (Cuello et al. 
2011). Furthermore, glycogen synthase kinase 3 β (GSK3β) was described as 
another protein kinase to phosphorylate cMyBP-C outside the M-domain in the P/A 
linker at S133 in human myocardium (mouse S131, (Kuster et al. 2013)). It is 
generally accepted that cMyBP-C is extensively phosphorylated at basal levels, with 
mono-, di- and tri-phosphorylated forms (Sadayappan et al. 2005), and that 
phosphorylated cMyBP-C improves force of contraction and is involved in the 
regulation of cross-bridge cycling by reversibly binding to the S2 region of myosin in 
the dephosphorylated state (Shannon et al. 2003). Importantly, phosphorylation of 
cMyBP-C by PKA removes its normal inhibition of the rate of force redevelopment 
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and acto-myosin kinetics, which contributes towards improved diastolic function 
(Sadayappan et al. 2005). Further, the dephosphorylated cMyBP-C form can be 
released of protein from the sarcomere, with detectable levels of full-length cMyBP-C 
in the cytosol (Decker et al. 2012; Kuster et al. 2014; Baker et al. 2015). Notably, the 
increased rate of cMyBP-C dephosphorylation and subsequent degradation has been 
associated with pathological conditions, as observed in patients with heart failure, 
ischemia-reperfusion injury and pathological hypertrophy (El-Armouche et al. 2007; 
Decker et al. 2012; Govindan et al. 2012; Kuster et al. 2014; Baker et al. 2015). 
Transgenic expression of a phosphomimetic cMyBP-C mutant was shown to protect 
hearts from myocardial infraction (MI) injury (Sadayappan et al. 2005) and reduce the 
appearance of a 40-kDa proteolytic calpain degradation fragment of cMyBP-C 
(Govindan et al. 2012). Notably, a recent study by (Kooij et al. 2013) identified that up 
to 17 phosphorylation sites can be detected in vivo, 10 of which have not been 
Figure 1.5 Proposed model of cMyBP-C organization in the sarcomere. cMyBP-C domain C8-C10 are 
responsible for anchoring the protein to the thick filament backbone, whereas remaining domains C0-
C7 are extended to reach thin/thick filament. Adapted from (Lopes and Elliott 2014). 
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previously reported. Taken together, phosphorylation of cMyBP-C is considered as 
beneficial for cardiomyocyte function, and preservation of phosphorylation is 
cardioprotective.  
 
1.3.4.2 Other post-translational modifications of cMyBP-C 
In addition to phosphorylation, cMyBP-C function is also regulated by an ever-
growing spectrum of posttranslational modifications. Several cMyBP-C acetylation 
sites were identified, and found to promote proteolysis and decrease stability of 
cMyBP-C in contrast to phosphorylation (Govindan et al. 2012), whereas S-
glutathionylation was shown to abrogate protein phosphorylation and contribute 
towards increased myofilament Ca2+ sensitivity and human heart failure 
(Stathopoulou et al. 2016). Further, carbonylation of cMyBP-C was proposed as 
contributor to cardiac dysfunction observed during chemotherapy due to prolonged 
oxidative stress (Aryal et al. 2014). Notably, citrullination (Fert-Bober and Sokolove 
2014) and S-nitrosylation (Kohr et al. 2011) of cMyBP-C were also reported, however 
they yet await further functional characterization. 
 
1.3.5 Pathophysiology of MyBP-C in skeletal and cardiac muscle 
disorders 
The importance of MyBP-Cs as essential sarcomere components and key regulators 
of muscle function is highlighted in pathological conditions, where they are involved 
in the development of skeletal and cardiac myopathies. Genomic linkage analysis 
has demonstrated that mutations in sMyBP-C are causally linked to the development 
of distal arthrogryposis type-1 (DA-1) (Gurnett et al. 2010), while cMyBP-C mutations 
can lead to various forms of cardiomyopathies, such as HCM, DCM and left 
ventricular non-compaction (LVNC) (Carrier et al. 2015). 
DA-1 is an autosomal dominant disorder characterized by congenital contractures of 
the hands and feet. Two missense mutations have been identified to date, W236R 
and Y856H, which are present in the M-motif and C8 domain, respectively (Gurnett et 
al. 2010). Skeletal muscle biopsies obtained from affected individuals show that slow 
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twitch fibres are significantly smaller than fast twitch fibres, with reduced 
phosphorylation of sMyBP-C detected in aged and diseased muscles (Ackermann et 
al. 2015). 
HCM is defined by the presence of increased ventricular wall thickness and diastolic 
dysfunction in the absence of loading conditions (i.e. hypertension) sufficient to 
cause the observed abnormality (Cecchi et al. 2012). Familial HCM is an autosomal-
dominant myocardial disease caused by mutations in genes that encode different 
proteins of the cardiac sarcomere, with myosin heavy chain (MYH) and cMyBP-C 
genes together contributing towards nearly 80% of all inherited HCM cases (McNally 
et al. 2015). In contrast to MYH, where majority of HCM mutations are amino acid 
substitutions, most (>60%) cMyBP-C pathogenic variants are premature stop codons 
or frame-shift mutations, expected to produce truncated forms of the protein that lack 
the C-terminus (van Dijk et al. 2012). Importantly, despite being transcribed to 
mRNA, these expected shortened cMyBP-C proteins have not been detected in 
myocardial tissue from affected HCM patients (Rottbauer et al. 1997; Marston et al. 
2009; van Dijk et al. 2009) or mouse cMyBP-C HCM models (Yang et al. 1999; 
Palmer et al. 2004). On the other hand, a lower relative level of full-length protein 
content was reported for both truncation and missense mutations in affected 
heterozygous (HET) patients (Marston et al. 2009; van Dijk et al. 2009). HET 
phenotype is usually characterized as asymptomatic or mildly asymptomatic and 
displaying late disease onset (Dhandapany et al. 2009), suggesting 
haploinsufficiency as the major mechanism underlying the disease. In addition, HET 
mouse models of several MYBPC3 (gene encoding cMyBP-C) truncation mutations 
have shown various changes in cMyBP-C protein level, ranging from normal content 
to almost 50% reductions and variable phenotypes, including mild hypertrophy, 
diastolic dysfunction and altered Ca2+ sensitivity of force development (Harris et al. 
2002; Carrier et al. 2004; Fraysse et al. 2012; Cheng et al. 2013). Furthermore, 
(Ingles et al. 2005) reported that about 5% of HCM patients carry more than one 
gene mutations encoding sarcomeric proteins, either in the same gene (compound 
mutations) or in two different genes, which result in a more severe clinical phenotype 
(i.e. greater left ventricular wall thickness) because of a ’double dose’ effect.  
Interestingly, ablation of cMyBP-C has been shown to accelerate the kinetic of force 
development at submaximal Ca2+ activation and myocardial relaxation (Korte et al. 
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2003; Stelzer et al. 2006a; Stelzer et al. 2006b), whereas other studies showed 
slowed kinetics and phase of relaxation (Harris et al. 2002; Carrier et al. 2004; 
Palmer et al. 2004). These divergent findings are most likely related to alterations in 
Ca2+ handling as a result of functional remodelling of the heart as part of 
compensatory response to cMyBP-C ablation. Consistent with this idea, the 
intracellular Ca2+ transients have been reported to be altered in single 
cardiomyocytes from cMyBP-C null animals, which displayed slowed kinetics of Ca2+ 
transient decay (Song et al. 2003; Brickson et al. 2007; Pohlmann et al. 2007). 
Notably, faster Ca2+ transient decay was seen in myocytes isolated from a knock-in 
(KI) mouse model expressing an HCM missense mutation in MyBP-C that resulted in 
decreased MyBP-C expression (~20% in HET and ~90% in homozygous animals, 
when compared to wild-type, WT) (Fraysse et al. 2012), whereas (Cheng et al. 2013) 
has shown that HET mice presenting decreases in MyBP-C expression similar to 
those of HCM (~32% when compared to WT) displayed unchanged Ca2+ transient 
kinetics. These data indicate the presence of a compensatory mechanism(s) required 
to improve diastolic relaxation in the HCM cMyBP-C mutant hearts, with detected 
alternations directly linked to perturbed Ca2+ transients.  
Furthermore, cMyBP-C mutations show substantial genotypic and phenotypic 
variability, implicated in multiple forms of cardiomyopathy. Interestingly, progression 
of HCM to DCM occurs in 10–15% of patients with HCM (Spirito and Bellone 1994). 
A cMyBP-C HCM model of transgenic mouse (corresponding to HET human HCM 
mutation in C8 domain) showed little or no truncated mutant with typical HCM 
phenotype, while homozygous mice carrying the same mutation developed DCM 
(McConnell et al. 1999). Another cMyBP-C missense variant, R820Q, has been 
found to be associated with variable clinical features, which are often delayed until 
middle age, with HCM progression to DCM in about 40% of the elderly patients 
(Konno et al. 2003). Further, another cMyBP-C variant initially associated with HCM 
(deletion in intron 32 leading to a frameshift) has also been also found in patients 
with DCM and restrictive cardiomyopathy (Waldmuller et al. 2003), with yet another 
HCM/DCM variant that causes truncation of cMyBP-C (R945fs/105) reported by other 
group (Hitomi et al. 2010). The observed DCM/HCM phenotypic variation, with single 
mutation capable of causing different effects of on fibre contractile velocity, force and 
Ca2+ sensitivity is still not well understood, although as a general rule, mutations that 
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increases cardiac output are predicted to contribute towards HCM phenotype, while 
those that diminish motor function causative of DCM (Moore et al. 2012).  
The clinical DCM is characterized by left ventricular dilatation and global systolic 
dysfunction in the absence of coronary artery disease or other identifiable causes 
(Cecchi et al. 2012). A recent multi-national study has shown that MYBPC3 
mutations represent the second highest number of previously reported DCM-causing 
variants, found to contribute towards ~13% cases (Haas et al. 2014). Further, a 
follow-up study by (Lynch et al. 2015) (using the homozygous mouse cMyBP-C DCM 
model by (McConnell et al. 1999)), has reported elevated oxidative stress and 
proposed it to serve as additional factor which could add to DCM disease severity. 
Compared to HCM, DCM is thought to be far more genetically heterogeneous, with 
mutations found in genes encoding cytoskeletal, nucleoskeletal, mitochondrial, and 
calcium-handling proteins (McNally et al. 2015). Mutations in cMyBP-C have also 
been described in patients with LVNC, a cardiomyopathy characterized by deep 
trabecular invaginations in the left ventricle (Cecchi et al. 2012). A study by (Probst et 
al. 2011) identified 5 LVNC-linked mutations in cMyBP-C, however phenotypic 
variants in other sarcomeric proteins, i.e. MYH and Tm have also been reported, 
which shows genetic heterogeneity of LVNC. Together, these studies reveal 
MYBPC3 as one of the major mutated genes in cardiomyopathies and heart failure. 
Similar to HCM, both missense and truncating mutations were found in DCM and 
LVNC (Probst et al. 2011; Haas et al. 2014). 
Although the role of the cMyBP-C in heart disease seems quite clear, little is known 
about an association between cMyBP-C and cardiac arrhythmia, though the mouse 
models have indicated that cMyBP-C mutations are likely to also induce ventricular 
arrhythmias (Berul et al. 2001), with single E334K mutation reported to cause HCM 
accompanied by arrhythmia (Bahrudin et al. 2008). This mutation was shown to 
induce ubiquitin–proteasome system impairment which led to accumulation of cardiac 
channel proteins, leading to electrophysiological dysfunction (Bahrudin et al. 2011). 
However, any direct relationship between cMyBP-C pathophysiology and altered 
Ca2+ transients remains a question requiring further scientific investigation.  
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1.4 Hypothesis and Aims 
Impaired relaxation and altered Ca2+ transients have been reported in several 
cMyBP-C KO animal models (Song et al. 2003; Brickson et al. 2007; Pohlmann et al. 
2007), pointing that cMyBP-C contributes not only to regulation of contraction, but 
also might be involved in modulation of Ca2+ homeostasis. The main hypothesis of 
this thesis is that cMyBP-C could constitute a novel retrograde link between 
contraction and its trigger, i.e SR- Ca2+ release, mediated by the direct cMyBP-
C:RyR2 binding. Thus, the principal aim of this study was to characterise this novel 
interaction both biochemically and functionally. In particular, the following points will 
be addressed: 
 Verify if the native cMyBP-C:RyR2 binding can be detected from the animal heart 
tissue preparations in vitro; 
 Co-express full-length recombinant human RyR2 with cMyBP-C in a heterologous 
cell system and assess the interaction in vitro;  
 Identify the minimal interacting regions/motifs involved in RyR2:cMyBP-C 
association in the chosen experimental system in vitro and in vivo; 
 Assess the functional role of cMyBP-C in RyR2 channel regulation using 
recombinant expression system; 
 Assess if single point RyR2 mutations can disrupt protein-protein association 
between the RyR2 and cMyBP-C. 
  
Chapter 2  
 
Materials and Methods 
  Chapter 2 
 
34 
 
2 Materials and Methods 
 
2.1. Materials 
All chemicals and reagents were obtained from Sigma-Aldrich or Fisher Scientific, 
unless stated otherwise. All solutions were prepared using dH2O, pH adjusted as 
required and stored at room temperature unless an alternative is noted. Solutions 
were filter sterilised where required using a 0.22 µM Millex syringe filter (Millipore). 
 
2.1.1. Molecular biology 
 TAE buffer 50x stock: 2 M Tris, 2 M acetic acid, 50 mM EDTA. 
 Ethidium Bromide: 1% (w/v). 
 Agarose: Hi-Res Standard Agarose (Geneflow). 
 DNA loading buffer, 5x stock: 25% (v/v) glycerol, 0.25% (w/v) orange G. 
 Molecular weight DNA markers: 1 kb plus DNA ladder (Life Technologies), 
stored at -20°C. 
 DNA polymerase: Pfu DNA polymerase (Promega), together with optimised PCR 
buffer (with MgSO4, 10x), all stored at -20°C. 
 dNTP mix, 20 mM: dATP, dCTP, dGTP and dTTP, stored at -20°C. 
 Human cardiac muscle cDNA library (BD Biosciences). 
 Plasmid purification kits: Qiagen Plasmid Maxi Kit (Qiagen) and Wizard Plus 
SV Minipreps DNA Purification System (Promega). 
 PCR purification kit: QIAquick PCR Purificatin Kit (Qiagen). 
 Gel extraction kit: QIAquick Gel Extraction Kit (Qiagen). 
 Restriction endonucleases and ligase: purchased from NEB, together with 
optimised reaction buffers (10x), all stored at -20°C. 
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2.1.2. Protein biochemistry 
 Homogenisation buffer:  
 organic-salt-based: 150 mM NaCl, 20 mM Tris, pH adjusted to 7.4 with HCl, 
stored at 4oC.  
 iso-osmotic: 5 mM HEPES, 0.3 M sucrose, pH adjusted to 7.4 with NaOH, 
stored at 4oC, filtered prior each use. 
 Protease inhibitors: Protease Inhibitor Cocktail Tablets (Roche), dissolved in 2 
ml of dH2O, resulting in 25x stock solution, stored at -20oC. 
 Glass beads: acid-washed, 425-600 µm, 30-40 U.S. sieve (Sigma-Aldrich). 
 Protein assay kit: Pierce BCA Protein Assay Kit (Pierce), stored at 4oC. 
 Co-IP buffer: 150 mM NaCl, 20 mM Tris, 0.5% (w/v) CHAPS, pH adjusted to 7.4 
with HCl, stored at 4oC. 
 PBS buffer: 1.37 M NaCl, 27 mM KCl, 100 mM Na2HPO4, 18 mM KH2PO4. 
 DTSSP, 2 mM in PBS, freshly made prior to use. 
 Protein beads: nProtein A and nProtein G Sepharose 4 Fast Flow beads (GE 
Healthcare Life Science), stored at 4oC. 
 Tris-HCl, 0.5M (stacking buffer): pH adjusted to 6.8 with HCl. 
 Tris-HCl, 1.5M (separating buffer): pH adjusted to 8.8 with HCl. 
 SDS, 10% (w/v). 
 Ammonium persulphate: 10% (w/v), stored at 4oC for up to 3 weeks. 
 Protein loading buffer, 5x: 0.3 M Tris, 10% (w/v) SDS, 50% (v/v) glycerol, 0.025 
mM EDTA, 0.25% (w/v) bromophenol blue. 
 Reducing protein loading buffer, 5x: as above, supplemented with 10% β-
mercaptoethanol. 
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 SDS-PAGE running buffer, 10x: 3% (w/v) Tris, 14.4 % (w/v) glycine, 1% (w/v) 
SDS. 
 Acrylamide: 40% acrylamide/Bis mix solution, in 37:5:1 ratio (Bio-Rad), stored at 
4oC. 
 TEMED. 
 Protein molecular weight markers: Precision Plus Protein Standards (Bio-Rad) 
and Kaleidoscope Prestained Standards (Bio-Rad), stored at -20oC. 
 Semi-dry transfer buffer: 48 mM Tris, 39 mM glycine, 0.0375% (w/v) SDS, 
freshly made prior to use. 
 TBS buffer, 10x: 200 mM Tris, 1.37 M NaCl, pH adjusted to 7.4 with HCl. 
 TBS-T: 1x TBS, 0.1% (v/v) Tween-20, freshly made prior to use. 
 TBS-T/Marvel: as above, supplemented with 5% (w/v) non-fat powdered milk 
(Marvel), pH adjusted to 7.4 with NaOH. 
 Sodium Azide: 5% (w/v). 
 ECL system: Pierce ECL Western Blotting Substrate (Thermo Scientific) used 
with Amersham Hyperfilm ECL (GE Healthcare). 
 BCA Protein Assay Kit: (Pierce) 
 
2.1.3. Bacterial culture 
All glassware and sterile plastics were purchased from Fisher Scientific or Greiner 
Bio-One. Prior to use, all glassware was washed with dH2O and autoclaved (135oC, 
90 min). All bacterial growth media were autoclaved under the same conditions, 
before cooling to approximately 50°C prior to the addition of antibiotic.  
 LB medium: purchased in form of pre-made powder and prepared at 2% (w/v) 
(Formedium), 1.5% (w/v) agar (for plates only), stored at 4oC for up to a month.   
 Ampicillin: 100 mg/ml stock (Formedium), stored at -20°C. 
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 LB/Ampicillin medium: LB medium supplemented with 100 µg/ml Ampicillin, 
1.5% (w/v) agar (for plates only), stored at 4oC for up to a month. 
 Bacterial cell freezing medium: 50% (v/v) LB/Ampicillin, 50% (v/v) glycerol 
(autoclaved). 
 SOC medium: 2% (w/v) tryptone, 0.5% (w/v) yeast extract, 0.05% NaCl, 0.018% 
(w/v) KCl, 0.095% (w/v) MgCl2·6H2O), 0.4% glucose (added after autoclaving), 
stored at -20°C. 
 
2.1.4. Yeast culture 
All glassware and sterile plastics were purchased from Fisher Scientific or Greiner 
Bio-One. All glassware was treated similar as in bacterial culture. All solutions were 
also autoclaved in the same manner, and stored at 4oC. 
 YPD medium: 2% (w/v) peptone, 1% (w/v) yeast extract, 2% w/v glucose (added 
after autoclaving), 2% (w/v) agar (for plates only). 
 SDY medium (lacking leucine and tryptophan): 6.7 g/L of Yeast Nitrogen Base, 
1.6 g/L Dropout supplement lacking leucine and tryptophan, 2% w/v glucose 
(added after autoclaving), 2% (w/v) agar (for plates only). 
 PEG 3350 stock solution: 50% (w/v). 
 TE solution, 10x stock: 100 mM Tris, 10 mM EDTA, pH adjusted to 7.5 with HCl. 
 LiAc solution, 10x stock: 1 M lithium acetate, pH adjusted to 7.5 with 
CH3COOH. 
 PEG/LiAC solution: 40% (w/v) PEG 3350, 1x TE, 1x LiAc. 
 TE/LiAc solution: 1x TE, 1x LiAc. 
 Z buffer: 100 mM Na2HPO4, 40 mM NaH2PO4, 10 mM KCl, 1 mM MgSO4, pH 
adjusted to 7.4. 
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 X-gal stock solution: 2% (w/v) X-Gal in DMF, stored in dark at -20oC. 
 Z buffer/X-gal solution: 0.27% (v/v) β-mercaptoethanol, 0.033% (w/v) X-Gal in Z 
buffer, prepared fresh prior to use. 
 Z buffer/ β-mercaptoethanol: 0.27% (v/v) β-mercaptoethanol in Z buffer, 
prepared fresh prior to use. 
 Herring testes carrier DNA (Clontech). 
 Yeast Protein Extraction buffer: 20 mM Tris, 150 mM NaCl, 1% Triton X-100, 
pH adjusted to 7.4 
 
2.1.5. Mammalian culture 
Sterile plastic ware was purchased from Greiner Bio-One and Corning. All cell culture 
reagents were from Gibco, unless otherwise stated. Saline and sterile water were 
obtained from Fresenius Kabi.  
 L-glutamine: 100x, stored at -20oC, filter sterilised before use. 
 FBS (heat inactivated): stored at -20oC, filter sterilised before use. 
 DMEM: containing D-glucose, L-glutamine, sodium pyruvate, sodium bicarbonate, 
phenol red, stored at 4°C. 
 mDMEM: DMEM supplemented with 1x L-glutamine (all filter sterilised), stored at 
4°C. 
 cDMEM: DMEM supplemented with 10% (v/v) FBS, 1x L-glutamine (all filter 
sterilised), stored at 4°C. 
 Trypsin-EDTA, 0.05%, 1x, with phenol red, stored at -20°C, warmed to room 
temperature and filter sterilised before use. 
 CaCl2, 2.5 M stock: filter sterilised and stored at -20°C (1 ml aliquots). 
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 HBS, 2x: 280 mM NaCl, 10 mM KCl, 1.5 mM Na2HPO4, 12 mM glucose, 50 mM 
HEPES, pH adjusted to 7.05 with 1 M NaOH, stored at -20°C, filter sterilised 
before use. 
 Transfection reagents: TurboFect Transfection Reagent (Thermo Scientific), 
Effectene (Qiagen) 
 Mammalian cell freezing medium: 10% (v/v) DMSO in FBS, freshly made prior 
to use and filter sterilised. 
 
2.1.6. Immunocytochemistry (ICC) 
 Poly-L-lysine (Sigma): used at 0.01% working dilution in saline, stored at 4°C.  
 Fixing solution: 4% (w/v) paraformaldehyde in PBS. 
 Cell permeabilisation solution: 0.1% (v/v) Triton X-100 in PBS. 
 Blocking solution: 10% FBS in PBS 
 Mounting reagent: ProLong Gold Antifade Mountant (Life Technologies) 
 
2.1.7. Ca2+ imaging  
 Fluo-3 AM (Life Technologies), prepared in a solution of 20% Pluronic acid in 
DMSO. Added to minimal mDMEM to generate a working concentration of 10 µM. 
 KRH buffer: 120 mM NaCl, 5.5 mM Glucose, 25 mM Hepes, 4.8 mM KCl,1.2 mM 
KH2PO4, 1.2 mM MgSO4, 1.3 mM CaCl2, pH 7.4. Filter sterilised. 
 Caffeine: 100 mM stock prepared in KRH buffer. 
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2.1.8. [3H]ryanodine binding 
 Ryanodine binding buffer: 1 M KCl, 25 mM PIPES, 1 mM EGTA, 1 mM HEDTA, 
1 mM NTA, pH adjusted to 7.4 with KOH. 
 Caffeine, 100 mM, prepared fresh prior to use. 
 CaCl2, 20 mM. 
 ‘Cold’ Ryanodine stock, 1 mM, stored in the dark at -20oC. 
 Hot [3H]ryanodine stock (PerkinElmer), 1µM (9.25 MBq, 250 µCi), stored at 
 -20oC. 
 Ultima Gold Scintillation Fluid (Perkin Elmer). 
 
2.1.9. Oligonucleotides 
Custom oligonucleotide primers were designed and ordered from Sigma Aldrich. 
Following the manufacturer’s instructions, lyophilised pellets were re-suspended in an 
appropriate volume of sterile dH2O to give 100 µM stock concentration, which was 
further confirmed by spectrophotometric quantification. Briefly, a 1:50 dilution aliquots 
were made and the absorbance at 260 nm (A260) was measured (in triplicates) in a 
quartz cuvette using a spectrophotometer (MBA2000, Perkin-Elmer). Using the 
nucleotide sequence, the molecular weight and the melting temperature of the 
oligonucleotides (given that A260 = 1 corresponds to ~20-39 pg/ml of ssDNA 
depending on the base composition, with ~ 33 pg/ml taken on assumption of an 
equal mixture of the four bases), the concentration was calculated. Working stocks 
(20 µM for PCR amplification; 3.2 µM for DNA sequencing) were prepared and stored 
at -20°C. Full list of primers used in this study is provided in Table 2.1.  
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Table 2.1 Full list of primers. 
Primer Sequence Restriction 
site 
Length Content Tm 
(C) 
MW Notes 
HcMyBPC.FOR.27-56 CTC AGG ATC CCT GAG 
CCG GGG AAG AAG CCA 
BamHI (M) 30b, 
29b match 
HcMyBP-C 
A 8, C 9, G 
10, T 3 
83.2 9255 F, includes 6b of the 5’ UTR, 
1b changed to produce a 
BamHI site, 4b clamp 
HcMyBPC.REV.3849-
3876 
TCC CCT CGA GCC AGC 
CTG GTC ACT GAG G 
XhoI (M) 28b, 
26b match 
HcMyBP-C 
A 4, C 11, G 
8, T 5 
82.8 8530 R, includes 19b of the 3’ UTR, 
2b changed to produce a 
XhoI site, 4b clamp 
HcMyBPC.REV.2611-
2630 
TTA ACT CGA GGC ATG 
AAG GGC TGG GAG G 
XhoI (A) 28b, 
20b match 
HcMyBP-C 
A 7, C 4, G 
12, T 5 
77.9 8762 R, 4b clamp 
HcMyBPC.FOR.2481-
2508 
CGG TGA ATT CAG CTG 
AAC TTC GAC CTG A 
EcoRI (M) 28b, 
26b match 
HcMyBP-C 
A 7, C 7, G 
7, T 7 
75.6 8592 F, 2b changed to produce a 
EcoRI site, 4b clamp 
HcMyBPC.REV.3217-
3237 
A AGTC TCG AGG ACT TGG 
CTT GTC AAC AA 
XhoI (A) 28b, 
21b match 
HcMyBP-C 
A 8, C 6, G 
7, T 7 
72.8 8616 R, 3b added to create XhoI 
site, 4b clamp 
HcMyBPC.FOR.2925-
2949 
CAG GGG ATC CTG CAA 
CGG CCA CGG C 
BamHI (M) 25b, 
24 match 
HcMyBP-C 
A 5, C 9, G 
9, T 2 
84.2 7681 F, 1b changed to produce 
BamHI site, 4b clamp 
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HcMyBPC-FOR.2331 -
2360 
AGG GGG ATC CAC GTG 
CCA GAC GCA CTT GCG 
BamHI (M) 30b, 27 match 
HcMyBP-C 
A 7, C 10, 
G10, T 3 
88.1 9247 F, 3b changed to produce 
BamHI site, 4b clamp 
HcMyBPC.REV.2931-
2958 
GCA GCT CGA GCC GTG 
GCC GTT GCA GGA T 
XhoI (M) 28b, 25 match 
HcMyBP-C 
A 4, C 8, G 
11, T 5 
85.6 8650 R, 2b changed to create XhoI 
site, 4b clamp 
HcMyBP-.FOR.2625-56 
 
ATG CGG ATC CGT CCC 
CCC AGC GAA CCC ACC CA 
BamHI (M) 32b, 29 match 
HcMyBP-C 
A 7, C 16, G 
6, T 3 
90.5 9649 F, 3b changed to produce 
BamHI site, 4b clamp 
HcMyBP-.REV.3519-
3488 
GG TCT CTA GAT AAA GAC 
GGG CTC CTT GTT GTT 
XbaI(M) 32b, 29 match 
HcMyBP-C 
A 6, C 6, G 
11, T 9 
75.5 9915 R, 3b changed to create XbaI 
site, 4b clamp 
HcMyBP-.FOR.3204-35 
 
CTG GGG ATC CAG GTT 
GTT GAC AGG CCA AGT CC 
BamHI(M) 32b, 29 match 
HcMyBP-C 
A 7, C 8, G 
10, T 7 
80.9 9869 F, 3b changed to produce 
BamHI site, 4b clamp 
HcMyBP-.REV.2316- 
47 
GG CAT CTA GAT GAC CTT 
GAC TGT GAG GTT GAC 
XbaI(M) 32b, 29 match 
HcMyBP-C 
A 7, C 6, G 
10, T 9 
74.5 9899 R, 3b changed to produce 
XbaI site, 4b clamp 
HcMyBP-.REV.825- 
864 
C TCC CTC GAG CTA GCG 
GCG GAA GGC TGA TAG 
GAG GTC CAG 
XhoI (M) 40b, 30 match 
HcMyBP-C 
A 8, C 11, G 
15, T 6 
87.2 10159 R, 4b clamp, stop codon 
added 
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HcMyBP-.FOR.792-824 
 
CTC AGG ATC CAC GAG 
GCC ATG GGC ACC GGA 
GAC 
BamHI (M) 33b, 30 match 
HcMyBP-C 
A 8, C 11, G 
11, T 3 
87 12388 F, 3b changed to produce 
BamHI site, 4b clamp 
mCherry.FOR.1-27 CGG CAA GCT TCC ACC 
ATG GTG AGC AAG GGC 
GAG GAG GAT AAC 
HindIII (A) 42b, 31 match 
mCherry 
A 12, C 10, 
G 15, T 5 
88.6 13047 F, 4b clamp. 
mCherry.REV.689-708 T GGC GCT AGC CTT GTA 
CAG CTC GTC CAT GC 
NheI (M) 30b, 22 match 
mCherry 
A 4, C10, G 
8, T 8 
81.2 9150 R, 3b changed to produce 
NheI site 
Notes: restriction site underlined, (M) modified residue shaded in yellow, (A) added residues highlighted in blue, (F) forward, (R) reverse. 
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2.1.10. Plasmid vectors 
All constructs used in the Y2H screen were previously made and kindly provided by 
Dr S. Zissimopoulos. The following plasmid vectors were used for co-transformation 
and recombinant protein expression in Saccharomyces cerevisiae: 
 pGBKT7, Figure 2.1 (A): cloning vector used to generate fusion of protein X/bait 
with GAL4 DNA-BD. It contains Kanamycin resistance gene for positive selection 
in E.coli and TRP1 prototrophic selection gene enabling identification of positive 
yeast clones. 
 pACT2, Figure 2.1 (B): cloning vector used to generate GAL4 AD fusion with 
protein Y/ prey. It contains Ampicillin resistance gene for positive selection in 
E.coli and LEU2 prototrophic selection gene for allowing selection of positive 
yeast clones. 
 pVA3-1: positive control used with pTD1-1, encodes GAL4 DNA-BD fusion with 
murine p53 protein. 
 pTD1-1: positive control used with pVA3-1, encodes GAL4 AD fusion with SV40 
large T antigen. 
All aforementioned plasmid vectors were provided with Matchmaker Gal4 Two-Hybrid 
System (Clontech). 
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Figure 2.1 Illustration of plasmid vectors used in Y2H study. Restriction sites and a detailed map of multicloning site of (A) pGBKT7 vector and (B) pACT2 
vector. All images shown were taken from the Clontech website (www. clontech.com) and modified. 
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Full length human WT (hRyR2 WT) and series of N-terminal (BT) RyR2 constructs 
were previously made and obtained from Dr C. George and Dr S. Zissimopoulos, 
respectively. The following mammalian expression vectors were used in this study:  
 pcDNA3 (Invitrogen), Figure 2.2: cloning vector used to generate full length 
human RyR2 WT. It contains Ampicilin resistance gene for positive selection in 
E.coli and Neomycin resistance gene for allowing selection of stably transformed 
mammalian cells.  
Figure 2.2 Illustration of restriction sites of mammalian expression pcDNA3 vector used in this study. 
Image shown was taken from the Life Technologies website (www.lifetechnologies.com) and 
modified. 
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 pCR3 (Invitrogen), Figure 2.3: cloning vector that contains Ampicilin resistance 
gene for positive selection in E.coli and Kanamycin/Neomycin resistance genes 
for allowing selection of stably transformed mammalian cells. 
Figure 2.3 Illustration of restriction sites of the original mammalian expression pCR3 vector. Image 
shown was taken from the Life Technologies website (www.lifetechnologies.com) and modified. 
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 mCherry-pCR3, Figure 2.4: modified pCR3 vector, where original multiple 
cloning site has been altered to enable expression of mCherry tagged proteins. 
The coding sequence for synthetic peptide mCherry was obtained from Dr C. 
George and cloned into pCR3 vector as described in Chapter 5. 
Figure 2.4 : Illustration of restriction sites and a detailed map of multicloning site of mCherry- pCR3 
tagged vector. All images shown were taken from the Life Technologies website 
(www.lifetechnologies.com) and modified. 
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 c-Myc-pCR3, Figure 2.5 (A): modified pCR3 vector by Dr S. Zissimopoulos, 
where original multiple cloning site has been altered to enable expression of c-
Myc (EQKLISEEDL) tagged proteins. 
 HA-pCR3, Figure 2.5 (B): modified pCR3 vector by Dr S. Zissimopoulos, where 
original multiple cloning site has been altered to enable expression of influenza 
hemagglutinin HA (YPYDVPDYA) tagged proteins. 
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Figure 2.5 Illustration of restriction sites and a detailed map of multicloning site of (A) c-Myc-pCR3 tagged, (B) HA-pCR3 tagged vector. All images 
shown were taken from the Life Technologies website (www.lifetechnologies.com) and modified. 
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2.1.11. Antibodies 
The following antibodies (Ab) were used in this study: 
 Ab 1093, rabbit polyclonal antiserum, raised to residues 4454-4474 of human 
RyR2 (EDKGKQKLRQLHTHRYGEPEC) used in WB at 1:1000 dilution, in 
native co-IP at 1:10 dilution (2ug), and ICC at 1:100 dilution. 
 Ab C-t (AF7199, R&D Systems), polyclonal anti-mouse sheep IgG, raised 
against E. coli derived recombinant mouse cMyBP-C residues 998-1100, used 
in WB at 1:200 dilution. 
 Ab N-t (E7, Santa Cruz), mouse monoclonal IgG, raided against cMyBP-C 
amino acids 1-120 mapping at the N-terminus of human origin, used in WB at 
1:500 dilution, co-IP at 1 µg, and ICC at 1:100 dilution. 
 Ab HA (Y-11, Santa Cruz), rabbit polyclonal IgG, raised against internal region 
of the influenza hemagglutinin protein, used in co-IP at 1 µg. 
 Normal rabbit IgG (Santa Cruz), used as negative control: 2 µg in native 
proteins co-IP, 1 µg recombinant proteins co-IP. 
 Ab HA (16B12, Covance), mouse monoclonal IgG2a, raised against internal 
region of the influenza hemagglutinin protein, used in WB at 1:500 dilution. 
 Ab c-Myc (9E10, Santa Cruz), mouse monoclonal IgG1, raised against 
epitope corresponding to amino acids 408-439 within the carboxyl terminal 
domain of c-Myc of human origin, used in WB at 1:500 dilution. 
 Anti-mouse goat HRP conjugated Ab (Santa Cruz), used in WB at 1:10.000 
dilution. 
 Anti-sheep HRP conjugated Ab (R&D Systems), polyclonal donkey IgG, 
used in WB at 1:5000 dilution. 
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 Anti-rabbit polyclonal HRP conjugated Ab, used in WB at 1:10.000 
 Alexa Fluor 488 conjugate (A-11034, Life Technologies), goat anti-rabbit IgG 
secondary antibody, used in ICC at 1:500 dilution.  
 Alexa Fluor 594 conjugate (A-11005, Life Technologies), goat anti-mouse 
IgG secondary antibody, used in ICC at 1:500 dilution. 
 
2.2 Methods 
General molecular biology and biochemistry techniques were performed according to 
protocols outlined in the Molecular Cloning laboratory manual (Sambrook et al. 1989) 
and procedures optimised by other members of Professor Lai’s laboratory. When 
applicable, the manufacturer’s instructions were followed. All equipment used for 
agarose and polyacrylamide gel electrophoresis, semi-dry transfer and image 
acquisition were purchased from Bio-Rad, unless stated otherwise. Centrifugation 
steps were undertaken using a range of Beckman Coulter and Eppendorf 
centrifuges. Where required, aseptic technique was employed and surfaces were 
swabbed with 70% (v/v) ethanol before and after use. All techniques conformed to 
local safety guidelines included in the WHRI Health and Safety Handbooks. 
 
2.2.1 Molecular biology methods 
 
2.2.1.1 Standard Polymerase Chain Reaction (PCR) 
A series of PCR reactions were carried out using a GeneAmp PCR system 9700 
thermal cycler (Applied Biosystems). To generate high-fidelity amplification products, 
Pfu (a Pyrococus furiosus) DNA polymerase was used, which possess 5’- 3’ DNA 
polymerase activity and 3’- 5’ exonuclease (proofreading) activity, allowing 
recognition and excision of any misincorporated bases during polymerisation. 
Annealing temperature of standard PCR reaction was usually set at approximately 5-
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10oC below primers’ melting temperature. The extension time was calculated based 
on the length of expected PCR product, assuming 2 min for every 1kb to be 
amplified. Typical PCR reaction set-up and cycling conditions are presented in Table 
2.2 and 2.3, respectively. 
Table 2.2 PCR reaction components. 
Reagent Final concentration  Volume 
DNA template (20-300 ng of 
cDNA) 
100 ng 0.5 µl of 200 ng/µl 
Upstream primer (5-50 pmol) 20 pmol 1 µl of 20 µM 
Downstream primer (5-50 
pmol) 
20 pmol 1 µl of 20 µM 
PCR buffer  1x 5 µl of 10x stock 
dNTP mix 0.2 mM 0.5 µl of 20 mM stock 
Pfu DNA polymerase 1 u 0.5 µl of 2 u/µl stock 
Nuclease-free sterile dH20 Up to 50 µl final volume 39 µl 
 
Table 2.3 PCR amplification thermal cycling conditions. 
Step Temp (oC) Time (min) Number of cycles 
Initial denaturation 95 2 1 
Denaturation 
Annealing 
Elongation 
95 
42-65 
72 
1 
1 
≥1 
 
30 
Final elongation 72 5-10 1 
Incubation 4 Indefinite 1 
 
2.2.1.2 Agarose gel electrophoresis 
Agarose gel electrophoresis was used to verify DNA fragments following PCR 
amplification (Section 2.2.1.1) or restriction digest (Section 2.2.1.3). An agarose gel 
was prepared by dissolving the appropriate amount of agarose (see Table 2.4); 
typically, 1% was used for fragments >1 kb) in 1x TAE buffer by boiling for ~1-2 min. 
Subsequently, the mixture was cooled to ~50°C and 0.01 % of ethidium bromide was 
added. The agarose solution was left to set in a gel cast, and then assembled into a 
minisub gel tank according to the manufacturer guidelines. DNA loading samples 
were prepared with 1x DNA loading buffer (containing Orange G for visualisation, 
which co-migrates with DNA fragments at ~100 bp), and for each gel a 1 kb DNA 
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molecular weight marker was run alongside the samples as a reference of fragment 
molecular mass. Electrophoresis was carried out under constant voltage (typically 80 
V) until sufficient DNA fragment separation was obtained. The Gel UV Imaging 
System (Alpha Innotech) was used to visualize the resolved DNA fragments by UV 
illumination. 
Table 2.4 Agarose concentrations for DNA electrophoresis. 
% (w/v) Agarose Effective range of separation of linear DNA (kb)  
0.7 0.8-10 
1.0 0.5-8 
1.2 0.4-6 
1.5 0.2-3 
2.0 0.1-2 
 
2.2.1.3 DNA restriction endonuclease digest 
DNA was digested with appropriate restriction endonucleases according to the 
manufacturer’s recommendations. Briefly, each reaction was set in 10 µl, with 0.5-2 
µg of DNA (depending on the subsequent downstream application). For double-
enzyme-digest reaction, buffers compatibility was evaluated using the NEB online 
site (http://www.neb.uk.com). All reactions were incubated at 37oC for 2 h and 
analysed by agarose gel electrophoresis. For DNA cloning, the restriction digest set-
up was preceded by DNA fragments visualisation using U.V transilluminator light box 
(Syngene) to evaluate the amount of DNA, excision of appropriate gel fragment and 
subsequent purification using the gel extraction kit. For two-step PCR reactions, the 
sample was first purified with the PCR purification kit. Both procedures were carried 
out according to the manufacturer’s instructions.  
 
2.2.1.4 DNA ligation 
DNA ligation was conducted according to the manufacturer’s guidelines.  Briefly, a 
reaction was set-up in 30 µl and contained 20-200 ng of total DNA, with 3:1 molar 
ratio of insert:vector. Reaction was incubated for 2 h at room temperature before 
proceeding to bacterial transformation (Section 2.2.3.1). 
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2.2.1.5 Spectrophotometric DNA quantification 
Nucleic acids have absorbance maxima at 260 nm, therefore DNA plasmid 
concentration was determined by spectrophotometric quantification of a 1:50 dilution 
sample at this wavelength. The concentration was calculated (in triplicate) taking into 
account that A260= 1 corresponds to 50 pg/ml of double stranded DNA. Any 
contaminating proteins present will have a peak light absorbance at 280 nm, 
therefore plasmid purity can be quantified by using the ratio of A260/A280, with values 
of ~1.8 being generally accepted as pure. Additionally, the ratio A260/A230 was also 
used as means of measure the presence of other contamination (i.e. ethanol 
carryover resulting from DNA purification), with the expected values in the range of 
2.0-2.2 for pure DNA. 
 
2.2.1.6 DNA sequencing 
DNA sequencing was carried out by DNA Services & Sequencing facility, Dundee 
University (http://www.dnaseq.co.uk/). Each sequencing PCR reaction was prepared 
according to their guidelines, set up in 30 µl and contained ~500-600 ng of plasmid 
DNA and 3.2 pmol of given primer. Obtained electropherogram fluorescence 
intensities were visualised using Seq Scanner 2 software (Applied Biosystems). NCBI 
Basic Local Alignment Search Tool (BLAST, http://blast.ncbi.nlm.nih.gov/Blast.cgi) 
was used for pairwise sequence alignment, whereas multiple sequence alignment 
was produced using EMBL-EBI Clustal Omega 
(http://www.ebi.ac.uk/Tools/msa/clustalo/). 
 
 
 
2.2.2 Protein biochemistry methods 
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2.2.2.1 Mammalian cell homogenization  
Cell pellets of HEK293 cells expressing the proteins of interest (~2x 107 cells 
harvested from one 100 mm Petri dish) were re-suspended in appropriate volume of 
ice-cold homogenization buffer supplemented with protease inhibitors (typically 500 
µl in total per one pellet, type of used buffer depending on the downstream 
application) and kept on ice.  
For co-IP assay, cells were re-suspended in organic-salt-based buffer (see Section 
2.1.2) with added protein inhibitors and homogenised by 20 passages through a 0.6 
mm needle in the presence of 250 µl of glass beads (pre-washed in the 
homogenisation buffer). Nuclei and unbroken cells were removed by centrifugation at 
1500 xg for 5 min at 4oC and the post-nuclear supernatant was collected and 
subsequently solubilized with 0.5% CHAPS (500 μl total volume) and incubated 
overnight at 4oC with continuous mixing.  Further, sample was subjected to 
centrifugation at 20.000 xg for 10 min at 4oC to pellet the insoluble material and the 
supernatant fraction was collected (referred to from this point on as ‘cell lysate’) and 
used in co-IP assay.  
For [3H]ryanodine binding assay, cells were first re-suspended in ice-cold iso-osmotic 
buffer (500 µl per cell pellet) with added protein inhibitors and passaged forcefully 
20x through a sterile 23G needle aided by the use of an automated cell homogeniser 
(the “montygeniser”, designed and constructed by Richard Montgomery). The 
resultant homogenate was centrifuged at 2600 rpm (1000 xg) for 5 minutes, at 4°C 
and the resulting supernatant was collected and stored at 4oC until further use. 
 
2.2.2.2 Determination of protein concentration 
Protein concentration was estimated with the use of BCA Protein Assay Kit according 
to the manufacturer’s guidelines. Briefly, the method is based on reduction of Cu2+ to 
Cu1+ by protein in an alkaline environment with the selective colorimetric detection of 
the Cu1+ by bicinchoninic acid (BCA). Duplicates of two dilutions (1/10 and 1/20) of 
the sample of interest were prepared together with serial dilutions of BSA protein 
(2000-62.5 µg/ml) and incubated with kit reagents for 30 min at 37oC. Subsequently, 
absorbance at 560 nm of each prepared sample was measured using Multiscan EX 
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(Labsystems) spectrophotometer. Protein concentration was calculated using a 
standard curve produced by the linear regression of the absorbance against the 
known concentrations of BSA protein samples. 
 
2.2.2.3 Co-immunoprecipitation (co-IP) assay 
Co-IP was performed by adding the desired Ab to pre-washed 3x with IP buffer 
Protein A or G beads slurry (typically 25-30 μl of slurry with 2 μg of Ab in 200 μl of co-
IP buffer) and incubated overnight at 4oC with continuous mixing.  
Where appropriate, samples were subjected to DTSSP crosslinking, where protein A 
beads slurry was washed 3x with PBS buffer (instead of IP buffer) before adding the 
relevant antibody and incubated ~3 h at 4oC with continuous mixing. The beads were 
then washed once with PBS buffer and to each pre-captured Ab, 200 μl of freshly 
made 2 mM DTSSP in PBS was added and incubated for 30 min at room 
temperature. The reaction was stopped with addition of 200 μl IP buffer and followed 
by one subsequent 30 min wash with IP buffer and further incubated in 200 μl of IP 
buffer overnight at 4oC with continuous mixing.  
To each pre-captured Ab (whether normal or crosslinked), 200 μl of cell lysate was 
added and incubated for 3 h at 4oC with continuous mixing. The beads were washed 
2x with IP buffer and collected by centrifugation at 1500 xg for 2 min at 4oC. 
Immunoprecipitated proteins were eluted with 1x protein loading buffer (either 
reducing- to prevent formation of protein aggregates, or non-reducing- for DTSSP-
treated samples to preserve crosslinked Ab complexes) and stored at -20oC prior to 
analysis by SDS-PAGE and WB. 
 
2.2.2.4 Polyacrylamide gel electrophoresis (SDS-PAGE) 
Depending on the size of the proteins to be separated, typically 6-12% 
polyacrylamide mini gels (8 cm x 10 cm, 0.75 cm thick) were prepared a day before 
electrophoresis. Detailed gel compositions are outlined in Tables 2.5 and 2.6. 
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Table 2.5 Separating gel composition Volumes given for 2 mini gels (μl). 
 Separating gel % 
 Reagents 4% 6% 8% 10% 12% 15% 
Acrylamide/Bis (37.5:1) 40% 1000 1500 2000 2500 3000 3750 
Water 6345 5845 5345 4845 4345 3595 
Tris-HCl 1.5M, pH 8.8 2500 2500 2500 2500 2500 2500 
SDS 10% 100 100 100 100 100 100 
Ammonium Persulphate 10% 50 50 50 50 50 50 
TEMED 5 5 5 5 5 5 
 
 
Table 2.6 Stacking gel composition. Volumes given for 2 mini gels (μl). 
Stacking Gel 
Acrylamide/Bis (37.5:1) 40% 500 
Water 3170 
Tris-HCl 0.5M, pH 6.8 1250 
SDS 10% 50 
Ammonium Persulphate 10% 25 
TEMED 2.5 
 
Briefly, the separating gel mixture was poured into assembled gel casting system up 
to 2/3rd of the glass plates’ height. The solution was overlaid with dH2O and allowed 
to polymerise for ~ 2 h. Subsequently, dH2O was removed and the top of separating 
gel was dried with paper. Stacking mixture was poured to the top of glass plates and 
the comb was inserted to form loading wells. Gels were left to set for at least 2 h 
before transferring into mini-gel tank and immersing in the 1 x SDS-PAGE running 
buffer.  
Native and recombinant RyR2 WT protein samples were separated using 4% 
polyacrylamide gel, strengthened with 0.5% agarose (4% acrylamide/0.5% agarose 
gel). To 5 ml of 8% polyacrylamide solution, 5 ml of 1% (w/v, freshly dissolved by 
boiling) agarose was added. The mixture was immediately poured into a pre-chilled, 
assembled gel casting system up to the top and the comb was inserted (no stacking 
gel). Gel stand was placed back into an ice-cold bath and left for 10 min for the 
agarose to solidify and allowed to polymerise overnight at room temperature. 
Following morning gels were transferred into mini gel tank as before. 
  Chapter 2 
59 
 
Prior to loading, pre-made samples containing 1 x protein loading buffer were heated 
at either 85oC (small protein fragments) or 50oC (RyR2 WT samples) for 5 min 
followed by 3 min centrifugation at 14.000 xg. Samples were loaded alongside 
protein molecular weight markers and electrophoresis was run under constant current 
(typically 40 mA for gel tank containing 4 gels) until the appropriate separation of 
coloured markers were obtained. Following electrophoresis, gels were either 
processed for WB or stained with dye based protein stain. 
 
2.2.2.5 Western blot (WB) analysis 
SDS-PAGE separated proteins were transferred onto PVDF membranes using a 
semi-dry system, following the manufacturer’s instructions. Briefly, following the 
electrophoresis, gels were washed in dH2O and incubated ~5 min in transfer buffer 
together with blotting paper and methanol-activated PVDF membranes. The blotting 
sandwich was assembled and transfer was conducted at constant current, either 400 
mA for 1 h at room temperature (small protein fragments blots), or 600 mA for 4 h at 
4oC (RyR2 WT blots). Following the transfer, blots were first blocked for 1 h in TBS-
T/Marvel buffer, and then incubated overnight at 4oC with the appropriate primary Ab 
(diluted in blocking buffer). The incubation with the corresponding secondary Ab 
(HRP-conjugated) was conducted for ~2-4 h at room temperature and was followed 
by 2x TBS-T washes, 5 min each. Proteins were visualised by chemiluminescence 
detection with ECL kit, following manufacturer’s recommendation. X-ray films were 
developed using an automatic X-ray film processor (X-ograph Compact X4, Xograph 
Healthcare). Film exposure was adjusted to the signal strength, typically ≤15 min. 
 
2.2.3 Bacterial culture 
 
2.2.3.1 Chemical transformation of bacteria  
Transformation of small plasmids (i.e., cMyBP-C constructs) was carried out using 
two chemically competent E. coli strains, either (1) OneShotTOP10 (Fisher Scientific) 
or (2) Sure2 (Stratagene). For (1), following the manufacturer’s instructions, 15 µl of 
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bacterial suspension was incubated on ice for 30 min in the presence of 10 ng of 
plasmid DNA. For (2), 50µl aliquot was first incubated with 2 µl of β-mercaptoethanol 
for 10 min on ice, with gentle agitation every 2 min. Subsequently 1ng of the ligation 
reaction was added, briefly mixed and incubated on ice for 30 minutes. Following 
steps were identical for (1) and (2). Bacteria were subjected to 45 sec heat shock 
treatment at 42°C in a water bath, followed by 2min incubation on ice. Further, 800 µl 
SOC medium was added and bacterial suspension was incubated at 37°C for 1 h 
with shaking at 225 rpm. Cultures were plated at two different densities (1/10th and 
9/10th) onto pre-warmed LB/Ampicillin agar plates, and incubated overnight at 37°C 
(Heraeus Incubator, Thermo Scientific) before the colony selection. 
Due to large size and the fragile nature of the hRyR2 WT plasmid construct, an 
optimised transformation method was employed with the following differences: 25 µl 
of XL-Gold Ultracompetent cells (Agilent Technologies) were incubated in the 
presence of 1 µl ß-mercaptoethanol, with 1 ng of hRyR2 WT, followed with 30 min 
incubation as described previously and heat pulsed for 30 sec at 42oC. After 
transformation, all culture steps were as above, apart from incubation temperature 
(30°C). 
 
2.2.3.2 Colony screen and plasmid isolation 
Following bacteria transformation, a number of colonies were screened for the 
presence of the recombinant plasmid of interest (containing the correct orientation 
and size of the DNA insert) using small-scale plasmid DNA isolation (‘mini-prep’) with 
Wizard Plus SV Miniprep plasmid purification kit.  Briefly, following O/N incubation, 
individual colonies were selected and used to inoculate ~3 ml of pre-warmed 
LB/Ampicillin growth medium and further incubated for 16-18 h at 37°C with 
continuous shaking at 225 rpm. 1.5 ml of each saturated culture was subsequently 
pelleted at 13,000 xg for 2 min and processed for plasmid isolation following the 
manufacturer protocol.  
Briefly, it employs the alkaline bacterial lysis, salt-detergent precipitation of impurities 
and DNA binding to kit columns followed by two ethanol-based washing steps.  After 
purification, plasmid DNA was eluted with 30 µl of sterile dH2O and further verified 
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(by DNA restriction endonuclease digests and agarose gel electrophoresis, Sections 
2.2.1.3 and 2.2.1.2, respectively) before being prepared on a larger scale. 
Small-scale cultures which produced plasmid DNA giving the correct endonuclease 
digest pattern were used to inoculate large volumes at a 1/400 dilution. Typically, 200 
ml (small protein constructs) or 4x 400 ml (hRyR2 WT plasmid construct) flasks of 
LB/Amplicillin medium were processed for DNA purification. Each flask was 
incubated overnight at 37°C (for small protein constructs, for 16-18 h until saturated,) 
or 30°C (hRyR2 WT plasmid construct, unsaturated cultures were collected at OD600 
≤1-1.1), with shaking at 225 rpm, and processed with Qiagen Plasmid Maxi Kit 
(‘maxi-prep’). It employs modified alkaline lysis procedure, followed by binding of 
plasmid DNA to anion-exchange resin under low salt and appropriate pH conditions. 
Briefly, bacteria were harvested by centrifugation at 10.000 xg for 5 min and obtained 
cell pellet was subjected to cell lysis followed by lysate filtration, DNA column binding 
and medium-salt washing in order to remove impurities. Bound DNA plasmid was 
then eluted from the resin column with high-salt buffer, desalted with isopropanol and 
precipitated onto new filter module. Subsequently the filter was subjected to more 
washes, briefly air-dried and DNA plasmid was eluted with 500 µl of sterile dH2O. 
Further, DNA was spectroscopically quantified (Section 2.2.1.5) and verified by DNA 
restriction endonuclease digests and agarose gel electrophoresis (Sections 2.2.1.3 
and 2.2.1.2), before storing at -20°C. For confirmation of correct localisation and size 
of the DNA insert, all generated constructs were sent for DNA sequencing (Section 
2.2.1.6). 
 
2.2.3.3 Long term storage 
For long-term storage of transformed bacteria, 1 ml of liquid culture grown in the 
presence of antibiotic for 16 h were subjected to centrifugation at 10.000 xg for 1 min 
at room temperature. Frozen glycerol stocks were made by resuspending the cell 
pellet in glycerol:LB/Ampicillin medium in a 1:1 ratio and frozen on dry ice and stored 
at -80oC in cryo-tubes. Bacteria from this frozen stock were revived by streaking 
small portion (~10 µl) of the stock onto LB/Ampicillin plates and further cultured at 
37oC as required. 
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2.2.4 Yeast culture 
All yeast two-hybrid techniques were carried out according to the Matchmaker GAL4 
User Manual (Clontech) and Yeast Protocols Handbook (Clontech). 
 
2.2.4.1 Yeast transformation 
S. cerevisiae Y190 yeast strain (Clontech) was revived from glycerol stocks (stored in 
YPD medium with 50% glycerol at -80oC), plated on YPD agar plates and incubated 
at 30oC until yeast colonies reached ~2mm in diameter (4-5 days). Next, 50 ml of 
YPD growth medium was inoculated with single colony and incubated at 30oC O/N 
with shaking at 250 rpm for 16-18 h until saturated (i.e. A600≥1.5). The culture was 
then refreshed to early log phase (A600= 0.2-0.3) by appropriate dilution in 400 ml of 
YPD and further cultured for 3-5 h until yeast reached mid-log phase (A600=0.5-0.6). 
Cells were collected by centrifugation at 1000 xg for 5 min and washed once in sterile 
dH2O. The final cell pellet was resuspended in 1.5 ml TE/LiAc solution. Competent 
cells were used immediately after preparation for highest transformation efficiency 
For co-transformations using two different plasmids, 500 ng of each plasmid (an 
approximately equal molar ratio) was used, together with 100 µl of prepared 
competent cells and 100 µg of herring testes carrier DNA. 600 µl of PEG/LiAc was 
subsequently added before incubation at 30oC for 30 min with shaking at 200 rpm. 
DMSO (80 µl, 10% of final volume) was then added and mixed by gentle inversion. 
Cells were subjected to 15 min heat shock treatment at 42oC (mixed gently every 2-3 
min), followed by immediate 2 min incubation on ice. Further, cells were collected by 
centrifugation at 14.000 xg for 10 sec, and the cell pellet was resuspended in 200 µl 
of TE buffer. Each 100 µl of cell suspension was plated onto SDY agar plate and 
incubated at 30oC until ~2 mm colonies appeared (4-5 days). 
 
2.2.4.2 β-galactosidase colony-lift filter paper assay 
A filter paper disc was pre-soaked in Z-buffer/X-gal solution, whereas a second dry 
filter paper was placed over the surface of the plate with the co-transformed yeast 
colonies to be assayed, and gently rubbed onto the plate with forceps and left for ~5 
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min for colonies to attach. The filter paper was then completely submerged into a 
pool of liquid nitrogen for ~30 sec in order to permeabilise the cells, let to thaw at 
room temperature for 2 min and placed on top of the pre-soaked filter paper inside 
the 100 mm plate (colony side up). The filters were incubated at 30°C and 
periodically (typically every 30 min) inspected for the appearance of blue colonies. 
Yeast co-transformed with the pVA3 and pTD1 were used as positive controls.  
 
2.2.4.3 Cell homogenisation and protein extraction 
For analysis of protein expression, yeast transformed with the construct of interest 
was grown in SDY minimal media. An overnight culture, which was inoculated with a 
single transformed colony, was used to obtain 100 ml of culture at A600 = 0.2-0.3 
which was further incubated until mid-log phase (A600=0.5-0.6) was reached. At this 
point, cells were collected by centrifugation (1500 xg for 5 min at 4 °C), washed in 
ice-cold dH2O and again recovered by centrifugation. The cell pellet was re-
suspended in 500 μl of ice-cold protein extraction buffer supplemented with protease 
inhibitors. Cells were homogenised by three rounds (1 min each) of vigorous 
vortexing in the presence of glass beads, which were earlier washed 3x with the 
protein extraction buffer. Cell debris was removed by centrifugation at 14 000 xg for 5 
min. Protein concentration was evaluated as described in Section 2.2.2.2. Protein 
extracts were stored at -80°C and subsequently analysed for protein expression by 
WB. 
 
2.2.5 Mammalian culture 
 
2.2.5.1 HEK293 cell maintenance 
All cell culture work was undertaken in a designated laboratory in HEPA filtered class 
II laminar flow containment hoods. In order to revive HEK293 cells, frozen aliquot 
was thawed to room temperature and re-suspended in cDMEM medium. Cells were 
recovered by centrifugation at 1000 xg for 3 min, the resulting pellet was re-
suspended in 20 ml of medium and cells were seeded in a T75 flask and placed in 
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the 37oC humidifying incubator with 5% CO2. To maintain a healthy adherent cell 
population, routine sub-culturing (passage) of the cell monolayer (at 80-90% 
confluency) was carried out. At this point, cells were washed with saline and were 
detached enzymatically with 1.5 ml of trypsin-EDTA, for ≤2min. Trypsin was 
inactivated by addition of 7.5 ml of cDMEM and cells were recovered by 
centrifugation (1000 xg, for 3 min). Resulting pellet was re-suspended in 10 ml of 
fresh medium and transferred into new T75 flask for further growth. The split ratio 
varied from 1:3 to 1:50, depending on the cell growth and the downstream 
application.  
 
2.2.5.2 Long term storage 
For long term storage, 90% confluent HEK293 cells were harvested from 100 mm 
Petri dish. Collected pellet was washed in saline, recovered by centrifugation and re-
suspended in cell freezing medium. Cells, divided into 3x 1 ml aliquots, were slowly 
frozen down at -80oC and stored until needed. 
 
2.2.5.3 Calcium phosphate transfection 
For large scale preparations, approximately 1.5x 106 cells were seeded in one 100 
mm Petri dish a day before transfection in order to be 60-70% confluent the following 
day. Routinely, this was achieved by allowing cells to grow until 90% confluence and 
passaging 18h before transfection at a ratio of 1:5. To generate calcium phosphate-
DNA precipitates, plasmid DNA (24 µg DNA in total per 100 mm dish) was mixed with 
60 µl od 2.5 M CaCl2 and dH2O to a total volume of 600 µl. Subsequently, it was 
added dropwise to 600 µl of 2x HBS, with continuous, vigorous vortexing. To allow 
precipitate formation, the mixture was incubated for 20 minutes at room temperature, 
before adding dropwise (1200 µl per 100 mm Petri dish) to the cell monolayer. After 
~6 h, the growth medium was changed and cells were further incubated in 37oC 
humidifying incubator with 5% CO2 for 24 h, before being harvested by trypsinisation 
and centrifugation at 1000 xg, 3 minutes. Pellets were re-suspended in saline, 
centrifuged and allowed to dry. Cell pellets were stored at -80°C. 
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2.2.5.4 TurboFect transfection 
For small scale preparations and use in ICC, 0.25 x 106 cells were seeded onto poly-
lysine coated glass coverslips (22 mm x 22 mm), and left to adhere overnight at 37°C 
with 5% CO2. On the day of transfection, cells were washed 2x with saline and 2 ml 
of serum-free DMEM was added and cells were further incubated for 3-4 h at 37°C, 
5% CO2. Following manufacturer instructions, 4 µg of recombinant DNA (in total per 
well) was diluted in 400 µl of mDMEM. Subsequently 6 µl of TurbofFect transfection 
reagent was added and mixture was immediately vigorously vortexed. Following 20 
min incubation at room temperature, mixture was added drop-wisely to the well and 
cells were incubated in 37oC humidifying incubator with 5% CO2 for 4 h. At this point 
medium was supplemented with 2.4 ml 20% FBS in DMEM and cells were further 
grown for 24 h until transgene expression analysis.  
 
2.2.5.5 Effectene transfection 
To prepare for Ca2+ imaging (Section 2.2.6), on the day of transfection, cells were 
seeded at a density of 0.7x105 cells into 35 mm glass bottom dishes (MatTek), pre-
coated with poly-L-lysine the day before seeding. The cells were maintained in 200 µl 
menisci of cDMEM for 3-4 h (to encourage adhesion) before adding 2 ml fresh growth 
medium to each well. According to the manufacturers guidelines, 0.25 µg of 
recombinant DNA (per micro well) was mixed with 2 µl of enhancer and 30 µl DNA-
condensing buffer, and incubated for 5 min (room temperature) before addition of 
6.25 µl of Effectene reagent. Following incubation for 10 min at room temperature, 
the resultant Effectene-DNA complexes were mixed with 190 µl of cDMEM and 
added directly to the cells. Cells were incubated in 37oC humidifying incubator with 
5% CO2 for 18 h and supplemented with 2 ml of fresh growth medium. Cells were 
further grown for 48 h prior to Ca2+ imaging. 
 
2.2.6 Ca2+ imaging 
Fluo-3 AM (50 µg) was dissolved in 15 µl DMSO containing 20% w/v Pluronic F-127, 
making a 3 mM stock. 5 µl of stock was added to 1500 µl mDMEM to make 10 µM 
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solution and vortexed well to dissolve. Growth medium from transfected cells was 
removed and cells were loaded with 150 µl of prepared mixture per well. Further, 
cells were incubated at 30°C with 5% CO2 for 45 min, and then de-esterified in 2 ml 
of mDMEM for 10 minutes. Image acquisition was completed on a Leica SP5 laser 
scanning confocal microscope (Leica, Heidelberg, Germany), with x63 objective lens 
and oil immersion. To visualise Ca2+ dependent Fluo-3 fluorescence, excitation was 
initiated at a wavelength of 488 nm with Argon laser and detected by a 
photomultiplier tube (PMT) set at 500-550 nm. MCherry fluorescence from co-
transfected cells was excited using HeNe 594 laser at a wavelength of 594 nm and 
collected by a PMT set at 600-650 nm.  Prior to view, the cells were immersed in a 
200 µl meniscus of KRH buffer containing 1.3 mM CaCl2 and spontaneous Ca2+ 
release events were imaged (100 msec time interval) for 3 min in total at 512 x 512 
pixel resolution. To estimate cell ER load, 10 mM caffeine was added after 2 min 30 
sec (20 µl of 100 mM caffeine stock dissolved in KRH) and recorded for further 30 
sec. A caffeine response also allowed to verify the presence of functional RyR2 
channels in non-oscillating cells since untransfected HEK cells loaded with Fluo3-AM 
did not display any SCR-like events (Jiang et al. 2002). 
Obtained traces were further exported to Microsoft Excel for off-line examination and 
analysis: for RyR2 + mCherry-FL cMyBP-C n=70 cells were analysed, RyR2 alone 
n=73, and RyR2 + mCherry n=33, from ≥8 independent experiments (n=13, 21 and 4 
outliers were determined, respectively and removed from the dataset based on 
numbers higher than 1.5x interquartile range). All subsequent statistical analysis was 
conducted using GraphPad prism using either one-way ANOVA (with Bonferroni's  
 
post-test) or the Kruskal-Wallis test (with Dunn's multiple comparisons test) (see 
Section 2.2.11). For summary of raw data  see Appendix, Figure 8.6. 
Figure 2.6 illustrates all examined parameters of the Ca2+ SCR events, as follows: 
Basal Signal Intensity: The basal signal intensity (F0) was calculated by taking an 
average of all inter-duration (i.e. baseline) fluorescence values of the single trace 
(measured in seconds). In example, F0 of trace shown in Figure 2.6 was calculated 
as F0 = [(S2 -E1) + (Sc-E2)]/2, where F0 is the basal signal intensity; S2 is the time at 
which SCR event 2 has started; E2 is the time at which SCR event 1 has finished; Sc 
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is the time at which caffeine has been applied; E2 is the time at which SCR event 2 
has finished. 
Amplitude: Subtraction (denoted as FΔ) of the mean basal signal intensity (F0) from 
peak signal intensity of each event (F), further normalized to mean basal signal 
intensity (FΔ/F0). 
Duration: Measured in seconds, the duration of each event (single oscillation, i.e. 
corresponding to F1 in Figure 2.6) was established by obtaining the difference 
between the time at which the event was initiated (S1) and the time when the signal 
intensity returns to basal levels (E1).  
Rate of Ca2+ Release: Shown as a change in the signal intensity over time 
(amplitude/duration). Firstly, the time taken to reach peak Ca2+ levels (Figure 2.6, 
green arrow) was established by subtracting the time at which the SCR-event was 
initiated (S2) from the time taken to reach peak signal intensity (F2). To obtain the rate 
at which spontaneous Ca2+ release occurred, the amplitude (FΔ/ F0) was divided by 
the calculated duration (measured in seconds). 
Figure 2.6 Illustration of the SCR kinetic parameters measured in RyR2 transfected HEK293 cells. 
A representative trace obtained from single Fluo-3 loaded HEK293 cell (in the presence of 1.3mM 
external Ca2+) is shown in pink, where the parameters assessed are indicated with appropriate 
arrows. F0 represents the basal Fluo-3 signal intensity (dashed line). The ER Ca2+ store load, was 
estimated by measuring the amplitude of caffeine-induced Ca2+ release. 
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Rate of Ca2+ Decay: Also shown as a change in the signal intensity over time 
(amplitude/duration). The time taken for the Ca2+ peak to return to F0 (Figure 2.6, 
red arrow) was first established by subtracting the time at peak signal intensity (F2) 
from the time taken for the SCR-event to return to baseline levels (E2). To obtain the 
rate at which spontaneous Ca2+ release decayed, the amplitude of the event (FΔ/ F0) 
was divided by the calculated duration (measured in seconds).  
Inter-SCR duration: Measured in seconds, the inter-SCR duration (representing the 
time period in between each event) was established by taking the time at which a 
new event occurred (i.e. S2) and subtracting from it the time at which the previous 
event ended and returned to baseline (E1). 
Frequency of events: Measured as number of events per minute, the frequency was 
determined by first adding together each event duration and the following inter-
duration (measured in seconds), and subsequently calculating the occurrence of 
these events per minute.  
ER Ca2+ load: Estimated by calculating the Ca2+ release amplitude induced by 
caffeine application (10mM, supramaximal caffeine concentration that should fully 
activate all recombinant RyRs, and therefore result in complete Ca2+ release from ER 
to the cytosol (Jiang et al. 2002)). It was obtained by subtraction (denoted as FΔ) of 
the average basal signal intensity (F0) from peak caffeine-induced signal intensity (Fc) 
further normalized to mean basal signal intensity (FΔ/F0). 
 
2.2.7 Immunocytochemistry (ICC)  
Transfected HEK293 cells growing on poly-lysine coated glass coverslips were 
washed three times in PBS solution before fixing with 4% paraformaldehyde/PBS 
solution (pH 7.4) for 10 min at room temperature. The fixed cells were washed and 
re-hydrated with 2 ml of PBS solution for 1 h before permeabilisation at room 
temperature in 0.1% v/v Triton X-100 in PBS for 30 min. The cells were further 
washed twice in PBS before blocking in 10% FBS in PBS for 1 h at room 
temperature. Primary Abs (used at 1:100 dilution in PBS) were then added as a 150 
µl meniscus, followed with 2 h incubation at room temperature. Coverslips were then 
washed three times with PBS, 5 min each with gentle rocking, and appropriate Alexa 
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fluorescent secondary Abs were added (used at 1:500 dilution), again at room 
temperature for 2 h. Following three final wash steps in PBS and dH2O, 5 min each, 
the coverslips were dried and mounted onto ethanol washed glass slides using 
mounting reagent. Control specimens were produced with the same protocol (1) 
without the use of any primary Abs or (2) without the use of any secondary Abs or (3) 
using only one primary Ab and probing with both secondary Abs. The slides were left 
to dry for 24 h at room temperature before storing at 4°C until required. To visualise 
the transfection efficiencies of recombinant RyR2 with cMyBP-C FL, the cells were 
imaged using an SP5 confocal microscope (Leica) with an oil immersion, x63 
objective lens. The HEK293 cell expressing RyR2 and cMyBP-C were counted using 
LEICA software and obtained values were further normalized towards the total 
number of all cells present in selected field of view, represented as % transfection 
efficiency (see Appendix, Figure 8.2). 
 
2.2.8 3D co-localisation analysis 
Confocal images were acquired using a confocal Leica SP5 microscope (Leica, 
Heidelberg, Germany), with an oil immersion, x63 objective lens, and excitation 
lasers at 488 nm (PMT set at 500-550 nm) and 594 nm (PMT set at 600-700 nm). 
HEK293 with weakly fluorescent proteins were selected for analysis, to minimize any 
possible deleterious effect of RyR2 protein overexpression on the morphology and 
function of transfected cells.  Based on 2D intensity histograms generated form single 
primary and both secondary Abs labelled control specimens, the range of settings for 
acquiring images were adjusted to fall within the response range of the system and to 
minimise the spectral cross-talk between channel 1 (Alexa 488) and channel 2 (Alexa 
594).  In selected settings, non-specific fluorescence from single-primary Ab controls 
generally accounted for <10% of mean fluorescent intensity, and autofluorescence 
levels in only-secondary Ab controls measured <5% of mean fluorescent intensity. All 
confocal images of the cells were acquired with 0.5 µm z-spacing and stored in 8-bit 
format for offline processing. 
Next, using Leica Microsystems LAS-AF software, the threshold intensity values were 
defined for each cell, considering every singular layer of stack separately to 
discriminate between signal and background, with minimum of 40 grey levels signal 
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threshold used for each channel (being equal to calculated non-specific signal, ~15% 
of mean fluorescent intensity). Except of adjustment of intensities to the full dynamic 
range, no further image processing was applied. Obtained thresholds were 
subsequently applied to imported z-stacks in IMARIS (Bitplane) for image analysis. 
The Coloc module of IMARIS was used to calculate and generate a new channel 
corresponding to the co-localised voxels (3D pixel volumes). Pearson’s correlation 
coefficient of whole acquired field of view was calculated to describe the correlation 
of the intensity distribution between the two thresholded channel intensities being 
tested. To test for random voxel distribution, scrambled z-stack images were 
generated in IMARIS by (1) turning the channel 2 image by 90o versus channel 1 and 
(2) 3D shifting of 100 voxels the channel 2 in x-y plane and 5 voxels in z-plane, thus 
creating random voxel distribution with equal number of voxels and intensities. 40 
new images were created in this way, 20% of the all images analysed (total of 224 z-
stack images used in the co-localisation analysis). The images to be scrambled (10 
z-stack images) were selected randomly form the original 184 z-stacks. The 
observed correlation between channel 1 and channel 2 were considered significant if 
they were greater than 95% of the correlation between channel 1 and scrambled 
channel 2 (p ≤ 0.05). The statistical differences between the co-localisation results 
and scrambled images were calculated using unpaired, 2-tailed Student’s t-test. In 
order to normalize the obtained % overlap to the cell volume, in Leica LAS-AF 
software, ROI was selected (representing the 2D area of cell at the maximum 
projection) and total number of 3D pixel intensities (0-255 grey levels) for each 
channel was calculated by multiplying by the number of z-stacks acquired for the 
given cell. These values were plotted versus number of total co-localised voxels from 
IMARIS to test for relationship between each channel pixel intensity values and 
number of co-localised voxels, Pearson’s correlation coefficient was also calculated 
to assess the degree of correlation.  
 
2.2.9 [3H]ryanodine binding 
[3H]ryanodine binding assay was performed on cell homogenates obtained from 
HEK293 cells expressing recombinant RyR2 with or without full length (FL construct) 
cMyBP-C (prepared in triplicate). Prior to the assay, in order to have equal amounts 
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of RyR2 protein in both samples expressing RyR2 alone versus RyR2 + cMyBP-C 
(n=3, prepared in pairs on three different days), RyR2 amounts were initially 
determined by WB and quantified by densitometry; they were subsequently evaluated 
by [3H]ryanodine binding assay performed in the presence of 100 µM free Ca2+ and 
10 mM caffeine (conditions promoting maximum channel activation and thus allowing 
to measure the total RyR2 content). The quantity of used homogenates was adjusted 
as required to have equal RyR2 content, and any discrepancies in total protein 
content were standardized to 600 µg of total protein with homogenate from 
untransfected HEK293 cells. For comparison of the general expression levels 
achieved using recombinant protein, 200 µg of pig cardiac SR was processed in 
parallel in the same assay as positive control, where it could be guaranteed that high 
RyR2 amounts are present.  
Each reaction contained 600 µg of total protein and 8 nM [3H]ryanodine and was 
prepared to a final volume of 500 µl using ryanodine binding buffer (containing the 
desired free Ca2+ concentration). Free Ca2+ content was calculated using 
MaxChelator software (http://maxchelator.stanford.edu./). For maximum channel 
activation, experiments were performed in the presence of 100 µM free Ca2+ and 10 
mM caffeine.  For estimation of channel activation at specific Ca2+ concentration, six 
Ca2+ concentration points were used: 100 nM, 250 nM, 500 nM, 1 µM, 5 µM and 100 
µM. For estimation of non-specific binding, control samples were prepared (in 
duplicate) with 10 µM of ‘cold’ (non-radiolabelled) ryanodine. Following thorough 
mixing, all samples were incubated in a water bath at 37°C for 2h.  Subsequently, 5 
ml of ryanodine binding buffer was added to each sample and reactions were filtered 
through pre-soaked glass fibre filters and washed once with another 5 ml of 
ryanodine binding buffer, all under vacuum suction conditions. Each filter was placed 
into a scintillation vial and fully submerged in 5 ml of scintillation liquid. All samples 
were mixed and incubated overnight at room temperature, followed by the 
measurement of decays per minute (DCM) over a period of 2 min using Packard (Tri-
Carb 2900TR) liquid scintillation analyzer. Analysis was performed in at least three 
separate biological samples each in technical replicates (n≥3) for each given Ca2+ 
concertation. 
Subtraction of the non-specific counts obtained in control samples (in the presence of 
excess unlabelled ryanodine) from the total counts from the test samples was used to 
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calculate specific [3H] ryanodine binding (n=3 for specific and n=2 for non-specific for 
each tested point). The statistical difference between the cumulative RyR2 alone 
versus RyR2 + cMyBP-C activation results (n≥15 for each calcium point, after n=6 
and n=7 outliers in total were removed, respectively, based on the values higher than 
1.5x interquartile range) were calculated using unpaired, 2-tailed Student’s t-test, with 
dose-response curves fitted with GraphPad Prism using a non-linear regression, four-
parameter sigmoidal model with bottom constrained to 0. The two generated models 
(with or without cMyBP-C) were statistically assessed using the extra-sum of squares 
F test (GraphPad Prism). For summary of raw data analysis see Appendix, Figure 
8.7. 
 
2.2.10 Densitometry analysis 
All image processing and densitometry analysis of Western blots were carried out 
using Quantity-one (Bio-Rad) software. First, background density of the X-ray film 
was subtracted from the density of the bands of interest. Subsequently, in order to 
correct for the potential differences in the expression level of input protein, optical 
density values obtained for co-immunoprecipitated proteins were normalised against 
the background and the amount of the input protein in the lysate (corresponding to 
1/200th of the lysate volume processed in the co-IP sample). Statistical analysis was 
carried out using paired, 2-tailed Student’s t-test (see Section 2.2.11) for specific co-
precipitated protein and negative co-IP (non-specific) control. Comparison across the 
relative specific binding (calculated as the specific binding subtracted of the non-
specific binding) of group of interest was assessed using either ANOVA or Kruskal-
Wallis test (see Section 2.2.11). 
 
2.2.11 Computer analysis and software 
Microsoft Excel was used to store numerical data, while graph plotting (data 
expressed ±SD, standard deviation), fitting of sigmoidal curves and statistical 
analyses were carried out using GraphPad Prism (GraphPad Software Inc). Data 
were first subjected to Brown-Forsythe test for equality of group variances, and 
populations with equal variance (no significantly different standard deviations, 
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p<0.05) were analysed using parametric tests: either Student’s t-test (to determine if 
two sets of data are significantly different from each other) or ANOVA (with 
Bonferroni’s post-test for multiple group comparison). For non-parametric data, 
Kruskal-Wallis test (with Dunn’s post-test) was used instead of ANOVA. PyMOL 
(Molecular Graphic System) was used for protein structure visualisation and 
presentation, while remaining figures were prepared using Microsoft Power Point.  
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3 Assessment of cMyBP-C as a potential binding 
partner for RyR2 
 
3.1 Introduction 
Up until recently, the possibility of direct link between cMyBP-C and Ca2+ regulation 
of cardiac contraction has not been investigated due to lack of biochemical evidence 
linking cMyBP-C with a Ca2+ signalling protein. The work of (Lu et al. 2012) combined 
fluorescence, NMR, and light and X-ray scattering to propose for the first time that 
cMyBP-C can participate in Ca2+ signalling pathways, evident via Ca2+ dependent 
interaction of the M-domain with calmodulin. This potentially could have 
consequences for synchronizing events between cMyBP-C and its binding partners 
during heart muscle contraction. Also, the recent data from two independent labs 
have suggested that phosphorylation of cMyBP-C may result in the formation of a 
calcium-binding motif within the M-domain (Colson et al. 2016; Previs et al. 2016), 
which previously has been proposed as a low affinity zinc binding site (Ababou et al. 
2008), suggesting that phosphorylation and Ca2+ may antagonistically tune cMyBP-C 
function. Further, a new model of calcium activation of contraction has been 
proposed in which cMyBP-C, based on its the location in the C-zone, corrects the 
inhomogeneity in RyR2 released Ca2+ gradient across the sarcomere by sensitizing 
the contractile apparatus to calcium to ensure uniform force development across the 
sarcomere (Previs et al. 2015). In addition, in cMyBP-C KO models, impaired 
relaxation and altered Ca2+ transients have been reported (Song et al. 2003; Brickson 
et al. 2007; Pohlmann et al. 2007). Thus, cMyBP-C emerges as a multifaceted 
signaling node in cardiac myocytes that contributes to the maintenance of sarcomeric 
structure and regulation of systolic and diastolic function, with its precise role in 
relation to Ca2+ homeostasis yet to be determined. 
Unpublished findings from our laboratory imply that cMyBP-C functionality might not 
be restricted exclusively to modulation of sarcomere cross-bridge kinetics, but is also 
relevant to the Ca2+ signalling toolkit, in particular to RyR2, the calcium release 
channel. This hypothesis is based on pilot data from Y2H and GST-pull down binding 
assays, where positive interaction was detected between truncated fragments of the 
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human cMyBP-C C-terminus (817-1273 amino acids, CT) and the RyR2 N-terminus 
(1-906 amino acids, BT4L). Further analysis by co-IP assays indicated that the same 
synthetic cMyBP-C CT construct is capable of interaction with native RyR2 from 
solubilised cardiac SR vesicles (Zissimopoulos, unpublished data). Those preliminary 
results were the foundation of further investigation of putative cMyBP-C:RyR2 binding 
presented in this work. Since the originally detected interaction was observed 
between recombinant proteins/truncated fragments expressed in bacteria, yeast or 
cell-free systems (TNT, rabbit reticulocyte lysate), question remained whether the 
detected binding can be reproduced with the native and/or recombinant full-length 
proteins in a more physiological context.  
The co-IP assay is a well-established method which involves the isolation of the 
native or recombinant protein of interest out of complex sample mixtures i.e. cell 
lysates, serum or tissue homogenates (Elion 2007; Kaboord and Perr 2008). An 
important consideration for co-IP assay is the choice and concentration of detergent 
to be included: higher concentrations and/or stronger detergents will substantially 
reduce non-specific binding but may also abolish protein-protein interaction, whereas 
lower concentrations and/or milder detergents may allow a weak interaction to be 
observed but could result in excessive non-specific binding. For this reason, in our 
experiments we used an intermediate strength detergent CHAPS at 0.5-1% 
concentration. Several optimizing approaches were employed to further reduce non-
specific binding: (1) increase the number and/or duration of washes, and/or (2) use a 
neutral protein (e.g. bovine serum albumin, BSA) in the IP buffer to block non-specific 
binding sites, and/or (3) preclear the cellular lysate prior to incubation with protein-A 
resin alone, and/or (4) increase/reduce the salt content and/or detergent 
concentration in the IP buffer (Chi et al. 2003; Yang et al. 2008).  In our experimental 
setting, the co-IP technique was used with the intention to determine the binding 
between the native proteins from animal heart tissue preparations, and once scored 
as positive, it was also used with recombinant human proteins, following co-
expression in a heterologous mammalian system. 
The benefits of using a mammalian cell line for protein expression are significant, 
since conformation, post-translational modifications and subcellular localization are 
likely to be similar to the native protein (Thomas and Smart 2005). Cloned RyRs have 
been heterologously expressed in various cell lines including CHO, COS-1 and 
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HEK293, with the latter being the most commonly used RyR2-deficient cell line 
(Takeshima et al. 1989; Chen et al. 1997; Du et al. 1998), for studies of recombinant, 
WT and mutant RyR2 function (Li and Chen 2001; Thomas et al. 2004; Jiang et al. 
2005).  HEK293 was generated by transfection of adenovirus DNA into normal 
human embryonic kidney cells (Graham et al. 1977) and despite epithelial in origin, 
the cells’ biochemical machinery is able to reproducibly express large-scale, 
functional, recombinant proteins. The ability to efficiently express the protein of 
interest in a transient fashion in HEK293 cells by introduction of plasmid containing 
the cDNA for the protein of interest, depends on the selected transfection technique. 
One of the most widely used, and employed routinely in this study, is the calcium 
phosphate precipitation, based on spontaneous salt precipitation that occurs in 
supersaturated solutions (Jordan and Wurm 2004). The Co-IP assay using both 
native cardiac tissue and following transient expression in a HEK293 has been used 
extensively by the Lai laboratory i.e. to investigate oligomerization properties of RyR 
channel (Zissimopoulos et al. 2013; Zissimopoulos et al. 2014; Seidel et al. 2015) 
and to assess FKBP:RyR2 binding (Zissimopoulos and Lai 2005; Zissimopoulos et al. 
2007; Zissimopoulos et al. 2012). 
Since the DNA plasmids encoding cMyBP-C and RyR2 used in this study were both 
of human origin, the transfection efficiency of co-expressed proteins and their 
intracellular trafficking were assessed by immunocytochemistry experiments. 
However, observed severe changes in cell morphology induced by calcium 
phosphate transfection proved this approach to be unsuitable for co-localisation 
study. Instead, the commercial cationic polymer-based reagent TurboFect was used 
for small scale protein expression. The polymer forms positively-charged complexes 
with plasmid DNA that are both compact and stable. These complexes protect the 
DNA from degradation and facilitate efficient plasmid delivery into the cell, without 
any evident cytotoxic effect (Jordan and Wurm 2004; Thomas and Smart 2005).  
Immunocytochemistry co-localisation analysis is often used to support the claim that 
two molecules are potential binding partners based on detection of their respective 
fluorescent signals in a very close physical location within the intact cell. The most 
common approach to co-localisation relies on 2D colour-coded pixel overlap, despite 
the fact that its scientific applicability is known to be frequently misleading (as it can 
be perceived differently by the eye). Therefore, the method applied in this study 
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evaluates 3D co-localisation by objectively determining its quantitative characteristics 
(Pompey et al. 2013). Because it is conducted in three dimensions, observation of 
repeated coincidence of the two fluorescent probes in multiple regions throughout the 
cell volume increases the confidence that the two proteins occupy the same structure 
(Dunn et al. 2011). However, given that the optical resolution of confocal microscopy 
is <250 nm, these data should be only seen as support for our in vitro Co-IP results, 
rather than stand-alone evidence for protein-protein interactions occurring within 
atomic distance, as there may still be sufficient separation between molecules to 
prevent their binding. Another problem with confocal images analysis is the presence 
of considerable background fluorescence and/or auto-fluorescence levels (up to 30% 
maximum intensity), thus images of double-stained sections (with appropriate 
fluorescently-labelled Abs) must always be subjected to background correction prior 
to quantitative analysis to obtain reliable results. It includes the adjustment of all 
photomultiplier tubes to their respective channel intensities followed by the imaging of 
single-labelled control specimens. This allows to estimate a threshold value suitable 
for processing of double-labelled z-stack images, which corresponds to background 
and unspecific primary/secondary Abs binding captured by the confocal microscopy 
(Landmann and Marbet 2004).  
The conducted mathematical investigation presented here utilizes microscopy image 
analysis software IMARIS, that calculates a percentage of fluorescent signal overlap 
together with Pearson’s correlation coefficient (PCC) to quantify the degree of co-
localisation occurring between two fluorophores. PCC is a standard statistical 
measure widely used in image correlation analysis and introduced to fluorescence 
microscopy by (Manders et al. 1993). It measures the intensity correlation based on 
voxel-by-voxel (voxel being the reconstructed 3D pixel volume) covariance in the 
signal levels of two images, which can give a PCC value between -1 and 1 (1 being 
perfect co-localisation, 0 random co-localisation, -1 anti-co-localisation). Because 
PCC subtracts the mean intensity from each individual voxel, it is independent of 
signal intensity levels and signal offset (background). Therefore, it can be measured 
in double-labelled images without any form of pre-processing, making it both simple 
and relatively safe from user bias. The square of PCC (denoted as r2), also known as 
the ‘coefficient of determination’ was also used to aid the correlation analysis. It is a 
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statistic that estimates the % fraction of variability in X that can be explained by its 
linear regression with Y (Adler and Parmryd 2010).  
 
3.2 Chapter objectives 
The current hypothesis tested in this study is that cMyBP-C C is capable of 
interaction with the SR-located RyR2 Ca2+ release channel. RyR2:cMyBP-C 
association could be physiologically relevant since cMyBP-C is known to dissociate 
form the sarcomere in its dephosphorylated form (Section 1.3.4.1), allowing cytosolic 
cMyBP-C to target RyR2. Therefore, cMyBP-C could provide a novel modulatory link 
between cardiac muscle contraction and SR Ca2+ release. The aim of this Chapter 
was to assess the sub-cellular cMyBP-C localisation and to biochemically test the 
putative cMyBP-C interaction with RyR2. Specifically, the following points will be 
discussed: 
 the presence of cMyBP-C in sub-cellular fractions from animal cardiac tissue by 
Western blot analysis; 
 detection of binding between the endogenous cMyBP-C and RyR2 proteins form 
animal cardiac tissue using the co-IP assay; 
 verification of interaction between the full-length human recombinant proteins 
using the co-IP and ICC/3D co-localisation assays; 
 assessment of initial findings that N-terminal region of RyR2 is responsible for 
cMyBP-C C-terminus binding using the co-IP assay. 
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3.3 Methods 
 
3.3.1 cMyBP-C immunoblotting from different animal cardiac subcellular 
fractions 
All animal cardiac tissue fraction samples were obtained from Dr S. Zissimopoulos 
(prepared as described previously by (Zissimopoulos et al. 2012)). Briefly, 200 g from 
one pig heart, 2 g from 16 mouse adult hearts (C57BL6/J), 2.5 g from three adult rat 
hearts (Wistar), 4 g from one adult rabbit heart (New Zealand white) were processed 
and ventricle muscle was homogenised in four volumes of homogenisation buffer (10 
mM Na2PIPES, 0.3 M sucrose, and protease inhibitors: 2 mM benzamidine, 0.2 mM 
AEBSF and 10 mM leupeptin, pH adjusted to 7.4) with the use of a blender. The 
obtained homogenate was centrifuged 100,000 xg for 1 h and collected supernatant 
represented the cytosolic fraction. Further, remaining pellet was re-homogenised in 
two volumes of homogenisation buffer and the SR fraction was prepared by sucrose 
density gradient centrifugation (collected at 30%–40% sucrose interface). 
10% SDS-PAGE gels were made (Section 2.2.2.4) and 25 µl aliquots consisting of 
50 µg of the homogenate/cytosol/SR from appropriate animal fractions were 
prepared with 5x reducing protein loading buffer and dH2O. Subsequently, samples 
were loaded as follows: (1) pig, (2) guinea pig (G/P), (3) rat, (4) rabbit and (5) mouse. 
Following protein separation and transfer, immunoblotting analysis was carried out 
(Section 2.2.2.5) using cMyBP-C N-terminal and C-terminal specific antibodies (Ab 
N-t and C-t, respectively, see Section 2.1.11). Secondary anti-mouse and anti-goat 
HRP-conjugated Abs were used for protein visualisation using enhanced 
chemiluminescence detection. 
 
3.3.2 Co-immunoprecipitation of endogenous cardiac proteins 
Co-IP of native RyR2 and cMyBP-C from pig and rabbit cardiac muscle homogenates 
was performed using a diverse set of experimental conditions aiming to optimise the 
final result. For details of each experimental setting please refer to Table 3.1. The 
optimised version (experiment 6) was performed as follows: 8 mg pig cardiac 
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homogenate was solubilised overnight with 0.5 % CHAPS and 100 µg/ml BSA in total 
volume of 1 ml. Concurrently, four 25 μl aliquots of pre-washed Protein A beads 
(supplemented with 100 µg/ml BSA) were incubated overnight with 10 µl of RyR2 
specific Ab or 5 µl of non-immune Ab (2 µg each, Ab 1093 or normal rabbit IgG, 
respectively, see Section 2.1.11). The next day the insoluble material was removed 
by centrifugation at 20.000 xg for 10 min at 4oC and the supernatant fraction was 
collected. 200 µl of pig lysate was incubated with beads-Ab complexes (~2 mg of 
lysate per IP sample) for 3 h and washed 2x for 10 min with BSA-supplemented IP 
buffer (Section 2.2.2.3). Precipitated proteins were eluted with 5x reducing protein 
loading buffer and stored at -20oC. The next day, samples were separated through 
6% SDS-PAGE gels (Section 2.2.2.4) and subsequently the presence of co-
precipitated native cMyBP-C (6 % gel) was tested by WB analysis (Section 2.2.2.5) 
using cMyBP-C Ab N-t or C-t (Section 2.1.11). In parallel experiments, successful 
precipitation of RyR2 was confirmed by immunoblotting with Ab 1093 (4%/0.5% 
agarose gel). Aliquots of lysate were also included in the gels to serve as molecular 
mass standard. The level of co-precipitated proteins was quantified by densitometry 
(Section 2.2.10) and statistical analysis was analysis conducted using GraphPad 
Prism (Section 2.2.11).  
 
Table 3.1 A summary of experimental conditions undertaken in the immunoprecipitation of RyR2 and 
detection of cMyBP-C. 
Exp. Matrix Protein 
precipitated 
Amount of 
homogenate 
used per IP 
sample 
IP buffer Pre-
clearing 
steps 
Ab Final 
washing 
steps 
1 Protein 
A 
beads 
RyR2 1 mg 150 mM NaCl, 20 
mM Tris, 0.5% 
(w/v) CHAPS 
n/a 1093 
(2 µg) 
2 x, 10 
min  
2 As 
above 
As above As above 20 mM NaCl, 20 
mM Tris, 0.5% 
(w/v) CHAPS 
n/a As 
above 
2 x, 15 
min  
3 As 
above 
As above As above 150 mM NaCl, 20 
mM Tris, 1% (w/v) 
CHAPS 
n/a As 
above 
2 x, 15 
min  
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4 As 
above 
As above As above 150 mM NaCl, 20 
mM Tris, 0.5% 
(w/v) CHAPS, 2 
mM DTT 
n/a As 
above 
3 x, 10 
min  
5 As 
above 
As above As above 150 mM NaCl, 20 
mM Tris, 0.5% 
(w/v) CHAPS 100 
µg/ml BSA 
IP buffer  As 
above 
2 x, 15 
min 
6 As 
above 
As above 2 mg 150 mM NaCl, 20 
mM Tris, 0.5% 
(w/v) CHAPS 100 
µg/ml BSA 
IP buffer  As 
above 
3 x,10 
min  
 
Reciprocal co-IP experiments (direct precipitation of cMyBP-C and co-precipitation of 
RyR2) with use of Protein G beads and Ab C-t were unsuccessful as the Ab C-t 
proved to be not suitable for co-IP experiments, i.e. it did not precipitate cMyBP-C. 
Further, cMyBP-C precipitation with Ab N-t were also carried out, but despite 
significant amounts of cMyBP-C being precipitated, robust co-precipitated RyR2 band 
could not be detected (see Section 3.4.2). The same range of different experimental 
conditions (Table 3.1) were used in attempts to co-immunoprecipitate cMyBP-C from 
rabbit cardiac homogenate (2 mg per IP sample), and also from pig SR fraction 
(200µg per IP sample), however these proved also to be unsuccessful (see Section 
3.4.2). It should be noted that while Ab N-t has been previously used by other labs in 
ICC (Barefield et al. 2014) and WB analysis of native cMyBP-C (Govindan et al. 
2012; Barefield et al. 2014), Ab C-t has not been validated and was recommended 
only for cMyBP-C WB analysis (according to manufacturer’s guidelines), thus might 
explain the unsuccessful outcome of aforementioned native co-IP experiments with 
Ab C-t.   
 
3.3.3 Generation of HA-tagged full length (FL) cMyBP-C construct 
PCR amplification (Section 2.2.1.1) was used to generate the full length cMyBP-C 
coding sequence (33-3857 (b)) from a human cardiac muscle cDNA library using 
forward and reverse primers (HcMyBPC.FOR.27-56 and HcMyBPC.REV.3849-76, 
respectively, Table 2.1) designed to the human cMyBP-C cDNA (accession number: 
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X84075). Obtained product was cloned into HA-modified pCR3 vector and used for 
large scale plasmid isolation (for details, see Sections 2.2.1.2-2.2.1.4, and 2.2.3.1-
2). 
 
3.3.4 Generation of the truncated HA-tagged N-terminal (NT) cMyBP-C 
construct 
The NT cMyBP-C DNA fragment was obtained by PCR using previously made FL 
cMyBP-C construct as a template using appropriate forward and reverse primer 
(HcMyBPC.FOR.27-56 and HcMyBPC.REV.2611-30, respectively, Table 2.1). 
Obtained product was cloned into HA-modified pCR3 vector and used for large scale 
plasmid isolation (for details, see Sections 2.2.1.2-2.2.1.4, and 2.2.3.1-2). 
 
3.3.5 ICC and 3D co-localisation analysis 
HEK293 cells were co-transfected using TurboFect transfection reagent with RyR2 
and cMyBP-C FL plasmids (Section 2.2.5.4). Transfected cells were ICC processed 
(Section 2.2.7) and probed with RyR2 1093 and cMyBP-C N-t primary Abs together 
with Alexa Fluor 488 and 594 labelled secondary Abs (Section 2.2.11), and 3D co-
localisation analysis was performed as described in detail in Section 2.2.8. 
 
3.3.6 Co-immunoprecipitation of recombinant human proteins 
 
3.3.6.1 Recombinant full-length proteins 
To assess the interaction between the recombinant human RyR2 and cMyBP-C, 
HEK293 cells were co-transfected using calcium phosphate transfection (Section 
2.2.5.3) with the two plasmid constructs: RyR2 and the cMyBP-C HA-tagged FL (at 
3:1 molar ratio, with 24 µg DNA in total per dish). Co-immunoprecipitation was 
performed as described in Section 2.2.2.3. RyR2 specific antibody or non-immune 
Ab (rabbit polyclonal Ab 1093 and normal rabbit IgG, see Section 2.2.11) were used 
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to immunoprecipitate RyR2 (Section 2.2.2.3) and tested by Western Blot analysis 
(Section 2.2.2.5) using mouse monoclonal HA antibody (Ab HA, see Section 
2.2.11). In parallel experiments, successful precipitation of RyR2 was confirmed by 
WB analysis with RyR2 specific mouse monoclonal antibody P12 (Section 2.2.11). 
The level of co-precipitated proteins was determined by densitometry (Section 
2.2.10) and statistical analysis was analysis conducted using GraphPad Prism 
(Section 2.2.11). 
Reciprocal co-IP experiments with direct precipitation of cMyBP-C FL (with Ab HA) 
were also attempted, but in those we failed to detect significant co-precipitated RyR2 
amounts (immunoblotting with Ab 1093) (see Section 3.4.4), similarly to previously 
attempted native reciprocal co-IP experiments (Section 3.3.2).  
 
3.3.6.2 Recombinant truncated protein fragments 
To assess the interaction between recombinant human RyR2 constructs (c-Myc-
tagged BT4L or BT7) and the HA-tagged cMyBP-C constructs (NT, FL or CT), 
HEK293 were co-transfected using calcium phosphate transfection (Section 2.2.5.3) 
with the RyR2:cMyBP-C pair of interest (at approximate 1:1 molar ratio, with 24 µg 
DNA in total per dish). Co-immunoprecipitation was performed as described in 
Section 2.2.2.3. Rabbit polyclonal HA antibody (Section 2.2.11) and protein A 
Sepharose beads were used to immunoprecipitate the cMyBP-C protein fragment, 
while the mouse monoclonal c-Myc Ab (Section 2.2.11) was used in WB to detect 
the presence of co-precipitated RyR2 protein fragment and assessed by 
densitometry (Section 2.2.10) and statistical analysis was analysis conducted using 
GraphPad Prism (Section 2.2.11). 
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3.4 Results 
 
3.4.1 Native cMyBP-C can be detected in pig, guinea pig and rabbit 
cardiac fractions with both cMyBP-C antibodies. 
Cardiac fraction preparations from 5 different animal species were used to screen for 
cMyBP-C expression in order to assess its presence in the homogenate and cytosolic 
and SR compartments. Since the coding sequence for extreme N-terminus and C-
terminus of cMyBP-C appears to be highly conserved amongst the different 
mammalian isoforms (for homology comparison of each region see Appendix, 
Figure 8.1), it was expected that both Ab N-t (raised against the N-terminus of 
cMyBP-C of human origin, amino acids 1-120) and Ab C-t (raised against 
recombinant mouse cMyBP-C, amino acids 988-1100) would detect cMyBP-C in all 
animal samples tested. The predicted size of a band corresponding to the wild type 
cMyBP-C for all species is ~140 kDa. As shown in Figure 3.1, panel A, cMyBP-C 
was successfully detected following immunoblotting (n=3) with the N-t Ab from pig 
and rabbit homogenates equally well, while in lesser extent from guinea pig (G/P) 
and with the weakest signal for mouse and rat homogenates. The C-t Ab was able to 
detect cMyBP-C from all tested homogenates (Figure 3.1, panel B), with somewhat 
weaker signal for guinea pig, probably due to general lower abundance of cMyBP-C 
in this species, in line with N-t Ab immunoblotting results. Overall, highest expression 
for full-length cMyBP-C was observed in pig and rabbit obtained with both N-t and C-t 
Abs. The N-t Ab was found to cross-react with additional lower molecular mass 
protein bands, especially in rat and mouse, whereas the C-t Ab was very specific for 
cMyBP-C irrespective of species. In the case of pig, additional bands were present at 
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30 and 40 kDa when probed with N-t Ab (Figure 3.1, panel A1), probably due to 
cMyBP-C degradation products and/or Ab non-specificity. 
In terms of cMyBP-C presence in the cytosol, rather surprisingly, both N-t and C-t 
Abs detected the ~140 kDa band corresponding to full-length cMyBP-C in all five 
species tested. The amount of cMyBP-C detected in the cytosolic fraction, which was 
prepared by ultra-centrifugation at 100,000 xg for 1 h to pellet microsomal 
membranes and contractile sarcomeric components, was in fact equivalent to that 
seen in whole cell homogenate. This suggests that cMyBP-C is normally found in the 
cytosol or it easily dissociated from the sarcomere (i.e. during this preparation). The 
results obtained for cMyBP-C presence in the SR were species dependent, but there 
was a general agreement between N-t and C-t Abs. High levels of full-length cMyBP-
C (~140 kDa band) was detected in pig SR WB, whereas its levels in mouse and rat 
cardiac SR were negligible. In particular, cMyBP-C levels found in the five species 
tested were in the following order: pig >> guinea-pig > rabbit > mouse ≈ rat. The SR 
was prepared by sucrose density gradient centrifugation of microsomal membranes, 
Figure 3.1 Representative blots of cMyBP-C distribution in different animal subcellular fractions. 
50 µg of homogenate, cytosol and SR fraction per each lane was loaded onto 10% SDS-PAGE 
gels and probed using Ab N-t (A, upper panel) or Ab C-t (B, lower pane) (n=3 for all tested 
samples). The following animal cardiac tissues were used (columns from left to right): (1) pig, (2) 
guinea pig (G/P), (3) rat, (4) rabbit and (5) mouse. Band of ~140 kDa corresponding to full-length 
cMyBP-C was detected in all animal fractions (red arrows), except of rat and mouse SR N-t Ab 
WB.  
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however contamination by contractile sarcomeric components cannot be excluded. 
Nonetheless, the presence of cMyBP-C in the SR, where RyR2 is located, could 
enable the interaction between the two proteins. Based on the obtained results, it 
was decided to proceed for in vitro co-IP experiments with pig and rabbit cardiac 
muscle homogenates, as they scored for the highest cMyBP-C detection using both 
antibodies. 
 
3.4.2 Endogenous cardiac cMyBP-C and RyR2 are capable of in vitro 
interaction 
To determine the physiological relevance of the RyR2:cMyBP-C association, co-IP 
experiments were performed using pig or rabbit cardiac muscle homogenates. RyR2 
was immunoprecipitated with 1093 Ab and the presence of co-precipitated cMyBP-C 
was analysed by WB using C-t Ab. Due to low expression levels of RyR2 and 
difficulty of purification compared to skeletal muscle RyR1 preparations (Lanner et al. 
2010), the task of obtaining sufficient quantities of native RyR2 by direct 
immunoprecipitation proved difficult. At the same time, there were problems with high 
non-specific binding for cMyBP-C. To overcome these issues, several optimising 
steps were taken, detailed in Table 3.1. Best results were obtained when the amount 
of pig homogenate used was increased two fold (from 1 mg to 2 mg). RyR2 
immunoprecipitation was performed in the presence of BSA and with introduction of 
Protein A beads pre-clearing steps. This optimised protocol (Table 3.1; experiment 
6) allowed for a successful direct immunoprecipitation of RyR2 and cMyBP-C co-
precipitation (560 kDa and 140 kDa immunoreactive bands, respectively). We could 
not obtain significant detection of cMyBP-C with N-t Ab for WB, due to the lower 
sensitivity of this Ab compared to C-t Ab (see Figure 3.1). 
Representative pig homogenate blots are shown in Figure 3.2. By applying the 
optimised conditions, cMyBP-C (~140 kDa) was successfully recovered from RyR2 
IP following WB with C-t Ab (Figure 3.2 A, 2nd lane) but not in the negative control 
using non-immune rabbit IgG (3rd lane). As shown in Figure 3.2 B, a control WB for 
RyR2 detection, low amounts of RyR2 were directly precipitated in the Ab 1093 IP 
(2nd lane) as expected, with no detectable non-specific binding (3rd lane). Co-
precipitated cMyBP-C protein band was considerably less intense than that of input 
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lysate (1st lane for both A and B), indicating weak RyR2:cMyBP-C interaction. 
Quantitative analysis (n=7) by densitometry (Figure 3.2 C) shows that the observed 
difference (approximately 20% higher) between specific and non-specific binding was 
statistically significant (p≤0.05, compared using paired, 2-tailed Student’s t-test, n=7), 
indicating that native pig RyR2 is capable of cMyBP-C interaction.  
Unfortunately, reciprocal co-IP experiments i.e. direct precipitation of cMyBP-C and 
testing for RyR2, failed to detect RyR2. The reason was simple in the case of the C-t 
Ab, since this Ab could not directly immunoprecipitate cMyBP-C, but not obvious in 
the case of N-t Ab, which resulted in reasonably high amounts of cMyBP-C being 
precipitated. The most likely explanation is that cMyBP-C exists in a large 
cytoplasmic pool (see Figure 3.1) and only a small proportion of it is associated with 
RyR2 in the SR compartment. Therefore, when immunoprecipitating cMyBP-C first, 
the RyR2-bound proportion is further diluted and co-precipitated RyR2 may be 
beyond the levels of WB detection. Further, despite several attempts with different 
experimental conditions, obtaining meaningful co-precipitation of cMyBP-C in direct 
RyR2 IP from rabbit homogenate was not possible due to much higher amounts of 
observed non-specific binding in this species compared to pig.  
In order to improve the signal of co-precipitated cMyBP-C in direct RyR2 IP from pig, 
it was speculated that co-IP experiments using the SR fraction would help. The 
reasoning was that the increased concertation of RyR2 in the SR compared to whole 
cell homogenate will enable higher amounts of cMyBP-C being co-precipitated, 
especially from pig SR found to have the highest amount of detected cMyBP-C 
(Figure 3.1). Contrary to expectations, cMyBP-C and RyR2 exhibited only occasional 
binding which failed to reach statistical significance (n=3), possibly because of lower 
cMyBP-C abundance in the SR fraction compared to homogenate, which might alter 
the native RyR2:cMyBP-C interaction and accelerate dissociation rates. As the rate 
of the binding is proportional to the concentrations of the reactants, at equilibrium, the 
rate of RyR2:cMyBP-C complex formation is equal to the rate of dissociation into its 
single components. Thus, higher RyR2 availability is SR sample, without 
simultaneous increase in concentration of cMyBP-C, will not result in greater 
propensity of the complexes formation, but rather a lower binding will be observed 
due to lower amount of cMyBP-C available for the interaction. Due to this  
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Figure 3.2 Representative blots of Co-IP and WB results illustrating native RyR2:cMyBP-C 
interaction and cumulative densitometry analysis. (A-B) RyR2 was immunoprecipitated from 
cardiac pig homogenate (2 mg per IP lane) and the presence of associated native cMyBP-C were 
analysed (A: 6% gel). The loading controls represent 1/200th and 1/10th of the processed sample 
for (A) and (B), respectively. The intense dark bands at ~100 kDa and ~50kDa of the blot in panel 
A are the IgG heavy chains of the immunoprecipitating Ab1093. In parallel experiment, the 
presence of directly precipitated RyR2 was also analysed (B: 4%/0.5% gel). Bands corresponding 
to native cMyBP-C (~140 kDa) and RyR2 subunit (~560 kDa) are shown (red arrows). RyR2 is 
partially cleaved by the endogenous calpain protease to generate a ~400 kDa C-terminal fragment 
as indicated (black arrow).  The amino acids coordinates are for pig cMyBP-C isoform ([Sus 
scrofa] (accession number: XP_013849807.1) and RyR2 C ([Sus scrofa] accession number: 
XP_013838665);(C) Densitometry analysis of native RyR2 and cMyBP-C binding in co-IP assay 
from pig heart homogenate. Percentage of relative binding corrected for the difference in 
expression levels are presented relative to lysate input (1/200th of the processed sample). Data 
are shown as mean ±SD, n=7; * statistical significance at p<0.05 calculated using paired, 2-tailed 
Student’s t-test 
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experimental variability, the native-based co-IP approach was not pursued further 
and instead the recombinant mammalian expression system was employed. It was 
hypothesised that native cMyBP-C binding might be affected by the presence of other 
RyR2-associated proteins, thus assessment of binding between recombinant human 
proteins would help to further verify the results obtained from native tissue. 
 
3.4.3 Generation of HA-tagged cMyBP-C constructs 
Both plasmid DNA constructs designed to express full length and the N-terminal part 
of cMyBP-C (FL and NT, respectively, see Table 3.2) were successfully generated 
and their DNA sequences were confirmed. A typical set of results representing 
intermediate steps of the cloning process is shown in Figure 3.3 
Table 3.2 List of cMyBP-C constructs and restriction nucleases used. Coordinates correspond to the 
human cMyBP-C mRNA, accession number: X84075. 
Construct Coordinates Length PCR primers Cloning sites 
cMyBP-C CT 
2483-3857 (b) 
817-1274 (aa) 
374 (b) 
456 (aa) 
- 
EcorI 
XhoI 
cMyBP-C FL 
33-3857 (b) 
1-1274 (aa) 
3824 (b) 
1273 (aa) 
HcMyBPC.FOR.27-56 
HcMyBPC.REV.3849-76 
BamHI 
XhoI 
cMyBP-C NT 
33-2630 (b) 
1-866 (aa) 
2597 (b) 
866 (aa) 
HcMyBPC.FOR.27-56 
HcMyBPC.REV.2611-30 
BamHI 
XhoI 
 
3.4.4 Recombinant human full-length RyR2 and cMyBP-C can be 
successfully co-expressed in HEK293 cells. 
In order to assess the interaction between recombinant human proteins, HEK293 
cells were used, an immortalised cell lineage that do not express endogenous RyR2 
nor cMyBP-C. Immunofluorescence analysis was first conducted to confirm that 
recombinant proteins were co-expressed within the same co-transfected cell and 
correctly localised in vivo. Both proteins were expressed to a levels clearly 
distinguishable from the background and yielded similar transfection efficiencies 
(~20%) as illustrated in Figure 3.4 and Appendix, Figure 8.2. Low transfection 
number was expected, and was linked to (1) low cell plating density, (2) poor RyR2  
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Figure 3.3 Intermediate steps of the experimental procedure generating the cMyBP-C NT 
construct. (A) DNA gel showing the amplification product obtained in the PCR amplification 
(expected band: 2.6 kb); (B) DNA gel showing indicative digest of clones following bacteria 
transformation with the ligated PCR product and the pCR3 vector (1-7: restriction digest of 
plasmid DNA preparations obtained from seven clones and cut with SpeI/XhoI, expected 
bands:3.3 and 4.4 kb as seen in 2,3 and 4); (C): restriction digest of the selected positive clone 
verified by sequencing. From left to right: Lane 1: SpeI/XhoI (expected bands: 3.3 and 4.4 kb), 2: 
BamHI/XhoI (expected bands: 2.6 and 5.1 kb), 3: ApaI (expected bands: 1, 2.4 and 5.3 kb), 4: 
SmaI (expected bands:1.5 and 6.2 kb). The partially digested plasmid in (C) 2 is shown with red 
arrow. 
Figure 3.4 Comparable transfection efficiencies of HEK293 cell populations expressing RyR2 and 
cMyBP-C, assessed with LEICA software. The transfection efficiencies of RyR2 and cMyBP-C 
were obtained by qualitative determination of number of positive cells (showing detectable 
fluorescent signal for either cMyBP-C or RyR2) within selected field of view and normalized 
towards the total number of cells present in given view. Data are shown as mean ±SD, n=3 
populations, in average 28 cells in each field of view were analysed. 
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plasmid uptake by HEK293 cells and (3) lower amount of cMyBP-C FL plasmid used 
for co-transfection (to yield comparable protein levels to RyR2). 
Nevertheless, a high number of co-transfected cells was obtained, labelled both 
green (for RyR2) and red (for cMyBP-C), calculated to be ~88% of all transfected 
cells. Figure 3.5 A and A’ shows a representative pair of images acquired from an 
identical field of view, visualising the level of non-specific signal present in the 
processed images of co-transfected cells (labelled with both primary and secondary 
Abs, 1093 + 488 and N-t + 594, for RyR2 and cMyBP-C, respectively). In order to 
easily distinguish the specific signal from non-specific (calculated as <15% of mean 
fluorescent intensity) from the background, the image intensity palette width in each 
image was adjusted form original 0-255 grey levels (8-bits colour depth) to the full 
dynamic range (A) or to the lower intensity range, causing over-saturation of the 
specific signal (A’, dashed region). Panels B and C show representative field of 
views acquired from co-transfected control specimens with the use of only one 
primary Ab at time (either N-t only, as in B; or 1093 only, as in C) and both secondary 
Abs (488 and 594), again with intensity palette adjusted as in (A’). Generally, 
fluorescence detected in those images was <10% of mean fluorescent intensity for 
un-labelled protein, either due to low levels of green autofluorescence (B, Ab 488 
panel), or green to red cross-talk between fluorophores (C, dashed region) or non-
specific binding of primary Abs (B, cMyBP-C panel and C, RyR2 panel), whereas 
green autofluorescence levels in no-primary, double labelled secondary Abs control 
was measured as <5% of mean fluorescent intensity for green channel (D, Ab 488 
panel). No detectable red autofluorescence was obtained (D, Ab 594 panel).  
As demonstrated in Figure 3.6, RyR2 (green) signals could be detected throughout 
the ER of the transfected HEK293 cells, both surrounding the nuclear envelope and 
extending towards the peripheral part of the cell (A-C, RyR2 panel). On the other 
hand, cMyBP-C (red) signal was found to be distributed throughout the cytoplasm (A-
C, cMyBP-C panel), with significant cMyBP-C expression being detected in 
peripheral lamellipodia (D, white arrows). Interestingly, cMyBP-C signal could not be 
detected in the cytoplasmic region spanning from bottom side of the nucleus to the 
areas of the cell surface in direct contact with the coverslip (D, dashed box), either 
due to cMyBP-C not being well expressed in this site or due to failure of N-t Ab to 
reach the cMyBP-C epitope. A proportion of cMyBP-C also seemed to co-localise 
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Figure 3.4  (previous page) Imaging of RyR2 co-expression with cMyBP-C in co-transfected HEK293 
cell populations(A-D); (RyR2) RyR2 green signal detection, (cMyBP-C) cMyBP-C red signal detection 
and (brightfield) corresponding bright field image. (A and A’) typical field of view of cells labelled with 
Ab 1093 and Alexa Fluor 488 and Ab N-t and Alexa Fluor 594. (A) representative image used for co-
localisation analysis and (A’) corresponding image with intensity level adjusted to show the non-
specific signal. Compare arrows pointing to cells without detectable green signal and red signal in A 
versus the same cells in A’. Dashed regions indicate cell used for co-localisation analysis. (B) typical 
field of view of cells labelled with Alexa Fluor 488 and Ab N-t and Alexa Fluor 594, or (C) Ab 1093 
and Alexa Fluor 488 and Alexa Fluor 594 or (D) Alexa Fluor 488 and Alexa Fluor 594, all (B-D) 
images had LUT table adjusted as in (A’) to show the non-specific signal. Dashed boxes in C show 
the cross-talk between the green and red channel. 
 
 
 
 
Figure 3.6 2D (x-y) slice representation of the immunofluorescence images of RyR2 and cMyBP-C 
localisation within the co-transfected HEK293. Shown are typical fields of view of three individual 
cells (A-C), taken in the middle of z-axis direction. (RyR2) detection of RyR2 with Ab 1092 and Alexa 
Fluor 488, (cMyBP-C) detection of cMyBP-C with Ab N-t and Alexa Fluor 594, (merge) overlay 
images and (merge +) higher magnification of dashed box region from (merge). (D) Higher 
magnification image of the orthogonal section (z axis) from (C), dashed box indicates region where 
no red cMyBP-C signal could be detected; white arrows show distal cMyBP-C distribution. Yellow 
colour shows RyR2 and cMyBP-C pixel overlap, and is indicative of co-localisation. 
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with RyR2, visible as yellow signal from green and red overlap (A-C, merge and 
merge +).   
 
3.4.5 Recombinant human RyR2 and cMyBP-C co-localise in HEK293 
cells   
To quantify the degree of co-localisation in 3D cell volume, IMARIS software Coloc 
module was used, as outlined in following Section 3.3.5. Fluorescence labelling of 
RyR2 and cMyBP-C using secondary Alexa Fluor Ab enabled the degree of co-
localisation between the two recombinant proteins to be calculated. The extent of 
Alexa 488 green channel (RyR2) and Alexa 594 red channel (cMyBP-C) 3D co-
localisation was quantified from confocal fluorescence image z-stacks and used to 
generate a new channel corresponding to the co-localised voxels (Figure 3.7).  
Consistent with simple 2D observations shown above, most of RyR2:cMyBP-C voxel 
overlap was identified in proximal ER regions (through the body of the cell but not 
immediately adjacent to the nucleus), with very little signal detected in distal regions 
and in the space between the bottom of peri-nuclear membrane and cell attachment 
site. Summary and statistical analysis of IMARIS generated results is presented in 
Figure 3.8. Overall, 2.04% total voxel co-localisation could be detected in the total z-
stack volume being assessed, which corresponded to 4.82% of cell volume (after 
normalisation to each respectable cell size, A and H). Importantly, this analysis 
demonstrated that 71.4% of total green (RyR2 signal) voxels present in the dataset 
(B) and 73.3% of total green intensity material (E) is co-localized with 29.9% of total 
red (cMyBP-C signal) voxels (D) and 34.62% of total red intensity material (F), 
respectively. The PCC intensity correlation analysis was performed to detect the 
synchrony of the two proteins and scored for PCC= 0.68 (G) and, r2 =0.46, which can 
be interpreted as positive co-localisation between RyR2 and cMyBP-C (PCC value of 
1 for full co-localisation) with 46% of RyR2 and cMyBP-C follow perfect linear 
regression. All assessed parameters were statistically significant when compared to 
their non-specific counterparts obtained from scrambled images (calculated using 
unpaired, 2-tailed Student’s t-test, Figure 3.8), i.e. with values of 0.75% total voxel 
co-localisation, PCC=0.25 (G) and r2 =0.06 were calculated for non-specific co-
localisation results. 
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 Further, obtained data were not dependent on region of interest selection (the 
approximate size of cell, r2 = 0.001, PCC= 0.04, Figure 3.9, A). Weak correlation was 
detected for co-localisation results with either green channel intensity (relative RyR 
expression, r2 =0.12, PCC= 0.35, (B)) or red channel intensity (relative cMyBP-C 
expression, r2 =0.18, PCC= 0.43, (C)). It can be interpreted as 12% of green signal 
and 18% of red signal fraction of variability, respectively, that can be explained by 
linear regression with co-localisation result. 
 
 
Figure 3.7 Visualisation of RyR2 and cMyBP-C partial co-localisation. (A) side and top view of 3D 
maximum intensity projection of RyR2 (green) and cMyBP-C (red) signal overlay, with IMARIS 
generated isosurface (ISO, in blue) corresponding to co-localised region; (B) side and top view of 3D 
projection of IMARIS generated isosurface corresponding to cMyBP-C signal (red) and co-localised 
region (ISO); (C) side and top view of 3D projection of IMARIS generated isosurfaces corresponding to 
RyR2 signal (green) and co-localised region (ISO). 
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Figure 3.8 Summary of IMARIS generated results of RyR2 and cMyBP-C co-localisation. (A-H) Data are shown as mean ±SEM, Samples: RyR2 + cMyBP-C 
n=184, negative control (representing the non-specific co-localisation results) n=40 fields of view, from four independent experiments; * statistical significance 
at p<0.05 calculated using unpaired, 2-tailed Student’s t-test. 
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Figure 3.9 Distribution of data used for correlation analysis using Pearson’s correlation coefficient 
(PCC) and square of PCC (denoted as r2) calculated using GraphPad Prism. (A) Correlation between 
co-localisation results and region of interest selection, r2 = 0.001, PCC= 0.04, (B) Correlation between 
co-localisation results and green (RyR2) channel intensity, r2 =0.12, PCC= 0.35 and (C) Correlation 
between co-localisation results and red (cMyBP-C) channel intensity, r2 =0.18, PCC= 0.43. Trend lines 
are shown in black.  
 
3.4.6 RyR2:cMyBP-C interaction detected between recombinant human 
proteins  
RyR2 and cMyBP-C were co-expressed in HEK293 cells, RyR2 was 
immunoprecipitated from solubilised HEK293 homogenate and the presence of co-
precipitated HA-cMyBP-C was tested by WB analysis using HA-specific antibody. 
Representative blots presented in Figure 3.10, A-B, show that cMyBP-C was 
recovered in the RyR2 immunoprecipitate, indicative of positive recombinant  
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RyR2:cMyBP-C binding. Cumulative data (n=5) following densitometry analysis are 
presented in panel C. The detected difference between specific and non-specific 
binding was comparable to the binding ability detected in native pig homogenates 
(~20% difference between specific vs non-specific), reinforcing that both native pig 
and recombinant human RyR2 are capable of cMyBP-C interaction. 
In similar way to native pig cardiac proteins, obtaining significant results from 
reciprocal co-IP experiments where HA-cMyBP-C was immunoprecipitated with HA 
Ab and the presence of co-precipitated RyR2 was tested by WB using 1093 Ab, were 
largely unsuccessful, most probably due to the large cytoplasmic cMyBP-C pool (see 
Section 3.3.2) 
 
3.4.7 The recombinant N-terminal region of RyR2 is responsible for the 
interaction with the C-terminus cMyBP-C  
To further assess the specificity of the interaction, the same mammalian expression 
system was employed to co-express either RyR2 c-Myc-tagged BT4L (N-terminal 
fragment, corresponding to RyR2 1-906 amino acids) or BT7 (residues 3071-3940; a 
similar size construct from RyR2 central region) with either the HA-tagged cMyBP-C 
C-terminal fragment (CT, residues 817-1274) or N-terminal fragment (NT, residues 1-
865) or FL (full length cMyBP-C). Co-IP experiments were carried out using HA Ab to 
immunoprecipitate HA-cMyBP-C constructs, while the presence of co-precipitated c-
Myc-tagged RyR2 constructs was analysed by WB with c-Myc Ab. These 
experiments resulted in the BT4L fragment reproducibly positive for robust cMyBP-C 
CT and FL interaction (Figure 3.11, B: (1) and (2)) and very weak positive signal for 
cMyBP-C NT (B:(3)); also neither of cMyBP-C constructs co- precipitated BT7 (used 
as a negative control). Cumulative results were further quantitatively evaluated by 
densitometry and statistical significance was calculated using paired, 2-tailed 
Student’s t-test (Figure 3.12). The difference between specific versus non-specific 
binding was statistically significant only for pairs CT + BT4L and FL+ BT4L and not 
for NT + BT4L. Further, the observed relative binding ability (calculated as the 
significant binding subtracted of the non-specific binding) of CT + BT4L was 
comparable to that of FL + BT4L (no significant difference calculated using Kruskal-
Wallis test with Dunn’s post-test, see Appendix, Table 8.1). Overall, the obtained  
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Figure 3.10 Representative blots of Co-IP and WB results illustrating recombinant RyR2:cMyBP-C 
association and cumulative densitometric analysis. (A-B). HEK293 expressed recombinant human 
RyR2 was immunoprecipitated with Ab1093 from CHAPS-solubilised HEK293 cell lysate (2 mg per IP 
sample) analysed by immunoblotting with Ab HA (A: 12% gel) and Ab P12 (B: 4% gel), respectively. 
Bands corresponding to full-length cMyBP-C FL (~150 kDa) and RyR2 subunit (~560 kDa) are shown 
(red arrows). The loading controls represent 1/200th and 1/10th of the processed sample for (A) and 
(B), respectively.  RyR2 is partially cleaved by the endogenous calpain protease to generate a ~400 
kDa C-terminal fragment as indicated (black arrow). The amino acids coordinates are for human 
cMyBP-C (accession number: CAA58882.1) and RyR2 (accession number: X98330; (C) 
Densitometry analysis of recombinant full-length RyR2 and cMyBP-C binding in co-IP assay from 
HEK 293 homogenate.  Percentage of relative binding corrected for the difference in expression 
levels are presented relative to lysate input (1/200th of the processed sample).  Data are shown as 
mean ±SD, n=5; * statistical significance at p<0.05 calculated using paired, 2-tailed Student’s t-test. 
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Figure 3.11 Representative results (n≥5)of c-Myc- tagged RyR fragments (BT4L or BT7) co-IP with HA-tagged cMyBP-C constructs (CT or FL or NT). 
cMyBP-C fragment of interest was immunoprecipitated with HA Ab from CHAPS-solubilised HEK293 cell lysate (2 mg) and normal, non-immune rabbit 
IgG was used as negative control. Co-IP samples were loaded on two separate SDS-PAGE gels (1/10th and 9/10th split) and analysed by immunoblotting 
with Ab HA and Ab c- Myc, respectively. upper panels (A), 1-3: WB using c-Myc Ab detecting c-Myc tagged BT4L and BT7; lower panes (B), 
corresponding WB using HA Ab detecting HA-tagged cMyBP-C CT (1), or cMyBP-C FL (2), or cMyBP-C NT (3). A cell lysate aliquot was loaded on the 
gels to verify expression in HEK293; in c-Myc WB, 1/200th of the volume processed in co-IP samples; in HA WB 1/100th of the volume processed in co-IP 
samples. All fragments are indicated as follows: BT4L, red arrows; BT7, black arrows, cMyBP-C fragments, violet arrows.  8% reducing SDS-PAGE gels 
were used for c-Myc WB and 12% gels for HA WB.  
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Figure 3.12 Densitometry analysis of recombinant RyR2 and cMyBP-C constructs binding in co-IP 
assay from HEK 293 homogenate. Results shown are presented as relative binding (the specific 
binding subtracted of the non-specific binding) and normalised to each fragments respectable lysate 
input (corresponding to 1/200th of the processed sample). Data are shown as mean ±SD, n≥5; * 
statistical significance at p<0.05 calculated using paired, 2-tailed Student’s t-test. 
 
data confirmed that RyR2 and cMyBP-C are able to form a complex in vitro and also 
highlighted the importance of the RyR2 N-terminal in cMyBP-C C-terminal binding.    
 
3.5 Discussion 
 
3.5.1 RyR2:cMyBP-C association may be applicable to larger mammal 
species 
The goal the work presented in this chapter was to verify the putative RyR2:cMyBP-C 
association between (1) the native proteins from animal cardiac tissue and (2) the 
recombinant human proteins. The most significant finding presented in this Chapter is 
the positive co-precipitation of endogenous pig cMyBP-C with RyR2 complex, 
pointing to the physiological significance of the observed association. However, the 
inconsistency between the positive interaction detected in pig cardiac homogenate 
(Figure 3.2) versus somewhat ambiguous results from SR preparations, and the high 
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non-specific binding observed for native cMyBP-C, particularly in the case of rabbit, 
could reflect limitations of the applied co-IP technique. 
As part of the normal sarcomeric protein turnover, cMyBP-C exists in two different 
forms in vivo, the predominant phosphorylated (associated with greater thick filament 
stability) and second, the dephosphorylated form (Kulikovskaya et al. 2007). The 
latter is relatively sensitive to release from the sarcomere, with detectable low levels 
of full-length cMyBP-C in the cytosol (Decker et al. 2012; Kuster et al. 2014; Baker et 
al. 2015). Notably, the increased rate of cMyBP-C dephosphorylation and 
subsequent degradation has been associated with pathological conditions, as 
observed in patients with heart failure, MI and ischemia-reperfusion injury, and 
pathological hypertrophy (Decker et al. 2012; Govindan et al. 2012; Kuster et al. 
2014; Baker et al. 2015). It has been shown that the proteolysis occurs in the C-
terminal region, involving domains C5 and C10, resulting in detection of anti-C0C2, 
but not anti-C5 or anti-C8-C9 bands (Kulikovskaya et al. 2007). Importantly, animal 
model study by (Decker et al. 2012) have shown that proteolytic fragments of cMyBP-
C are generated during MI and ischemia that were not present in either the 
myofibrillar or cytoplasmic myocardium from healthy, sham-operated hearts, whereas 
substantial degradation was observed after reperfusion. Therefore, at least under 
pathophysiological conditions, it is possible for full-length cMyBP-C and/or its 
proteolytic fragments to dissociate from the thick filament and be readily available for 
RyR2 binding. This observation is in line with our WB results of cardiac sub-cellular 
fractions indicating substantial amounts of intact full-length cMyBP-C in the cytosol 
and partly in the SR fraction, at least for pig, guinea pig and rabbit (Figure 3.1). 
Cytosolic and/or SR localisation for cMyBP-C may enable its interaction with RyR2 as 
observed in our co-IP experiments, probed with Ab C-t (detecting the epitope 988-
1100 within the C8 domain), resulting in co-precipitation of a single 140kDa band 
(Figure 3.2), indicating that cMyBP-C protein is intact and capable of interaction with 
RyR2. Given the fact that up to fifth part of RyR2 population can be localized outside 
the Z-line (Shacklock et al. 1995; Lukyanenko et al. 2007; Asghari et al. 2009; 
Jayasinghe et al. 2009), with non-junctional RyR2s detected between the Z-disks 
(Salnikov et al. 2009), present in the axial tubular system (Asghari et al. 2009) and/or 
on the periphery immediately under the sarcolemma but absent in the cell interior  
(Chen-Izu et al. 2006; Lukyanenko et al. 2007; Hiess et al. 2015), those RyR2s 
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positioned close to the C-zone may participate in the interaction with cMyBP-C. The 
Figure 3.13 depicts the proposed model of cMyBP-C and RyR2 location in the 
sarcomere.  
In order to assess the interaction between the human proteins, recombinant proteins 
had to be used, expressed in mammalian HEK293 cells. First of all, 
immunofluorescent staining assessment allowed to positively identify cells co-
expressing recombinant cMyBP-C and RyR2 (Figure 3.5). In agreement with 
previous reports (George et al. 2003b; Stange et al. 2003; Thomas et al. 2004), 
recombinant RyR2 displayed correct targeting to the endoplasmic reticulum 
according to the characteristic lattice-like morphology (Figure 3.6). By contrast, 
cMyBP-C, was distributed diffusely throughout the cytoplasm (Figure 3.6), in 
conformity with findings of transient expression observed in COS cells (Sebillon et al. 
2001; Welikson and Fischman 2002), HEK293 cells (Gedicke 2011) and also in 
agreement with the pattern described previously with the skeletal isoform (Seiler et 
al. 1996). Any additional nuclear localisation as reported by (Welikson and Fischman 
Figure 3.13 Graphical representation of RyR2 and cMyBP-C localisation within ventricular 
myocyte. T-tubules are depicted as regular invaginations of the sarcolemma perpendicular to the 
long axis of the myocyte and their relationship to the Z-line (Z) of sarcomere. The T-tubular 
lattice is crucial for the efficient spread of action potential and facilitates the spatiotemporal 
synchronisation of intracellular Ca2+ release. Adapted from (Bers and Shannon 2013). 
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2002) in COS cells was not observed, probably due to use of different cell line and/or 
Abs.  
Initial inspection of obtained co-labelled RyR2/cMyBP-C 2D pictures showed 
potential overlap of detected signals (Figure 3.6), which was further verified by 3D 
quantification and scored as co-localisation (Figure 3.8). In the course of cell 
topological analysis, it became evident that the cMyBP-C signal was not visible in a 
substantial proportion of cytoplasmic region, in particular the area spanning from 
bottom side of the nucleus to the cell surface in direct contact with the coverslip 
(Figure 3.6, D, dashed box). Later experimental analysis with mCherry tagged 
cMyBP-C (see Section 5.4.4) proved it to be caused not by the absence of protein in 
this region, but by failure of N-t Ab to reach the cMyBP-C epitope. Therefore, the 
obtained 2.04% total and 4.82% of volume of cell (selected region of interest, ROI) 
voxel co-localisation accounts only for part of the true cMyBP-C:RyR2 overlap, which 
should yield higher values with appropriate Ab detection. This error could be avoided 
by further optimization of the immunofluorescence staining protocol or by use of 
another primary, cMyBP-C specific antibody.  
The binding between the recombinant human full-length proteins was investigated 
following expression in HEK293 cells by the co-IP assay. The densitometric analysis 
revealed rather weak but reproducible and statistically significant interaction between 
human recombinant RyR2 and cMyBP-C proteins, comparable to native pig cardiac 
homogenate results (see Figure 3.2, C and 3.10,C respectively), The quantitative 
accuracy of densitometric analysis could have been further improved by use of an 
additional internal loading control (such as α actinin or β myosin heavy chain) 
alongside samples to correct for possible errors in loading/transfer efficiencies, or by 
generating a standard curve from serial dilutions of used sample and subsequent 
immunoblotting detection (Taylor et al. 2013). Cumulatively, the obtained data 
support the presence of cMyBP-C and RyR2 protein-protein interaction in larger 
mammal species, in particular pig and human.  
It should be noted that the phosphorylation levels of cMyBP-C have not been 
assessed in our experimental conditions, neither for native nor recombinant protein. 
Notably, it is widely accepted that the major cMyBP-C phosphorylation region is 
localized in the N-terminal domains C0-C2 (Sadayappan et al. 2005), with only a 
single phosphorylation site of unknown function reported in C9 domain (amino acids 
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S1066) (Kooij et al. 2013). Thus, is rather unlikely that phosphorylation state of 
cMyBP-C directly mediates the interaction with RyR2. Instead, considering that the 
requirement of cMyBP-C translocation to the sarcomere is the initial cMyBP-C 
dephosphotylation, it would be intriguing to speculate that it is a predominant from 
associated with RyR2.  
Structural arrangement for RyR2 coupling is markedly different in cells lacking a T-
tubules such as adult atrial myocytes, neonatal cardiac myocytes, sino-atrial node 
and Purkinje cells, where the junctional coupling exists at the cell periphery 
immediately under the sarcolemma (Bootman et al. 2006), thus the putative 
RyR2:cMyBP-C association may display different affinity than in ventricular 
myocytes. Further, the loss and disorganization of T-tubules is known to be causative 
of asynchronous and inhomogeneous Ca2+ release, due to the presence of orphan 
RyRs that have lost their coupling with the LTCC and are either not activated or 
activated with a delay (Song et al. 2006). Disease-related remodelling of the TATS 
can be found in a number of pathological conditions including human heart failure 
and dilated and hypertrophic cardiomyopathies, as well as in animal models of heart 
failure, chronic ischemia and atrial fibrillation (Biesmans et al. 2011; Guo et al. 2013; 
Zhang et al. 2013). Recently, several RyR2 mutations have been linked to the DCM 
phenotype (Haas et al. 2014), with arrhythmogenic phenotype emerging to be 
present in up to one-third of DCM cases (Spezzacatene et al. 2015). cMyBP-C is also 
involved in DCM pathology with arrhythmic events, thus, it is tempting to speculate 
that certain disease phenotypes may be linked to perturbation of the cMyBP-C:RyR2 
association. 
 
3.5.2 The regions responsible for the interaction are the RyR2 N-
terminus and cMyBP-C C-terminus. 
To reinforce the initial Y2H observation of interaction between cMyBP-C C-terminus 
(residues 817-1274) and RyR2 N-terminal region (residues 1-906), these protein 
fragments were co-expressed in the HEK293 cells and co-IP experiments were 
carried out. Densitometric analysis indicated strong binding between cMyBP-C CT 
(residues 817-1274) and RyR2 BT4L (residues 1-906) (Figure 3.12). Interestingly, 
the relative binding ability of cMyBP-C CT seems to be equal to the FL + BT4L, 
  Chapter 3 
 
107 
 
pointing that the cMyBP-C region 817-1274 contains the specific binding site 
responsible for the interaction with RyR2 BT4L. Importantly, BT7, an unrelated but 
similar size fragment form the central domain of RyR2, did not score for an 
interaction with any of the tested cMyBP-C constructs (NT, CT or FL), further 
highlighting the specificity of the interaction.  
The 3D visualization in published high-resolution cryo-EM RyR1 structure (Yan et al. 
2015) places BT4L (RyR2 residues 1-906, coordinates for RyR1: 1-894) at the very 
top of the cytoplasmic assembly forming a ring structure around the fourfold axis of 
the RyR channel, spreading towards the clamp region, whereas BT7 is located near 
transmembrane region (RyR2 residues 3071-3940, RyR1 coordinates 3071-3940), 
highlighting the spatial distance between the two regions (Figure 3.14 A-C). When 
compared to the RyR1 domain sequence boundaries proposed by (Yan et al. 2015), 
the BT4L appears to contain the sequences corresponding to that of NTD region 
(residues 1-631), part of the SPRY1 core β-sandwich (residues 632-826) and part of 
domain SPRY2 (residues 827–845) followed by sequence of the P1 domain 
(residues 851-1055). Notably, BT4L construct lacks the remaining SPRY1 two pairs 
of anti-parallel β-strands (residues 1466–1491 and 1615–1634), the primary 
sequences of which are connected to those of SPRY3 (see Figure 3.14, D), 
indicating that the latter does not directly participate in the interaction with cMyBP-C. 
 As each of the RyR2 domain seems to control different aspect of channel function, 
i.e. the NTD region is involved in regulation of channel gating whereas SPRY 
domains have been proposed to maintain channel structural integrity (Efremov et al. 
2015), mapping of the minimal RyR2 binding region would allow to shed some light 
on the potential effect of cMyBP-C interaction with RyR2.  
Many studies of cMyBP-C to date have focused on the N-terminal part of the protein, 
as it is involved in the interaction with both actin and myosin to regulate contraction, 
and to lesser extent on the C-terminal modules that anchors the protein to the thick 
filament. It has been shown that domains C5-C7 and C8-C10 interact with each 
other, based on which the collar model of cMyBP-C arrangement in the sarcomere 
was proposed (Moolman-Smook et al. 2002). Currently, there are no crystal 
structures for human cMyBP-C C6-C10 domains available, however NMR structure 
of human fMyBP-C C6 domain (PDB:2E7C), C7 (PDB:2YUW), C9 (PDB:2YUX) and 
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Figure 3.54 BT4L (RyR2 residues 1-906, coordinates for RyR1: 1-894) and BT7 (RyR2 residues 
3071-3940, RyR1 coordinates 3071-3940) location in 3D structure of the rabbit RyR1 at 3.8 Å. (A) 
The top view shows the large cytoplasmic assembly and its previously assigned N-terminal domains 
(see the color-coded regions in D). Single RyR1 subunits are depicted in orange, purple, grey and 
light green, respectively. BT4L and BT7 are indicated with navy blue and violet (see labels); (B)The 
same top view with four BT4L (navy blue, teal, purple and lime) indicated in each subdomain, 
forming ring-like structure around the fourfold axis of the RyR channel. Single RyR1 subdomain 
indicated in orange; (C) the side view of image presented in A; (D) A schematic illustration of domain 
organization in one RyR1, with indicated sequences corresponding to BT4L and BT7. Images 
created using The PyMOL Molecular Graphic Software (based on ((Yan et al. 2015), accession 
number 3J8H). 
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mouse fMyBP-C C7 (PDB:1X5Y) have been deposited in PDB and they display 
overall predicted Fn β-sandwich fold (Figure 3.15). The cMyBP-C fragment 
testedpositive for RyR2 interaction, CT (residues 817-1274), includes the Fn domains 
C6, C7 and C9, with the Ig domains C8 and C10. cMyBP-C Ig domains belong to the 
I-set, which can be found in several cell adhesion molecules (including vascular, 
intercellular and neural), as well as several tyrosine kinase receptors. More 
importantly, the Ig I-set is present in other Z- and M-line sarcomeric proteins, 
including titin and obscurin (Harpaz and Chothia 1994; Benian and Mayans 2015; 
NCBI 2016b). Notably, those muscle proteins, similarly to cMyBP-C, also have the Fn 
type 3 domains, topologically very similar to the Ig fold, with a notable difference 
being the lack of a conserved disulfide bond in the Fn domains (Leahy et al. 1992). 
Fn type 3 repeat homologs have also been found in various animal protein families 
including extracellular-matrix molecules and cell-surface receptors (tyrosine 
phosphatase, cytokine and growth hormone receptors) (Koide et al. 1998; NCBI 
2016a).  
Unlike titin, which is an integral component of sarcomeres, obscurin is not present 
within sarcomeres but intimately surrounds them, primarily at the level of the M-band 
and Z-disk, where it is appropriately positioned to participate in their assembly and 
integration with other sarcoplasmic elements. Notably, the first Ig domain within the 
11-domain super-repeats of titin in the C-zone has been shown to interact with 
MyBP-C C8-C10 domains, whereas N-terminal titin Ig domains Z8-9, which are more 
distal in the Z-disk, can associate with obscurin Ig domains 58-59 (Linke 2008).  
Further, invertebrate obscurin mutants lacking the large Ig domain-rich isoforms have 
Figure 3.65 Available NMR structures of fMyBP-C C-terminal Fn domains. From left to right: human 
C6 domain (PDB:2E7C), C7 (PDB:2YUW), C9 (PDB:2YUX) and mouse fMyBP-C C7 (PDB:1X5Y). 
Images shown were taken from the PDB website (www.rcsb.org/pdb/home/home.do )using 
appropriate accession numbers and modified. 
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been reported to display reduced Ca2+ signalling and reduced muscle activity 
(Spooner et al. 2012) suggesting a role of Ig domains in connectivity between the 
SR, the Z-disk, and other cytoskeletal structures. Further, work by (Ackermann et al. 
2009) has shown that disarray of the A-band and M-line of primary rat skeletal 
myocytes caused by overexpression of the single Ig type 2 domain of obscurin is 
mediated by direct interaction of this domain with Ig C10 domain of sMyBP-C variant 
1, but not by the corresponding C10 domains of the fMyBP-C and cMyBP-C. This 
sMyBP-C splice variant, which has a unique C-terminus containing a total of 26 new 
amino acids, was shown to be expressed in significantly lower amounts than other 
sMyBP-C variants, and notably was the only one demonstrated to localize 
preferentially to the M-band of the sarcomere instead of the C-zone, generally 
accepted for MyBP-Cs (Ackermann et al. 2009). This distinct localization of sMyBP-C 
due to changes in its C-terminus is not without a precedent, as an alternatively 
spliced form of mouse cMyBP-C, containing 10 additional amino acids in the Fn C9 
domain (30 bases insertion located in the exon 31) was also shown to not localize at 
the A-bands, but instead exhibited a diffuse distribution throughout the 
cardiomyocyte. Further, it also had a markedly decreased affinity for myosin and titin, 
and was reported to be the predominant form of cMyBP-C in aged atrial muscle (Sato 
et al. 2003). Interestingly, (Kuster et al. 2015) have recently reported that a human 
HCM-associated cMyBP-C C10 mutation (caused by a 25-basepair deletion in the 
MYBPC3 gene) resulted in improper localisation of this variant to the Z-line. An 
increased concertation of mutant protein in the cytosolic fraction was also shown 
(when compared to WT cMyBP-C), which was predicted to be the main cause of 
contractile dysfunction induced by this variant, as detected in the cultured adult rat 
cardiomyocytes. Notably, it has been shown that a significant portion of HCM-linked 
cMyBP-C sequence variants occur in the C-terminus domains, with variable 
phenotypic patterns and the mechanisms by which they cause disease only partly 
understood (Harris et al. 2011). A recent study by (Nadvi et al. 2016) assessed three 
HCM variants: D745G in C5, P873H in C7 and R820Q in C6, the latter being 
associated also with the DCM phenotype (Konno et al. 2003). Using bioinformatics 
and NMR modelling, it was predicted that those variants confer different disease 
outcomes based on their divergent structural consequences, with R820Q being 
surface exposed and proposed to interfere with interactions within the sarcomere, 
whereas the other two were shown to disrupt domain folding. Thus, since both Ig and 
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Fn domains appear to exhibit broad functional modularity, with the alterations in 
cMyBP-C C-terminal domains shown to be implicated in cMyBP-C-linked pathology, 
we decided to evaluate in the subsequent Chapter which one of the cMyBP-C 
domain/s are directly involved in the RyR2 N-terminal interaction. 
 
3.5.3 Conclusions 
Overall, obtained data support the conclusion that the cMyBP-C and RyR2 can 
readily form protein complexes, in particular in higher mammals, and that the regions 
responsible for the binding are RyR2 N-terminus and cMyBP-C C-terminus.  
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4 Mapping of RyR2 and cMyBP-C interaction sites 
 
4.1 Introduction 
Having established a gross mapping of RyR2 N-terminus interaction with cMyBP-C 
C-terminus in the previous Chapter, the subsequent aim was to further refine the 
region/domain/residues participating in the association. Therefore, a series of 
truncated cMyBP-C constructs spanning the entire length of the protein were 
generated by PCR amplification and cloning, and used to co-transfect HEK293 cells 
with BT4L (RyR2 construct, residues 1-906), followed by co-IP analysis for protein-
protein interaction. In a similar way, a series of truncated RyR2 N-terminal 
overlapping constructs within BT4L (previously made in our lab) were used to map 
the binding site within RyR2 by co-expression with CT (cMyBP-C construct, residues 
817-1274) and the binding was assessed by co-IP. To ease the detection of 
recombinant protein fragments, each cMyBP-C construct was cloned with 
immunoaffinity tag HA at the N-terminus, whereas each RyR2 construct was 
expressed as N-terminal c-Myc fusion protein. Since one of the disadvantages of the 
epitope-tagging approach is that the artificially introduced tag may interfere with 
protein stability and/or expression (Yang et al. 2008), the presence and expected 
molecular weight of all prepared new constructs in transfected HEK293 cells was 
verified by WB prior to commencing to the mapping studies. Notably, HA and c-Myc 
peptide epitopes have been used previously in our lab in connection with co-IP assay 
(Stewart et al. 2003; Zissimopoulos and Lai 2005; Zissimopoulos et al. 2013; 
Zissimopoulos et al. 2014).  
To extend the co-IP observations, an independent in vivo technique was employed, 
namely the Y2H system. In this approach, the interaction between two proteins (i.e. X 
and Y) is measured by the reconstitution of a functional hybrid transcription factor 
GAL4 and the concurrent activation of a reporter gene by introducing in yeast the 
following two fusion proteins: GAL4 DNA-Binding Domain (DNA-BD)/protein X fusion 
(bait) and GAL4 Activation Domain (AD)/protein Y fusion (target) (Stynen et al. 2012). 
When the recombinant DNA-BD and AD protein fusions are co-expressed in the 
yeast nucleus, the separated DNA-BD and AD peptides do not directly interact with 
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each other unless they are brought into close physical proximity by X and Y 
interaction to produce a hybrid GAL4 transcription factor. Positive growth selection of 
those colonies expressing prey which interacts with the bait is achieved using a 
prototrophic reporter gene, such as HIS3, which is transcribed in response to the 
bait–prey interaction. Parallel transcriptional activation of a colorimetric reporter, such 
as lacZ encoding β-galactosidase (β-gal), serves to confirm the specificity of the 
activation. The main advantage of the Y2H is that it detects even weak or transient 
protein-protein interactions, because it is amplified many-fold through a 
transcriptional process (Fashena et al. 2000; Stynen et al. 2012). In our study, the 
colony-lift filter paper β-gal assay was used as means to qualitatively measure the β-
gal activity of positive interaction between a series of RyR2 N-terminal construct with 
cMyBP-C CT.  
RyR2 N-terminus is known to self-associate in a tetrameric fashion (Tung et al. 2010; 
Zissimopoulos et al. 2013). This raises the possibility that cMyBP-C may be 
interacting with an RyR2 interface either provided entirely by the monomer or be 
composed of binding determinants provided by two adjacent RyR2 subunits. To test 
this, we used a BT4L construct with a small internal deletion of (residues 167-178, 
corresponding to the loop connecting β-strand 8 and 9 in NTD subdomain A) shown 
to disrupt RyR2 N-terminus tetramerisation (Seidel 2014). The BT4LΔβ8-β9 was co-
transfected HEK293 cells with cMyBP-C CT, followed by co-IP analysis for protein-
protein interaction. The detected binding ability was directly compared to that of the 
original BT4L + CT. 
Analysis of RyR mRNA expression pattern in adult atrial and ventricular myocytes by 
(Gorza et al. 1997) revealed that in fact the most abundant isoform in the heart is 
RyR2 while RyR3 was shown to be widely co-expressed in the same cell at relatively 
low levels. Further, a concomitant expression of all three isoforms was reported to 
take place in the vascular smooth muscle (Neylon et al. 1995). Notably, cMyBP-C C-
terminus has high sequence homology with two other mammalian MyBP-C isoforms, 
fMyBP-C and sMyBP-C (∼70%, for the residues 817-1274, similarity between 
sequences was calculated with NCBI BLAST tool), both being expressed in 
abundance in skeletal muscle (Dhoot et al. 1985), where RyR1 is the main RyR 
isoform involved in ECC. Further, since the RyR2 N-terminal region shares high 
homology with the two remaining RyR isoforms (∼85% for the first 900 residues, 
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NCBI BLAST tool), we tested the cMyBP-C CT interaction with RyR1 and RyR3 in 
parallel experiments, both in vitro (co-IP assay) and in vivo (Y2H analysis), in order to 
get some insights whether the MyBP-C:RyR interaction could also occur between 
different RyR isoforms.  
 
4.2 Chapter objectives 
The main aim of this Chapter was to identify the cMyBP-C and RyR2 binding sites. In 
particular, the following points will be addressed: 
 mapping of RyR2 region responsible for cMyBP-C binding using co-IP and Y2H 
assays; 
 assessment of cMyBP-C binding to monomeric N-terminal RyR2 construct using 
the co-IP assay; 
 mapping of cMyBP-C region responsible for RyR2 interaction using the co-IP 
assay; 
 verification of the RyR isoform-specificity of cMyBP-C association using co-IP and 
Y2H assays. 
 
4.3 Methods 
 
4.3.1 Generation of a series of truncated HA-tagged cMyBP-C constructs 
Truncated cMyBP-C cDNA fragments were generated by PCR from cMyBP-C FL 
construct as a template in the presence of the appropriate forward and reverse 
primer (see Table 2.1), designed to introduce suitable cloning sites at both 5’ and 3’ 
end of the PCR product. To ensure proper peptide folding, protein fragments were 
designed to start/stop within the linker sequences between individual cMyBP-C Ig or 
Fn domains, therefore, oligonucleotide primers annealing at the selected, 
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corresponding cDNA sequences were used. Obtained products were cloned into HA-
modified pCR3 vector and used for large scale plasmid isolation (for details, see 
Sections 2.2.1.2-2.2.1.4, and 2.2.3.1-2). Summary of all generated constructs can be 
found in Table 4.1 and Figure 4.1.  
 
Table 4.1 List of generated HA-tagged cMyBP-C constructs and corresponding primers and restriction 
nucleases used in this study. Coordinates correspond to the human cMyBP-C mRNA, accession 
number: X84075. 
Construct Coordinates Length PCR Primers Cloning Sites 
C6-C8 2490-3237 (b) 
820-1068 (aa) 
747 (b) 
248 (aa) 
HcMyBPC.FOR.2481-2508 
HcMyBPC.REV.3217-3237 
EcoRI 
XhoI 
C8-C10 2931-3857 (b) 
967-1274 (aa) 
926 (b) 
307 (aa) 
HcMyBPC.FOR.2925-2949 
HcMyBPC.REV.3849-3876 
BamHI 
XhoI 
fC6-C7 2337-2952 (b) 
771-972 (aa) 
615 (b) 
201 (aa) 
HcMyBP-C.FOR.2331-2360 
HcMyBP-C.REV.2931-2958 
BamHI 
XhoI 
C6-C7 2490-2952 (b) 
820-972 (aa) 
462 (b) 
152 (aa) 
HcMyBPC.FOR.2481-2508 
HcMyBP-C.REV.2931-2958 
EcoRI 
XhoI 
fC6 2337-2630 (b) 
771-866 (aa) 
293 (b) 
95 (aa) 
HcMyBP-C.FOR.2331-2360 
HcMyBPC.REV.2611-30 
BamHI 
XhoI 
C7 2635-2952 (b) 
869-972 (aa) 
307 (b) 
103 (aa) 
HcMyBP-C.FOR.2625-56 
HcMyBP-C.REV.2931-2958 
BamHI 
XhoI 
C8 2931-3237 (b) 
967-1068 (aa) 
306 (b) 
101 (aa) 
HcMyBPC.FOR.2925-2949 
HcMyBPC.REV.3217-3237 
BamHI 
XhoI 
C9 3213-3512 (b) 
1061-1160 (aa) 
299 (b) 
99 (aa) 
HcMyBPC.FOR.3204-3235 
HcMyBPC.REV.3519-3488 
BamHI 
XbaI 
C8-C9 2931-3512 (b) 
967-1160 (aa) 
581 (b) 
193 (aa) 
HcMyBPC.FOR.2925-2949 
HcMyBPC.REV.3519-3488 
BamHI 
XbaI 
C9-C10 3213-3857 (b) 
1061-1274 (aa) 
644 (b) 
213 (aa) 
HcMyBPC.FOR.3204-35 
HcMyBPC.REV.3849-3876 
BamHI 
XhoI 
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4.3.2 Co-immunoprecipitation 
Mammalian (c-Myc tagged) RyR constructs (BT fragments, obtained from Dr S. 
Zissimopoulos, see Table 4.2 and Figure 4.2 for summary) and (HA-tagged) cMyBP-
C plasmids were used to co-transfect HEK293 cells growing on 100 mm Petri dishes 
as described in (Section 2.2.5.3). RyR2 BT4L was used to screen the series of 
cMyBP-C truncated fragments, whereas cMyBP-C CT fragment was used to screen 
the series of RyR2 fragments (BT constructs). All plasmids were co-transfected in 
~1:1 molar ratio (12 µg + 12 µg per dish), apart from BT4C+ CT (4 µg +20 µg), 
BT4EL+CT (20 µg +4 µg), BT4B + CT (22 µg +2 µg) and BT4D + CT (22 µg +2 µg). 
Those adjustments were required due to higher (BT4C) or lower expression levels 
(BT4EL, BT4B, BT4D) in HEK293 when compared to other BT constructs. All 
Figure 4.1 Graphical representation of generated HA-tagged cMyBP-C constructs. Coordinates 
correspond to the human cMyBP-C cDNA, accession number: X84075 
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subsequent statistical analysis was conducted using GraphPad Prism (see Section 
2.2.11). 
 
Table 4.2 List of all RyR2 plasmids used. Coordinates correspond to the human RyR2 mRNA 
(accession number: X98330). 
Construct Coordinates Length 
BT4L 122-2840 (b) 
1-906 (aa) 
2718 (b) 
906 (aa) 
BT4 122-2398 (b) 
1-759 (aa) 
2276 (b) 
759 (aa) 
BT4Lβ8-β9 BT4L deletion, without 
167-178 (aa) 
896 (aa) 
BT4A 122-1711 (b) 
1-530 (aa) 
1589 (b) 
530 (aa) 
BT4B 1160-2398 (b) 
346-759 (aa) 
1238 (b) 
413 (aa) 
BT4C 122-2084 (b) 
1-654 (aa) 
962 (b) 
654 (aa) 
BT4D 605-2398 (b) 
161-759 (aa) 
793 (b) 
598 (aa) 
BT4BL 1160-2840 (b) 
346-906 (aa) 
1680 (b) 
560 (aa) 
BT4DL 605-2840 (b) 
161-906 (aa) 
2235 (b) 
745 (aa) 
BT4EL 1818-2840 (b) 
565-906 (aa) 
1022 (b) 
341 (aa) 
RyR1 BT4L 1-915 (aa) 915 (aa) 
RyR3 BT4L 
 
1-911 (aa) 911 (aa) 
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Cell pellets obtained 24 hours after transfection were homogenised (Section 2.2.2.1) 
and co-IP was performed as described in Section 2.2.2.3. Polyclonal HA antibody 
(Section 2.1.11) were used to immunoprecipitate the HA-tagged cMyBP-C fragment 
of interest. Non-immune rabbit IgG served as negative control. DTSSP was used to 
cross-link the immunoprecipitating Ab onto Protein A beads for BT4A + CT, BT4B + 
CT and BT4EL + CT pairs, and samples were co-immunoprecipitated (see Section 
2.2.2.3), due to the similar size of Ab heavy chain to that of BT4A/B/EL. For 
immunoblotting, Ab HA and Ab c-Myc (Section 2.2.11) were used to detect directly 
precipitated cMyBP-C fragment and indirectly co-precipitated RyR2 fragment, 
respectively. The level of co-precipitated proteins was determined by densitometry 
(Section 2.2.10).  
 
4.3.3 Yeast-two hybrid 
The C-terminus interaction of cMyBP-C with the series of truncated RyR2 N-terminus 
fragments was assessed in vivo using the yeast two-hybrid system. The series of bait 
plasmids containing the truncated N-terminal RyR2 fragments (BT fragments, 
spanning the RyR2 residues 1-906) fused to the GAL4 DNA-BD and c-Myc epitope 
(in pGBKT7 vector), and the prey plasmid (AD-CT) containing the C-terminal of 
cMyBP-C (CT) expressed as fusion protein with GAL4 AD and HA epitope (in pACT2 
Figure 4.2 . Graphical representation of BT fragments relative to RyR2 cDNA sequence 
(accession number: X98330). 
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vector) were obtained from Dr S. Zissimopoulos. Yeast co-transformations and β-
galactosidase colony-lift filter assay were performed as described in Section 2.2.4.1 
and 2.2.4.2 respectively. Table 4.3 enlist all tested combinations (pairs 1-10). The 
interaction between pVA3-1 coding for a DNA-BD/murine p53 fusion protein and 
pTD1-1 coding for an AD/SV40 large T-antigen fusion protein was used as assay 
quality positive control. The expression levels of all constructs used in this study were 
investigated with immunoblotting (Section 2.2.4.3). The Y2H obtained data were 
expressed relative to the positive interaction observed between the control proteins 
(pVA3 + pTD1).  
Table 4.3 Summary of all tested RyR2:cMyBP-C pairs used in Y2H assay. 
Pair GAL 4 DNA-BD GAL4 AD 
Control pVA3 pTD1 
1 BT4L CT 
2 BT4 CT 
3 BT4A CT 
4 BT4B CT 
5 BT4C CT 
6 BT4D CT 
7 BT4BL CT 
8 BT4DL CT 
9 RyR1 BT4L CT 
10 RyR3 BT4L CT 
 
4.4 Results 
 
4.4.1 Generation of a series of cMyBP-C truncated constructs 
All cMyBP-C constructs (see Table 4.1) were successfully generated and their DNA 
sequence was confirmed. For a typical set of results representing intermediate steps 
of the cloning process, see Section 3.4.3 and Figure 3.3. 
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4.4.2 Mapping of the minimal interacting region of RyR2 N-terminus 
involved in association with cMyBP-C C-terminus 
 
4.4.2.1 Several RyR2 binding determinants can be detected using in vitro co-IP 
assays  
To further localise the cMyBP-C binding site within BT4L (RyR2 residues 1-906), a 
series of eight overlapping BT sub-fragments (c-Myc-tagged) were co-expressed 
together with the same HA-tagged cMyBP-C CT fragment and used in co-IP. 
Representative blots are shown in Figure 4.3 and summary of the results following 
quantitative densitometry analysis is presented in Figure 4.4 A (shown as relative 
binding, calculated by subtracting the non-specific binding form the specific binding of 
given BT construct). Obtained data indicated that fragments BT4 (residues 1-759), 
BT4D (residues 161-759), BT4DL (residues 161-906), BT4EL (residues 565-906) 
scored as positive with CT when compared to their respective non-specific binding 
(calculated using paired, 2-tailed Student’s t-test, Figure 4.4 A), with BT4EL being 
the smallest but also the weakest of all obtained positive constructs. Interestingly, 
both BT4EL and a fragment consisting of additional 346-565 amino acids, BT4BL 
(residues 346-906) exhibited only an occasional interaction with CT (which did not 
reach the statistical significance in the case of BT4BL), whereas the smaller 
fragments within RyR2 residues 1-906 were negative, namely BT4A (residues 1-
530), BT4B (residues 346-759) and BT4C (residues 1-654) (Figure 4.4 A). Notably, 
lack of amino acids 1-161 or 755-906 appeared to result in a substantial reduction in 
the relative binding ability (BT4, residues 1-755; BT4D, residues 161-759, BT4DL, 
residues 161-906, BT4EL, residues 565-906) when compared to BT4L (~50%, ~70%, 
~30% and ~80%, respectively, Figure 4.4 A). Further, monomeric BT4LΔβ8-β9 (BT4L 
lacking residues 167-178) displayed comparable cMyBP-C relative binding to 
tetrameric BT4L (Figure 4.4 A and B), with only those two constructs (BT4L and 
BT4LΔβ8-β9) having the statistically significant difference in the relative binding ability 
across all tested BT RyR2 fragments when compared to the negative construct BT7 
(p< 0.0001 using Kruskal-Wallis test, with Dunn's multiple comparisons test, see 
Appendix, Table 8.2).
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Figure 4.3 Representative results (n≥4) of a 
series of BT c-Myc- tagged RyR fragments 
co-IP with HA-tagged cMyBP-C CT 
construct. CT was immunoprecipitated with 
HA Ab from CHAPS-solubilised HEK293 cell 
lysate (2 mg) and normal, non-immune rabbit 
IgG was used as negative control. Co-IP 
samples were loaded on two separate SDS-
PAGE gels (1/10th and 9/10th split, lower and 
upper panel, respectively) and analysed by 
immunoblotting with Ab HA (HA WB for CT, 
lower panels) and Ab c-Myc (c-Myc WB for 
BT, upper panels). A cell lysate aliquot was 
loaded on the gels to verify expression in 
HEK293; in c-Myc WB, 1/200th of the 
volume processed in co-IP samples; in HA 
WB 1/100th of the volume processed in co-
IP samples. All bands corresponding to 
appropriate fragments are indicated as 
follows: BT of interest, red arrow; CT, violet 
arrow. 8-12% reducing SDS-PAGE gels 
were used for c-Myc WB and 12% gels for all 
HA WB. Black arrows show Ab heavy chain 
and white arrows in BT4A, BT4B and BT4EL 
WB show bands corresponding to 
aggregates formation (due to non-reducing 
conditions required for Abs DTSSP cross-
linking). 
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Figure 4.4 Densitometry analysis of a series of recombinant RyR2 BT truncated fragments with 
cMyBP-C CT construct binding in co-IP assay from HEK293 homogenates and representative blot 
showing co-IP results of BT4L + CT and BT4LΔβ8-β9 + CT. (A) Results shown are presented as 
relative specific binding (specific binding subtracted of non-specific binding) and normalised to each 
fragments respectable lysate input (corresponding to 1/200th of the processed sample). Data are 
shown as mean ±SD, n≥4; * statistical significance at p<0.05 calculated using paired, 2-tailed 
Student’s t-test. For comparison, BT4L + CT and BT7 + CT relative binding (from Figure 3.10) are 
also included. (B, top panel) WB using c-Myc Ab detecting c-Myc tagged BT construct of interest; 
(B,lower panel) corresponding WB using HA Ab detecting HA-tagged cMyBP-C CT. A cell lysate 
aliquot was loaded on the gels to verify expression in HEK293; in c-Myc WB, 1/200th of the volume 
processed in co-IP samples; in HA WB 1/100th of the volume processed in co-IP samples. All 
fragments are indicated as follows: BT of interest, red arrow; CT fragment, violet arrow. 8% reducing 
SDS-PAGE gel was used for c-Myc WB and 12% gel for HA WB. 
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Importantly, when all used truncated BT fragments were compared to the positive 
BT4L, significant difference was observed for BT4A, BT4B, BT4C and BT4BL, which 
indicates that those constructs are negative, but not for BT4, BT4D, BT4DL and 
BT4EL, which appear to be positive for cMyBP-C interaction (Appendix, Table 8.2). 
Overall, the obtained data shown that although BT4L (residues 1-906) displays the 
strongest cMyBP-C interaction in vitro, the residues 1-346 and 654-906 (present in 
the weaker, positive BT constructs) appear to be the important determinants of the 
association. Importantly, none of the smaller BT constructs could retain comparable 
relative binding to BT4L, indicating the presence of several binding sites and/or 
regions important for the association within amino acids 1-906, which seems to be 
indispensable for comparable BT4L + CT binding ability. 
 
4.4.2.2 RyR2 binding site is contained within BT4L as assessed using in vivo Y2H 
assays  
The findings described in the previous sections, indicated that residues 654-759 and 
165-346 from RyR2 might be the important determinants of cMyBP-C C-terminus 
binding. The experiments described in previous section tested RyR2:cMyBP-C 
association in a test tube outside of the cell, an environment which substantially 
differs from the tightly controlled and intact cellular milieu. The Y2H system, where 
detection of protein-protein interactions takes place in living yeast, was employed to 
evaluate whether the in vitro observed effects can be reproduced in in vivo 
conditions. The cMyBP-C CT fragment was expressed in yeast strain Y190 as a 
fusion with GAL4 AD, co-transformed with one of the RyR2 truncated fragments, 
expressed as fusions with DNA-BD. The expression of all constructs used in this Y2H 
study was investigated by WB, as substantial differences in protein levels would 
affect the outcome of the assay. As shown in Figure 4.5, all recombinant proteins 
were successfully expressed, but to various levels. Summary of obtained Y2H results 
is shown in Table 4.4. The β-galactosidase colony-lift filter paper assay confirmed 
that interaction between CT and BT4L indeed takes place in vivo and also scored for 
an interaction for the CT + BT4 pair, albeit considerably weaker. Interaction with 
smaller RyR2 BT fragments could not be detected, also for BT4DL, probably due to  
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Figure 4.5 Representative western blots showing expression levels of recombinant proteins tested in 
Y2H system (n≥3); (A): c-Myc WB of recombinant proteins fused with DNA-BD, respective bands are 
shown with red arrows; (B): HA WB of recombinant CT fused with GAL4 AD, indicated with black 
arrow. 
 
Table 4.4 Summary of Y2H results for RyR2:cMyBP-C interaction.  
Pair GAL 4 DNA-BD GAL4 AD Y2H Results 
Control pVA3 pTD1 +++ 
1 BT4L CT ++ 
2 BT4 CT + 
3 BT4A CT - 
4 BT4B CT - 
5 BT4C CT - 
6 BT4D CT - 
7 BT4BL CT - 
8 BT4DL CT - 
9 BT4L RyR1 CT ++ 
10 BT4L RyR3 CT - 
Note: The 2nd column lists fusion proteins with the GAL4 DNA binding domain (BD) and the 3rd 
column lists fusion proteins with the GAL4 activation domain (AD). Interactions between two fusion 
proteins is shown in the third (β-galactosidase activity = lacZ Assay) column. Qualitative relative 
binding affinities after ~4 h are expressed as pluses in the table (+Light blue; ++Blue; +++Deep blue). 
Interaction between pVA3 and pTD1 served as the positive control. 
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general high variability of the BT4DL + CT binding when compared to BT4 + CT as 
seen in co-IP experiments (Figure 4.4 A), which likely was beyond sensitivity of Y2H 
assay. Further, despite several attempts successful BT4EL + CT co-transformation 
could not be achieved, thus results for this construct are not shown. 
 
4.4.2.3 Corresponding RyR1 and RyR3 N-terminal fragments can interact with 
MyBP-C 
Since both the C-terminal primary sequence of the mammalian MyBP-C isoforms and 
N-terminal sequence of RyR isoforms show high sequence homology, attempts were 
made to verify if cMyBP-C CT is capable of interaction with two other mammalian 
RyR isoforms, RyR1 and RyR3. 
Parallel Y2H and co-IP experiments with the corresponding RyR1/3 N-terminal 
fragments (RyR1 BT4L, amino acids 1-915 and RyR3 BT4L, amino acids 1-911) 
were conducted to test if MyBP-C interaction is RyR isoform specific. Robust 
interaction was detected only between cMyBP-C CT and RyR1 BT4L from Y2H 
experiments comparable to that of RyR2 (Table 4.4, 9-10). RyR1 BT4L interaction 
with cMyBP-C, equivalent to RyR2, was also found from co-IP experiments (Figure 
4.6, A). Unlike the Y2H, co-IP experiments showed that RyR3 isoform is also capable 
of interaction with cMyBP-C CT (when compared to their respective non-specific 
binding calculated using paired, 2-tailed Student’s t-test, Figure 4.2, B), and the 
relative binding ability (the specific binding subtracted of the non-specific binding) is 
comparable (no statistical difference) to those detected for BT4L and RyR1 BT4L (p= 
0.2626 using one-way ANOVA, with Bonferroni's post-test, see Appendix, Table 
8.3). In conclusion, these results might suggest that MyBP-C could be relevant in 
regulation of RyR not only in cardiac, but it also in skeletal muscle. 
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Figure 4.6 Representative blot showing co-IP results of RyR1 BT4L + CT and RyR3 BT4L + CT and 
cumulative densitometric analysis. (A, top panel) WB using c-Myc Ab detecting c-Myc tagged BT 
construct of interest; (A, lower panel) corresponding WB using HA Ab detecting HA-tagged cMyBP-C 
CT. A cell lysate aliquot was loaded on the gels to verify expression in HEK293; in c-Myc WB, 
1/200th of the volume processed in co-IP samples; in HA WB 1/100th of the volume processed in co-
IP samples. All fragments are indicated as follows: BT of interest, red arrow; CT fragment, violet 
arrow. 12% reducing SDS-PAGE gel was used for both c-Myc and HA WB. (B)Densitometry analysis 
of recombinant cMyBP-C CT constructs binding with different N-terminal RyR isoforms in co-IP assay 
from HEK 293 homogenate. Results shown are presented as relative specific binding (specific 
binding subtracted of non-specific binding) and normalised to each fragments respectable lysate 
input (corresponding to 1/200th of the processed sample). Data are shown as mean ±SD, n≥5; * 
statistical significance at p<0.05 calculated using paired, 2-tailed Student’s t-test. For comparison, 
BT4L + CT relative binding (from Figure 3.10) is also shown. 
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4.4.3 Mapping of the minimal interacting region of cMyBP-C C-terminus 
involved in association with RyR2 N-terminus 
 
4.4.3.1 Domains C6-C7 and C9-C10 are important for the interaction with RyR2 as 
assessed using in vitro co-IP assays  
To further examine the RyR2-binding site within the cMyBP-C CT fragment 
(consisting of half of C6 domain and whole domains C7-C10, residues 817-1274), 
initially two overlapping sub-fragments C6-C8 (consisting of half of C6 domain and 
whole domains C7 and C8, residues 820-1068) and C8-C10 (consisting of whole 
domains C8-C10, residues 967-1274) were co-expressed with BT4L (RyR2 
construct, residues 1-906) and used in co-IP experiments. Representative blot is 
shown in Figure 4.7, A. Statistical analysis with paired, 2-tailed Student’s t-test 
indicated that both construct retain the interaction with BT4L when compared to their 
respective non-specific binding with C6-C8 displaying ~2-fold stronger binding ability 
with BT4L than either C8-C10 or the original CT fragment (Figure 4.7, B), which did 
not reach the statistical significance when the relative binding abilities (the specific 
binding subtracted of the non-specific binding) of (1) C6-C8 + BT4L versus C8-C10 + 
BT4L or (2) C6-C8 + BT4L versus CT + BT4L or (3) C8-C10 + BT4L versus CT + 
BT4L were compared (calculated using Kruskal-Wallis test, with Dunn's multiple 
comparisons test, see Appendix, Table 8.4). This allowed for some preliminary 
conclusions regarding the possible location of the RyR2 binding site: (1) the 
candidate region could be the C8 domain (residues 967-1068) since it was present in 
both tested constructs; and/or (2) Fn domains could be required to mediate the 
interaction, as C6-C8 containing two Fn domains (C6 and C7) shown the strongest 
binding.  
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Figure 4.7 Representative blot showing co-IP results of C6-C8 + BT4L and C8-C10 + BT4L and 
cumulative densitometric analysis. (A, top panel) WB using c-Myc Ab detecting c-Myc tagged 
BT4L; (B, lower panel) corresponding WB using HA Ab detecting HA-tagged cMyBP-C 
construct of interest. A cell lysate aliquot was loaded on the gels to verify expression in 
HEK293; in c-Myc WB, 1/200th of the volume processed in co-IP samples; in HA WB 1/100th 
of the volume processed in co-IP samples. Band corresponding to BT4L is shown with red 
arrow; whereas cMyBP-C fragment of interest with violet arrow, 12% reducing SDS-PAGE gel 
was used for both c-Myc WB and HA WB. Black arrows show bands corresponding to Ab 
heavy chain. Densitometry analysis of a series of recombinant cMyBP-C truncated fragments 
with RyR2 BT4L constructs (residues 1-906) binding in co-IP assay from HEK 293 
homogenate. Results shown are presented as relative specific binding (specific binding 
subtracted of non-specific binding) and normalised to each fragments respectable lysate input 
(corresponding to 1/200th of the processed sample). Data are shown as mean ±SD, n≥5; * 
statistical significance at p<0.05 calculated using paired, 2-tailed Student’s t-test. For 
comparison, BT4L + CT relative binding (from Figure 3.10) is also shown. 
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Since the CT fragment, originally isolated from the Y2H screen, starts in the middle of 
the C6 domain sequence, it is possible that the C6 domain is not correctly folded. In 
order to test it, two new constructs fC6-C7 (consisting of whole domains C6-C7, 
residues 771-972) and C6-C7 (consisting of half of C6 domain and whole domain C7, 
residues 820-972) were generated. Representative blot is shown in Figure 4.8, (1). 
Both new constructs displayed positive interaction with BT4L when compared to their 
non-specific binding with paired, 2-tailed Student’s t-test (Figure 4.7, B). The 
introduction of the missing sequence at the start of the C6 domain had no statistically 
significant effect when (1) C6-C7 + BT4L versus fC6-C7 + BT4L or (2) CT + BT4L 
versus fC6-C7 + BT4L or (3) CT + BT4L versus C6-C7 + BT4L relative binding 
abilities (the specific binding subtracted of the non-specific binding of each tested 
pair) were compared (calculated using Kruskal-Wallis test, with Dunn's multiple 
comparisons test, see Appendix, Table 8.4). These results suggested that the 
truncated C6 domain did not have an effect on the cMyBP-C:RyR2 binding ability and 
highlighted possible role for Fn domain C7. 
In order to further assess the involvement of individual cMyBP-C Ig/Fn C-terminal 
domains in the interaction with RyR2, six new constructs were made: single domain 
fC6, C7, C8 and C9 (residues 771-866, 869-97, 967-1068 and 1061-1160, 
respectively) and double domains C8-C9 (residues 967-1160) and C9-C10 (residues 
1061-1274). Representative blots are shown in Figure 4.8, (2-4). When the specific 
binding was compared to the non-specific binging using paired, 2-tailed Student’s t-
test, none of the single domain constructs scored for an interaction with BT4L, 
whereas both C8-C9 + BT4L and C9-C10 + BT4L were positive (significance at 
p<0.05 calculated using paired, 2-tailed Student’s t-test, Figure 4.7, B). It appears 
that C9-C10 + BT4L display ~3x stronger relative binding ability than C8-C9 + BT4L, 
although this difference is not statistically significant (calculated using Kruskal-Wallis 
test, with Dunn's multiple comparisons test, see Appendix, Table 8.4). However, 
when considering only CT + BT4L, C9-C10 + BT4L and C8-C9 + BT4L, equal 
variance between populations enabled to use more powerful than non-parametric 
Kruskal-Wallis test, the one-way ANOVA test, which indeed, shown (1) a statistically 
significant difference between C8-C9 and C9-C10 binding and (2) comparable 
binding between CT and C9-C10 (see Appendix, Table 8.4). This suggests that the  
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Figure 4.8 Representative results of a series of HA-tagged cMyBP-C construcs co-IP with c-Myc-
tagged BT4L (n≥5). cMyBP-C fragment of interest was immunoprecipitated with HA Ab from CHAPS-
solubilised HEK293 cell lysate (2 mg) and normal, non-immune rabbit IgG was used as negative 
control. Co-IP samples were loaded on two separate SDS-PAGE gels (1/10th and 9/10th split, lower 
and upper panel, respectively) and analysed by immunoblotting with Ab HA and Ab c-Myc. A cell 
lysate aliquot was loaded on the gels to verify expression in HEK293; in c-Myc WB, 1/200th of the 
volume processed in co-IP samples; in HA WB 1/100th of the volume processed in co-IP samples. All 
fragments are indicated as follows: BT4L, red arrow; cMyBP-C construct of interest, violet arrow.  
12% reducing SDS-PAGE gels were used for both c-Myc and HA WB. Black arrows show bands 
corresponding to Ab heavy chain. 
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C8 domain is unlikely to be involved in the interaction, and reinforced the notion that 
the Fn domain/s mediate/s the RyR2 binding.  
Overall, two truncated C-terminal cMyBP-C constructs retained comparable strong 
RyR2 interaction, namely C6-C7 and C9-C10. Both fragments consist of Fn domains, 
either C6 and C7 or C9, suggesting the possible importance of a Fn domain as 
responsible for RyR2 binding, with the presence of minimum one of neighbour (either 
another Fn or Ig) domain being required for detectable BT4L association. 
 
4.5 Discussion 
 
4.5.1 The regions responsible for cMyBP-C binding are contained within 
the cytosolic RyR2 NTD subdomains A and B, and SPRY1 and P1 
The presented data provide several lines of evidence for a specific protein–protein 
interaction between RyR2 and cMyBP-C, further reinforcing findings reported in 
Chapter 3. Using complementary in vitro and in vivo assays, mapping of the binding 
region responsible for cMyBP-C:RyR2 interaction in each protein was attempted. The 
smallest positive RyR2 interacting construct obtained in vitro was the BT4EL 
fragment (residues 565-906) (Figure 4.4 A), indicating that this fragment may include 
the part of the cMyBP-C binding region. Notably, detected BT4EL relative binding 
ability was the weakest of all positive fragments (BT4, BT4D and BT4DL), implying 
that other region/s present in the missing 1-565, corresponding to the NTD 
subdomain A and B (residues 10-223 and 224-408 for RyR2 coordinates (Borko et al. 
2014)) contribute to the interaction. The summary of RyR2 residues mapped to be 
important for association with cMyBP-C CT are show in Figure 4.9 and Table 4.5. It 
appears that RyR2 residues 1-161, 161-346, 654-759 and 759-906 are involved in 
the interaction, with residues 654-759 most likely being the most important as this 
region is present in all positive constructs. Notably, presence of all four regions is 
indispensable for strong RyR2:cMyBP-C binding, as observed for BT4L + CT. Thus, 
lack of residues 1-161 results in ~30% reduction of relative binding ability of BT4DL + 
CT, deletion of residues 759-906 decreases relative binding ability of BT4 + CT by 
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~50%, lack of residues 1-161 and 759-906 causes ~70% reduction of relative binding 
ability of BT4D + CT, and amino acids 1-346 truncation seems to inhibit the BT4EL + 
CT binding by ~50% (all relative to positive BT4L + CT). Interestingly, BT4B (residues 
346-759) and BT4BL (residues 346-906) which also have amino acids 654-759, 
scored as negative, with the latter displaying weakly positive, but not reproducible 
results. 
It is possible that residues 346-530, without presence of flanking residues 161-346 
and 565-654, are responsible for the incorrect secondary structure of this region 
(Table 4.5, highlighted in orange), which appears to completely inhibit the 
interaction with CT. Also, residues 1-346 and 565-654 on their own are not sufficient 
to mediate the interaction, as observed for BT4C + CT. Further, deletion construct 
BT4LΔβ8-β9 lacking residues 167-175 did not display any difference in binding ability 
with CT when compared to BT4L + CT (Figure 4.1 A), therefore it seems that those 
residues are not important for RyR2:cMyBP-C association (for further explanation 
see Section 4.5.2). In conclusion, the determinants for the cMyBP-C:RyR2 binding 
are residues 1-167, 175-346, 654-759 and 759-906. As the residues 165-223 are 
included in the two β strands of the surface exposed region of subdomain A (Figure 
4.10, A’ and B’, black arrow), it is possible that those are directly involved in 
mediating the interaction, as observed in case of positive constructs BT4, BT4D and 
BT4DL (Table 4.5). 
Mapped RyR2 residues 654-906 (coordinates for RyR1: 642-894) are contained 
within the first part of SPRY1 domain and also overlap with first 43 amino acids of P1 
(residues 632-826 and 851-1055, respectively, RyR1 coordinates by (Yan et al. 
2015), residues 650-844 and 844-1054, RyR2 coordinates by (Borko et al. 2014)), 
whereas RyR2 residues 1-167 (coordinates for RyR1: 1-154) and 175-346 
(coordinates for RyR1: 162-330) belong to NTD subdomain A and B (residues 1- 205 
and 206–394, respectively, RyR1 coordinates by (Tung et al. 2010; Yan et al. 2015); 
and 10-223 and 224–408, respectively, for RyR2 (Borko et al. 2014)), which appear 
to be ~190Å apart in single RyR1 subunit (Figure 4.11). Notably, all regions seem to 
be surface exposed towards cytosol, thus physically accessible for the interaction to 
take place. Interestingly, (Borko et al. 2014) reported that while NTD subdomains A 
and C are structurally very similar in all published structures of human RyR2 (4JKQ, 
amino acids 1-606), rabbit RyR1 (2XOA; amino acids 1–559; (Tung et al. 2010))  
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Table 4.5 Summary of RyR2 residues mapped to be important for the association 
construct 1-
161 
161-
346 
346-
530 
565-
654 
654-
759 
759-
906 
+ CT binding description  
(versus BT4L + CT) 
BT4DL no yes yes yes yes yes positive, ~30 % reduction 
BT4 yes yes yes yes yes no positive, ~50% reduction 
BT4D no yes yes yes yes no positive, ~70% reduction 
BT4EL no no no yes yes yes variable, positive, ~80% reduction 
BT4BL no no yes yes yes yes variable, negative 
BT4A yes yes yes no no no negative 
BT4B no no yes yes yes no negative 
BT4C yes yes yes yes no no negative 
Notes: regions included in the mapped fragment are shown in green, proposed misfolded region 
contained within residues 346-530 is shown in orange,  
  
Figure 4.9 Graphical representation of fragments used in mapping of the minimal RyR2 region 
interaction with cMyBP-C CT using co-IP assays. Upper rectangle is the N-terminal 1-1054 amino 
acids RyR2 sequence, with depicted domain organisation according to (Borko et al. 2014). 
Rectangles below are RyR2 overlapping fragments tested for cMyBP-C binding. Rectangles in red 
(BT4L, BT4, BT4D, BT4DL, BT4EL) are fragments positive for the interaction with cMyBP-C CT. 
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and mouse RyR2 (4l4H; amino acids 1–547; (Kimlicka et al. 2013)), they show large 
differences between the structures of subdomain B. The largest dissimilarity can be 
observed in the region of the long loop composed of residues 333–361 in subdomain 
B, which are contained in our mapped 175-346 binding site.  
The N-terminal formed ring-like region has been shown to undergo large 
conformational changes upon channel activation (Samso et al. 2009; Efremov et al. 
2015; Zheng 2015), with this region known to harbour more than 50 disease 
mutations, almost all located at domain interfaces (Amador et al. 2009; Tung et al. 
2010). Based on these observations, it has been proposed that these disease 
Figure 4.10 Location of mapped cMyBP-C CT regions in 3D structure of the human RyR2 NTD 
residues 1-606 at 2.39 Å.  A depicts the structure as cartoon and B as sphere. A’ and B’ show 
corresponding mapped region. Subdomain NTD A is labelled in blue (residues 10-223), NTD B in red 
(residues 224-408) and NTD C in green (residues 409-544), whereas mapped regions are shown in 
pink (residues 1-167) and orange (residues 175-346).  Residues 165-223 exposed on the surface of 
subdomain A are indicated with black arrow. Images created using The PyMOL Molecular Graphic 
Software (based on (Borko et al. 2014), accession number 4JKQ). 
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Figure 4.11 Location of mapped cMyBP-C CT interaction regions in 3D structure of the rabbit RyR1 at 
3.8 Å. Proposed residues are labelled with pink (RyR2 residues 1-167, coordinates for RyR1: 1-154), 
orange (RyR2 residues 175-346, coordinates for RyR1:  162-330), blue (RyR2 residues 654-759, 
coordinates for RyR1: 642-747) and green (RyR2 residues 759-906, coordinates for RyR1: 742-894) 
within single RyR1 subunit (grey). Images created using The PyMOL Molecular Graphic Software 
(based on ((Yan et al. 2015), accession number 3J8H). 
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mutations might destabilize domain interfaces, which, in turn, would alter the 
conformational changes that are important in regulation of channel gating (Lobo and 
Van Petegem 2009; Lobo et al. 2011; Amador et al. 2013). Consistently, the RyR2 N-
terminal disease mutations have been shown to enhance the activation of the 
channel (Jiang et al. 2005; Jiang et al. 2010; Tang et al. 2012; Liu et al. 2013). 
Additionally, recent work of (Liu et al. 2015) found that each domain of NTD has a 
specific role in governing the RyR2 channel activity, with the NTD subdomain A 
(residues 1-217) being important for termination, but not for activation of Ca2+ 
release, with the subdomain B (residues 218-409) being involved in stabilizing the 
closed state of the channel important for both activation and termination of Ca2+ 
release, and subdomain C (residues 410-543) being critical for channel activation 
and expression. Thus, since part of the mapped RyR2 + CT binding region is 
contained within the NTD subdomains A and B (residues 1-346), it could be possible 
for cMyBP-C to affect channel function by directly altering channel gating, i.e. by 
inhibiting the RyR2 activity. 
The SPRY domains have one of the most common β-sandwich folds in eukaryotes 
and a broad range of functions, with the role in RyRs still poorly understood. In 
general, SPRY can be found as central domains in ligases, where they act as binders 
of regulatory proteins (Perfetto et al. 2013). Their positions in RyR1 suggest that 
among other possible functions, they might maintain channel structural integrity by 
mediating contacts between two large α-solenoid domains (helical and central) and 
provide a scaffold for the P1 domain (Efremov et al. 2015). Notably, the recently 
obtained crystal structures of SPRY1 and P1 region indicates that SPRY1 loop is a 
major FKBP binding determinant, with disease mutation in the SPRY1 domain 
affecting the FKBP binding (Yuchi et al. 2015). The same authors propose that those 
mutations, through interfering with the folding, might affect the closed state of the 
channel and decrease the appearance of RyR subconductance states. Therefore, 
cMyBP-C may either directly compete for FKBP binding site and/or disrupt the RyR2 
N-terminal and central region interactions.  
To test whether observed in vitro results can be reproduced in a living cell, the Y2H 
system was employed to verify binding of C-T fragment and the same set of 
truncated RyR2 fragments (Table 4.4). Detected with WB expression levels were not 
homogenous, with the smaller BT fragments expressed at higher levels than the 
  Chapter 4 
 
138 
 
bigger fragments BT4L and BT4. Interestingly, β-galactosidase assays indicated an 
interaction between CT + BT4L and weaker CT + BT4, whereas interaction with 
smaller RyR2 BT fragments could not be detected. These findings emphasize that 
protein abundancy does not have any bearing on the detection of interaction, with the 
identity of interacting fragments linked to true relative binding ability and specificity of 
cMyBP-C:RyR2 interaction. 
 
4.5.2 cMyBP-C appears to interact with single RyR2 subunit  
The NTDs are known to make key interactions stabilizing the cytosolic assembly of 
the channel, both with other domains in the same protomer, and with N-terminal 
domains contributed by neighbouring subunits. A major feature of this cytosolic 
assembly interaction is the apparent homotetramer formation by the RyR2 N-terminal 
region (Zissimopoulos et al. 2013), a property that is conserved in the inositol 1,4,5-
trisphosphate receptors, another Ca2+ release channel family that share ~30% 
homology with RyRs and display high conservation of structure-function relationship 
(Zissimopoulos et al., 2014). The interacting surfaces of subdomains A and B have 
been shown to display a prevalence of positive (D18, E22, D61) and negative (R276, 
R281, H288, R298, K319) electrostatic potentials distribution of amino acid 
sequences, respectively, suggesting a significant role of electrostatic interactions in 
RyR2 central rim tetramerization (Borko et al. 2014). For the RyR1, those sites 
included flexible loops connecting β-strand 20 and 21, β22-23 and a part of loop 
connecting β-strand 8 and 9, with the two latter proposed to mediate the 
homotetramer formation. Further, the β8-β9 loop contains three arrhythmia 
associated mutations (P164S, R169Q and R176Q) implying the functional 
importance of residues contained within this loop (Seidel 2014). Importantly, 
disruption of N-terminal inter-subunit interactions within RyR2 has been reported to 
increase channel activity at low Ca2+ concentrations, suggesting that N-terminus 
tetramerization is involved in RyR2 channel closure (Zissimopoulos et al. 2013). 
Since the part of the initial mapped CT binding region spans residues 1-346, we 
hypothesized that RyR2 N-terminus tetramerisation may be required for 
RyR2:cMyBP-C interaction to occur. However, deletion construct BT4LΔβ8-β9 lacking 
residues 165-195 did not display any difference in binding ability with CT when 
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compared to BT4L + CT (Figure 4.4 A and B), thus it is likely that cMyBP-C is 
interacting with an RyR2 interface provided by the single monomer rather than by two 
adjacent RyR2 subunits.  
 
4.5.3 RyR1:MyBP-C interaction may occur in skeletal muscle 
Parallel experiments with the corresponding N-terminal fragments from the skeletal 
muscle isoform RyR1 (amino acids 1-915) indicated robust interaction with cMyBP-C 
C-T by Y2H (Table 4.4) and form co-IP analysis (Figure 4.6). These results suggest 
that MyBP-C binding is conserved in other RyR isoforms and thus could be relevant 
in regulation of ECC coupling not only in cardiac muscle, but also in skeletal muscle. 
Further studies should help to unravel the precise molecular mechanism(s) by which 
MyBP-C binding is involved in the possibly dynamic, RyR isoform specific regulation 
of intracellular Ca2+ release. 
 
4.5.4 The cMyBP-C Fn domains are responsible for RyR2 binding  
The smallest cMyBP-C constructs retaining RyR2 BT4L interaction were C6-C7 
(residues 820-972) and C9-C10 (residues 1061-1274), which displayed comparable 
binding ability to the original cMyBP-C CT fragment isolated from the Y2H screen 
(Figure 4.7 B and Figure 4.12). Both fragments have Fn domains, and especially C7 
or C9 seem to be important for RyR2 interaction. C6 also belongs to the Fn fold, but it 
is unlikely to be as important because only half of it is present in the C6-C7 construct 
and also because the NT construct that contains the whole C6 domain does not 
interact with BT4L (see Section 3.4.5.). Comparable BT4L binding was obtained 
between C6-C7 and fC6-C7, which contains the whole C6 domain, further indicating 
that C7 rather than C6 is the main contributor to the interaction. Importantly, none of 
single domain constructs (fC6, C7, C8 or C9) could retain the interaction, suggesting 
that at least two domains are required to sustain the binding, one Fn and one 
additional neighbour being either Ig or Fn domain, and with each additional domain 
further strengthening the binding.  
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The requirement for an additional domain may simply be to enable and/or stabilise 
the correct folding of the C7/C9 domains, which are the primary RyR2 binding sites. 
Alternatively, secondary interaction may occur with this additional domain or within 
the linker sequence between the two domains. Altogether, Ig and Fn domains are 
connected linearly with  ~4nm repeats, creating a full-length cMyBP-C molecule of 
~50nm (~500Å) long (Furst et al. 1992). Crystal and NMR structures of cMyBP-C 
domains show that each Ig and Fn domain displays a compact, ~10kDa globular fold 
with dimensions ~2x3x4nm (Nadvi et al. 2016), thus the predicted length of cMyBP-C 
CT fragment, considering linear alignment of each globular domain, would appear to 
Figure 4.12 Graphical representation of fragments used in mapping of the minimal cMyBP-C 
region interaction with RyR2 BT4L using co-IP assays. Top rectangle represents the whole 
cMyBP-C FL sequence, while subsequent rectangles are cMyBP-C overlapping fragments tested 
for RyR2 binding. Rectangles encircled in red (CT, C6-C8, C8-C10, fC6-C7, C6-C7, C8-C9, C9-
C10) are fragments positive for the interaction. 
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be  ~180Å (~18nm), in line with the ~190Å distance calculated for the RyR binding 
site within the same protomer (Figure 4.11). 
Approximately 2% of all animal proteins contain the Fn type 3 repeat (Koide et al. 
1998). It belongs to one of the three types of internal Fn repeats found in the plasma 
protein fibronectin, with the 10th Fn type 3 domain shown to be directly involved in the 
interaction between fibronectin and its cell-surface receptors, integrins, a signalling 
process which is important for the wound healing (Pierschbacher and Ruoslahti 
1984). Further, (Martino and Hubbell 2010) reported that the fibronectin region 
spanning the 12th to 14th Fn type 3 repeats acts as growth factor-binding site, with 
recent evidence suggesting that the close proximity of this region to the Fn 12th to 
14th allows strong cross talk between the integrins and growth factor receptors (Lin et 
al. 2011). Further, it has also been shown that domains Ig 53 to Fn 2 of molluscs 
obscurin interacts with MEL-26 protein, pathway important for regulation of 
microtubule length (Wilson et al. 2012), whereas domains Ig-Ig-Fn 168-70 of titin are 
important its proteasome-dependent degradation by serving as direct binding site for 
an E3 ubiquitin ligase MURF1 (Mrosek et al. 2007). Thus, the proposed by us Fn/Ig 
or Fn/Fn domains cMyBP-C interaction with RyR2 would add to the already 
established functional diversity of Fn type 3 domain.  
 
4.5.5 Conclusions 
In conclusion, we have identified the C-terminus of MyBP-C as a novel interacting 
partner for mammalian RyR1/3 isoforms. Next, mapping of minimal binding regions of 
both proteins have shown that cMyBP-C residues 820-972 and 1061-1274, and 
RyR2 amino acids 1-167, 175-346 and 654-906 are important for RyR2:cMyBP-C 
interaction. We propose that cMyBP-C domains C6-C7 and C9-C10 mediate RyR2 
interaction, presumably by binding to both NTD A-B and SPRY1-P1 regions of single 
subunit simultaneously.  
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5 Functional modulation of RyR2 channel by cMyBP-C   
 
5.1 Introduction 
As discussed in Chapter 1, intracellular Ca2+ release from the SR store through 
RyR2 channels is a crucial event during ECC, which must be carefully regulated for 
normal contraction and subsequent relaxation of the mammalian heart (Bers 2004). It 
is well known that RyR2 activation is governed predominantly by cytosolic Ca2+, but 
also by Ca2+ accumulated within the SR lumen, where small increases in luminal 
Ca2+ load have been shown to generate large elevations in Ca2+ efflux (Gyorke et al. 
2004). RyR2 Ca2+ release is also modulated by several accessory proteins (see 
Section 1.2.3), and the findings presented in Chapters 3 and 4 highlight for the first 
time the possible link between the predominantly sarcomeric protein cMyBP-C and 
RyR2. The functional characterisation of the possible cMyBP-C impact on RyR2 
regulation was pursued in this Chapter. 
The possible implication with regards to the role that cMyBP-C plays in the shaping of 
myoplasmic Ca2+ transient can be deduced from the evidence provided by three 
independent cMyBP-C KO models reporting impaired relaxation and altered Ca2+ 
transients due to lack of cMyBP-C (Song et al. 2003; Brickson et al. 2007; Pohlmann 
et al. 2007). All of the aforementioned papers have shown that isolated cMyBP-C 
deficient cardiomyocytes exhibit prolonged Ca2+ transient decay time when compared 
with their wildtype counterparts, while (Pohlmann et al. 2007) also reported increased 
rate of Ca2+ transient activation (~27%). The study by (Song et al. 2003) using a 
homozygous mouse DCM model developed by (McConnell et al. 1999) (generated by 
the insertion of a neomycin resistance gene into exon 30 resulting in exon-skipping 
and a C-terminal truncated cMyBP-C, where little or no mutant protein is expressed) 
demonstrated 33% increase in Ca2+ transient decay. An increase by 19% was 
reported in the second study by (Brickson et al. 2007) using functional cMyBP-C KO 
(developed by (Harris et al. 2002) in which exons 3-10 of the endogenous cMyBP-C 
were replaced by a neomycin resistance gene), whereas a smaller but statistically 
significant increase of 11% was found in the third study by (Pohlmann et al. 2007) 
(employing transcriptional KO generated by (Carrier et al. 2004) with targeted 
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deletion of exons 1-2 of the mouse MYBPC3 gene, which includes the translation 
initiation site), without any evident changes reported in peak Ca2+ transient 
amplitude. As already outlined in Chapter 1, the rate of cytoplasmic Ca2+ transient 
decay is dictated by the actions of SERCA (which pumps Ca2+ into the SR) the NCX, 
(which is responsible for Ca2+ extrusion out of the cell), and the possible SR Ca2+ 
leak through the RyR2, which normally is minimal but could be substantial in 
pathological conditions (Marx et al. 2000; Kubalova et al. 2005). In the mouse heart, 
the contribution of SERCA is ~92% whereas that of the NCX is ~7% (Li et al. 1998; 
Yao et al. 1998; Fearnley et al. 2011), with phosphorylation of PLB known to relieve 
its inhibition on SERCA Ca2+ uptake activity (Bers 2002). While RyR2 expression 
and/or channel activity was not investigated in any of the aforementioned three 
papers, (Song et al. 2003) reported diminished SERCA levels (~20%) when 
compared to WT, with no difference in PLB expression, which could account for the 
increased SERCA-PLB inhibition and observed prolonged Ca2+ transient. However, 
they did not assess the PLB phosphorylation level, thus whether diminished SERCA 
activity is indeed exclusively responsible for the observed effect requires further 
investigation. Further, (Pohlmann et al. 2007) reported that the amount of NCX was 
34% lower, while SERCA and PLB expression was identical between both KO 
models versus wildtype, but the level of phosphorylated PLB was 3-fold higher in 
knockout than in WT. Therefore, the Ca2+ transient decay time would be expected to 
be reduced rather than increased, with the observed prolonged Ca2+ transient seen in 
cMyBP-C KO mice rather unlikely to be solely due to lower NCX levels given the 
relative contribution of SERCA (~92%) and NCX (~7%) in diastolic Ca2+ removal, 
thus it could involve potential SR Ca2+ leak through the RyR2. Interestingly, when 
cMyBP-C KO cardiomyocytes were stimulated with an β-AR agonist isoproterenol, 
the calcium transients in cMyBP-C KO cardiomyocytes appeared to be no different 
than WT (Brickson et al. 2007), which highlights the possibility that flight-or-fight 
response is capable of attenuation cMyBP-C KO phenotype. Therefore, it is possible 
that cMyBP-C may be involved in suppression of diastolic SR Ca2+ leak through its 
interaction with RyR2, thus be normally required to inhibit RyR2 function. On the 
other hand, a study by (Fraysse et al. 2012) showed faster Ca2+ transient decay in 
myocytes isolated from a KI mouse model expressing an HCM missense mutation 
(developed by (Vignier et al. 2009), where point mutation G to A transition in exon 6 
in MYBPC3 gene that resulted in decreased cMyBP-C expression by ~20% in HET 
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and by ~90% in homozygous animals versus WT). Interestingly, (Cheng et al. 2013) 
have shown that an HET mice model (developed by (Harris et al. 2002)) with 
decreased cMyBP-C expression similar to those of HET human HCM (~32% when 
compared to WT) displayed unchanged Ca2+ transient kinetics without any evident 
alterations in Ca2+ handling proteins (RyR2, SERCA, NCX, PLB or phosphorylated 
PLB). These data indicate the presence of several compensatory mechanism(s) 
required to improve diastolic relaxation in the cMyBP-C KO and HCM cMyBP-C 
mutant hearts, with observed changes directly linked to altered Ca2+ transients. The 
reported alterations may be also part of the adaptive process, and not be directly 
linked to cMyBP-C Ca2+ homeostasis regulation, since cMyBP-C phosphorylation is 
also known to influence the rate of thin filament deactivation and cross-bridge cycling 
(Moss et al. 2015), both of which contribute towards muscle relaxation (Biesiadecki et 
al. 2014). The above studies suggest that cMyBP-C can affect the Ca2+ transient 
through a possible inhibitory role on RyR2. We therefore assessed the action of 
cMyBP-C on RyR2 function using two independent functional assays: equilibrium 
[3H]ryanodine  binding and single cell Ca2+ imaging. 
Ryanodine is known to have a complex effect on the conductance and the gating of 
single RyR channels. In particular, ryanodine at submicromolar to micromolar 
concentrations (up to 1 μM) results in the channel exhibiting partially conducting or 
subconductance states (approximately 40-50% of the full conductance state), 
whereas prolonged exposure to micromolar concentrations (>10 μM) has inhibitory 
effect on RyR (Sutko et al. 1997). These effects are observed consistently and have 
become a signature for ryanodine:RyR binding, with the mechanism of interaction 
proposed to alter the conductance state of the RyR by stabilizing a specific 
conformation of the channel via allosteric effect. The complexity of ryanodine:RyR 
binding is most likely due to the presence of several binding sites exhibiting high (Kd 
∼1-10 nM) and low (Kd ∼1-10 μM) affinities (Lai et al. 1988). It is also generally 
accepted that the low affinity binding causes channel inhibition (with up to three sites 
being proposed), while binding to a single high affinity site per tetrameric channel 
results in RyR activation and conductance sub-states, indicating that ryanodine binds 
to a RyR conformation associated with an open state of the channel. This ryanodine 
property has proven to be useful as a tool for channel characterisation, because any 
detected changes in the ryanodine binding levels would also reflect changes in 
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channel function. Therefore, ryanodine binding can be used as an index of channel 
activation, with the introduction of radiolabelled [3H]ryanodine allowing an indirect 
quantification of Ca2+ sensitivity of channel populations (Pessah et al. 1985; Meissner 
and el-Hashem 1992). This method involves mixing SR vesicles or other RyR-
containing sample (i.e. HEK293 cell homogenates expressing recombinant RyR2) in 
buffered Ca2+ assay medium with the isotope-labelled (8 nM final concentration), 
while an excess of un-labelled ryanodine (10 µM final concentration) is used for 
determination of non-specific binding, followed by incubation period to allow 
equilibrium ryanodine binding. The bound [3H]ryanodine is further collected using a 
filtration device and the remaining radioactivity is determined by liquid scintillation 
counting (Du et al. 1998). Our experimental approach involved comparison of RyR2 
activation profile in the presence and absence of cMyBP-C in a wide range of calcium 
concentrations. The reasoning behind this was that cytosolic cMyBP-C could interact 
with the RyR2 at the N-terminus binding sites of single subunit and thus possibly alter 
channel function. 
Due to RyR intracellular location, techniques developed to study the channel 
behaviour both in situ (primary cells and tissues) and in vivo (heterologous systems) 
are based on the visualization of Ca2+ flux passing from SR/ER into the cytosol with 
the aid of fluorescent Ca2+ indicators. The changes in fluorescence intensity, 
captured with confocal laser scanning microscopy, reflect the changes in binding of 
free Ca2+ to the indicator, hence it becomes possible to monitor global variations of 
the [Ca2+]i (Cannell and Cody 2006). For this purpose, Fluo-3 AM was employed in 
this study as it is one of the most widely used Ca2+ probes, since it displays a large 
dynamic range, low compartmentalization and high Ca2+ binding affinity (Thomas et 
al. 2000). To assess the effect of cMyBP-C on RyR2-mediated intracellular Ca2+ 
handling in a more physiological context than equilibrium [3H]ryanodine binding, a 
cellular assay developed by (Jiang et al. 2002) was used, as it enables the 
recombinant proteins to be studied in a background not complicated by endogenous 
expression of RyR2 or its cardiac-specific accessory proteins (Chen et al. 1997). The 
paper by (Jiang et al. 2002) has shown that HEK293 cells expressing RyR2 display 
spontaneous Ca2+ release events in a manner indistinguishable from cardiac 
myocytes. Notably, this phenomenon is directly linked to RyR2 expression, as 
untransfected cells that do not have recombinant RyR2, neither display Ca2+ 
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transients nor respond to caffeine.  Using this technique, parameters of spontaneous 
Ca2+ release (SCR), such as amplitude, duration and frequency can be monitored to 
establish any differences in Ca2+ handling between HEK293 cells expressing RyR2 
channels in conditions of interest, i.e. with or without cMyBP-C presence. 
More than 150 disease-associated RyR2 mutations have been identified to date, with 
the majority shown to be clustered in four hotspots in the linear sequence of the 
channel. Notably, N-terminal hot-spot (amino acids 44-466) variants account for 
~18% of all cases reported (Priori and Chen 2011), demonstrated to be causative by 
aberrant activation and/or termination of Ca2+ release (Jiang et al. 2010; Tang et al. 
2012; Liu et al. 2013). It has been proposed that the functional impact of those 
variants is linked to destabilization of NTD domain interfaces, which, in turn, alters 
conformational changes in the N-terminal region that are important for channel gating 
(Tung et al. 2010; Lobo et al. 2011; Kimlicka et al. 2013). Consistent with this 
hypothesis, recent study by (Liu et al. 2015) using NTD deletion mutants shown for 
the first time that individual NTD subdomains of RyR2 are involved in distinct roles in 
channel function (with NTD A being important for Ca2+ release termination; NTD B- 
stabilization of the closed state and thus crucial for both activation and termination of 
Ca2+ release; and NTD C involved in channel activation) and thus providing valuable 
insights into the possible molecular basis of different functional phenotypes of N-
terminal RyR2 mutations pathogenesis. Notably, an increasing body of evidence 
suggests that defective RyR2 function can lead not only to cardiac arrhythmias but 
also cardiomyopathies. A recent multiscale DCM genotyping study by (Haas et al. 
2014) has shown for the first time that RyR2 mutations can be readily found in 
patients with DCM, with the majority of identified missense mutations located in the 
first 1100 residues of RyR2. In order to assess whether impaired cMyBP-C:RyR2 
interaction could contribute towards the reported functional variability of RyR2 N-
terminus-linked mutations, four missense variants were investigated in this study: 
S166C, R176Q, R420Q and L433P (previously made in our lab in BT4L construct). 
S166C is a newly-identified DCM variant found in the N-terminal hot-spot with 
unknown impact on channel function (Haas et al. 2014), while R176Q and L433P are 
known to be causative of ARVD/CPVT and ARVD, respectively (Tiso et al. 2001). 
Interestingly, while heterologously expressed RyR2R176Q have been reported to 
display hyper-sensitised caffeine activation (Thomas et al. 2004) and enhanced 
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sensitivity to luminal calcium (Jiang et al. 2005), the phenotype associated with the 
L433P mutation leads to a substantially desensitised response (Thomas et al. 2004), 
prolonged Ca2+ transients and reduced Ca2+ store content indicating defective 
channel closure (Tang et al. 2012; Seidel et al. 2015). Further, the missense 
RyR2R420Q variant linked to CPVT has been shown to have decreased amplitude and 
frequency of Ca2+ oscillations when compared to RyR2 wild-type cells  (Domingo et 
al. 2014). In light of apparently different mechanisms of channel regulation by NTD 
domains and since the cMyBP-C binding region is contained within subdomains A 
and B, we employed the recombinant HEK293 expression system and the co-IP 
binding assay to biochemically test whether the presence of those mutations alters 
cMyBP-C:RyR2 binding.  
 
5.2 Chapter objectives 
In this Chapter studies were undertaken to elucidate whether cMyBP-C binding could 
affect RyR2 channel activity. In particular, the following points will be addressed: 
 assessment of cMyBP-C impact on Ca2+ dependent RyR2 activation using 
equilibrium [3H]ryanodine binding assay; 
 assessment of cMyBP-C influence on spontaneous RyR2-mediated Ca2+ 
oscillations in HEK293 cells using single cell Ca2+ imaging; 
 test whether cMyBP-C interaction with RyR2 could be affected in disease-causing 
point mutations in RyR2 N-terminus (S166C, R176Q, R420Q and L433P) using 
the co-IP assay. 
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5.3 Methods 
 
5.3.1 [3H]ryanodine binding  
For the [3H]ryanodine binding assay, ten 100 mm Petri dishes were co-transfected 
with either (1) the full length RyR2 and the empty HA-pCR3 vector or (2) with the full 
length RyR2 in combination with the full length cMyBP-C HA-tagged (FL) construct, 
using calcium phosphate transfection (Section 2.2.5.3). After 24 hours, cells were 
collected and each sample was homogenised (Section 2.2.2.1) and total protein 
content was measured with the BCA assay (Section 2.2.2.2). The recombinant 
protein expression was confirmed by SDS-PAGE and Western blotting (Sections 
2.2.2.4 and 2.2.2.5, respectively) using Ab 1093 (anti-RyR2) and Ab HA (anti HA-
tagged cMyBP-C). To estimate channel activation of each sample at a specific free 
Ca2+ concentration (Section 2.2.9), six Ca2+ concentration points were used: 100 nM, 
250 nM, 500 nM, 1 µM, 5 µM and 100 µM. All subsequent statistical analysis was 
conducted using GraphPad Prism (see Section 2.2.9 and 2.2.11). 
 
5.3.2 Generation of mCherry-modified pCR3 vector and mCherry-tagged 
full length (mCherry-FL) cMyBP-C construct 
The full length mCherry cDNA coding sequence (accession number: AJN91097) was 
amplified using forward and reverse primers (mCherry.FOR.1-27 and 
mCherry.REV.689-708, respectively, Table 2.1) and obtained PCR product (708 b, 
with new HindIII restriction site at the 5’ end and NheI restriction site at the 3’ end, 
introduced by the primers) was cloned into the pCR3-HA-cMyBP-C (containing the 
full length cMyBP-C cDNA coding sequence, as described in Sections 2.2.1.2-
2.2.1.4, and 2.2.3.1-2).  
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5.3.3 ICC  
RyR2 co-expression with mCherry-FL cMyBP-C or mCherry alone following 
Effectene-mediated co-transfection in HEK293 cells was further verified by ICC as 
described in Sections 2.2.5.5 and 2.2.7, with additional optimization, as all 
incubation steps in ICC were conducted in the dark to avoid mCherry photobleaching. 
For recombinant RyR2 detection, Ab 1093 and Alexa Fluor 488 were used, whereas 
mCherry fluorescence from co-transfected cells was excited using HeNe 594 laser at 
a wavelength of 594 nm and collected by a PMT set at 600-650 nm. To visualise the 
transfection efficiencies of (1) RyR2 with mCherry-FL cMyBP-C and (2) RyR2 with 
mCherry alone, the cells were imaged using an SP5 confocal microscope (Leica) with 
an oil immersion, x63 objective lens. HEK293 cells expressing the proteins of interest 
were counted using LEICA software and obtained values were further normalized 
towards the total number of all cells present in the selected field of view, represented 
as % transfection efficiency. All subsequent statistical analysis was conducted using 
GraphPad Prism (see Section 2.2.11). 
 
5.3.4 Co-IP of mCherry-cMyBP-C and RyR2 
The possible influence of a new tag, the mCherry protein, on recombinant human 
cMyBP-C conformation and its association with RyR2 was tested by HEK293 calcium 
phosphate co-transfection, followed by cell homogenization (Sections 2.2.5.3 and 
2.2.2.1, respectively), co-IP, SDS-PAGE and WB (Section 2.2.2.3-5). To enable the 
direct comparison of relative binding ability, HA-FL cMyBP-C + RyR2 samples were 
co-expressed in HEK293 and processed in parallel to mCherry-FL cMyBP-C + RyR2. 
For immunoblotting, Ab 1093 and Ab C-t (Section 2.2.11) were used to detect 
directly precipitated RyR2 and indirectly co-precipitated cMyBP-C of interest, 
respectively. The level of co-precipitated proteins was determined by densitometry 
(Section 2.2.10). All subsequent statistical analysis was conducted using GraphPad 
Prism (see Section 2.2.11). 
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5.3.5 Ca2+ imaging 
HEK293 growing on 35 mm glass bottom dishes were transfected using Effectene 
reagent (Sections 2.2.5.5) with either (1) RyR2 alone or (2) RyR2 + mCherry-FL 
cMyBP-C or (3) RyR2 + mCherry. Subsequently, cells were loaded with Fluo3-AM 
and imaged in KHR buffer using a laser scanning confocal microscope (Section 
2.2.6). Data were acquired as regions of interest from all cells displaying SCR 
(visualised as calcium oscillations) and/or caffeine dependent Ca2+ release events. 
Obtained traces were further exported to Microsoft Excel for off-line examination and 
subsequent statistical analysis was conducted using GraphPad prism (see Sections 
2.2.6 and 2.2.11).  
  
5.3.6 Co-IP binding analysis of mutant RyR2 N-terminal constructs 
(BT4LS166C, BT4LR176Q, BT4LR420Q and BT4LL433P) with cMyBP-C CT 
Mammalian c-Myc tagged mutated RyR constructs (BT4L fragments, obtained from 
Dr S. Zissimopoulos, see Table 5.1) and cMyBP-C CT plasmid were used as cMyBP-
C:RyR2 pairs to co-transfect HEK293 cells growing on 100 mm Petri dishes as 
described in (Section 2.2.5.3). All plasmids were co-transfected in ~1:1 molar ratio 
(12 µg + 12 µg per dish), homogenized (Section 2.2.2.1) and assayed for protein-
protein interaction with co-IP (Section 2.2.2.3), followed by SDS-PAGE and WB 
(Sections 2.2.2.4-5). The level of co-precipitated proteins was determined by 
densitometry (Section 2.2.10) and statistical analysis was conducted using 
GraphPad Prism (Section 2.2.11).  
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Table 5.1 List of mutated BT4L RyR2 plasmids used. Coordinates correspond to the human RyR2 
mRNA (accession number: X98330). 
Construct Coordinates Length 
BT4LS166C 122-2840 (b) 
1-906 (aa) 
2718 (b) 
906 (aa) 
BT4LR176Q 122-2840 (b) 
1-906 (aa) 
2718 (b) 
906 (aa) 
BT4LR420Q 122-2840 (b) 
1-906 (aa) 
2718 (b) 
906 (aa) 
BT4LL433P 122-2840 (b) 
1-906 (aa) 
2718 (b) 
906 (aa) 
 
5.4 Results 
 
5.4.1 Optimisation of [3H]ryanodine binding assay 
Figure 5.1, A shows representative blot depicting successful cMyBP-C expression in 
RyR2 + cMyBP-C co-transfected samples (1+/2+/3+) and that remaining samples (1-
/2-/3-) did not have any detectable levels of cMyBP-C as predicted, since cMyBP-C is 
a cardiac specific protein and unlikely to be expressed in an embryonic-kidney-
derived cell line. To assure equal amounts of RyR2 in all samples to be tested (both 
RyR2 + HA-pCR3 and RyR2 + HA-FL cMyBP-C) by [3H]ryanodine binding, RyR2 
protein level was assessed by Western blotting and was adjusted accordingly to be 
comparable between the pairs 1+/1-, 2+/2-, 3+/3- (Figure 5.1, B). The paired 
homogenate sample aliquots (containing approximate equal RyR2 levels) were 
subjected to [3H]ryanodine binding using conditions promoting maximum channel 
activation (100 μM Ca2+, 10 mM caffeine, Figure 5.1 C). Typically, it enables to 
evaluate the capacity of cell preparations for maximum [3H]ryanodine binding which 
reflects the total amount of functional RyR2 protein expressed. Knowing the value of 
maximum [3H]ryanodine binding is necessary to normalise the data for comparison 
between samples of different origin. Furthermore, this step ascertains that WB 
adjustments indeed result in similar levels of RyR2 between the samples, as it can be 
prone to SDS-PAGE gel loading as well as protein transfer errors. 
  Chapter 5 
 
153 
 
 
  
Figure 5.1 Representative blots showing protein expression in six independent homogenate 
preparations used in [3H]ryanodine binding and graph summarising the cumulative maximum 
activation with 100 µm Ca2+ + 10mM caffeine. (A) WB for cMyBP-C HA-FL expression where equal 
amount of homogenates was loaded: (25 µg total protein); (B) WB for optimised RyR2 expression 
(left to right: 30, 40, 50, 40, 40 and 50 µg total protein were loaded). (+) corresponds to homogenates 
with co-expressed RyR2 + FL (lanes 1,3 and 5), whereas (-) is indicative of RyR2 + HA-pCR3 co-
transfected HEK293 cell homogenates (lanes 2,4 and 6). (C) Data presented relative to maximum 
binding obtained for the each pair RyR2 (+HA) and shown as mean ±SD, n=3 for each preparation 
(1-3). 
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5.4.2  [3H]ryanodine binding at different Ca2+ concentrations  
Figure 5.2 A presents the data obtained for calcium dependence of [3H]ryanodine 
binding for RyR2 + HA-FL cMyBP-C relative to RyR2 alone (+ HA empty vector). 
Dose-response curves of the above results are visualised in (B) (two model fits with 
three parameters, fourth parameter being bottom constrained) and best-fit values 
calculated with GraphPad Prism are outlined in Table 5.2. As shown in Figure 5.2 A, 
RyR2 activation appears to be weakly diminished by the presence of cMyBP-C 
relative to RyR2 at 1 μM Ca2+ (~20% decrease in RyR2 alone activity, statistical 
significance calculated using unpaired, 2-tailed Student’s t-test). Interestingly, 
channel activity appears to be also decreased by a similar extent at 500 nM, 5 µM 
and 100 µM Ca2+ when compared to RyR2, although it did not reach statistical 
significance at these Ca2+ concentrations. Comparison of the dose response curves 
fitted with GraphPad (Figure 5.2 B and Table 5.2) showed that for both conditions, 
calcium concentration threshold for activation was above p[Ca2+] = (-7) and reached 
plateau at p[Ca2+] ~(-6). Interestingly, cMyBP-C presence did not result in any 
noticeable shift of the Ca2+ activation curve (EC50 = 214.7±38.7 nM [Ca2+] for RyR2 
alone versus EC50 = 163.2±33.7 nM for RyR2 + HA-FL cMyBP-C) or slope factor (Hill 
slope = 2.955±1.673 for RyR2 alone versus Hill slope = 4.032±1.998 for RyR2 + HA-
FL cMyBP-C), but was responsible for lower maximal Ca2+ activation when compared 
to RyR2 only sigmoidal curve. Even though the observed differences for each data fit 
set scored as statistically significant (p≤0.05, assessed using the extra-sum of 
squares F test), high overlap of the error bars for each maximum Ca2+ binding point 
(Figure 5.2) made it difficult to provide a meaningful interpretation of the results. 
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Figure 5.2 Graph and model fits summarising the effect of the cMyBP-C HA-FL on RyR2 function 
as assessed in [3H]ryanodine binding assay over a range of free Ca2+ concentrations. (A) Data 
presented relative to maximum binding obtained for the RyR2 (+HA) at 100μmol Ca2+ and shown 
as mean ±SD, * statistical significance at p<0.05 calculated using unpaired, 2-tailed Student’s t-
test, n≥15 for each Ca2+ concertation point. (B) Dose-response curve of RyR2 (+HA) and RYR2 + 
cMyBP-C HA-FL fitted with GraphPad Prism using four-parameter logistic model with bottom 
constrained to 0. Data shown as shown as mean ±SD, n≥15 for each Ca2+ concertation point. 
  Chapter 5 
 
156 
 
Table 5.2 Best-fit values obtained for RyR2 (+HA) and RYR2 + cMyBP-C HA-FL presented in Figure 
5.2. 
Best-fit values 
RyR2 only  
(+ HA) 
RyR2 + HA-FL 
 (cMyBP-C) 
Bottom = 0.0 (constrained) = 0.0 (constrained) 
Top 
(95% Confidence Intervals) 
0.9564 
(0.8786 to 1.03) 
0.7653 
(0.7029 to 0.8276) 
Hill slope 
(95% Confidence Intervals) 
2.955 
(1.322 to 4.588) 
4.032 
(2.034 to 6.030) 
EC50 
(95% Confidence Intervals) 
214.7 nM 
(176 to 262 nM) 
163.2 nM 
(129.5 to 205.7 nM) 
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5.4.3 Generation of mCherry-pCR3 vector and mCherry-FL cMyBP-C 
construct 
Both plasmid DNA constructs designed to express mCherry protein and mCherry-
tagged full length cMyBP-C (mCherry-FL cMyBP-C) were successfully generated and 
their DNA sequences were confirmed. A typical set of results representing 
intermediate steps of the cloning process is shown in Figure 5.3. 
 
Figure 5.3 Intermediate steps of the experimental procedure generating the mCherry and mCherry-FL 
constructs. (A) DNA gel showing the amplification product obtained in the mCherry sequence PCR 
amplification (lane 1, expected band: 700 b) and empty pCR3 vector digested with HindIII/NheI (lane 
2, expected size: 5.1 kb); (B) restriction digests of the selected positive clone containing the mCherry 
insert, verified by sequencing. From left to right: Lane 1: HindIII/NheI (expected bands: 5.1 and 0.7 
kb), 2: MscI (expected bands: 2.8, 2.2 and 0.7 kb), 3: SpeI/ApaI (expected bands: 4.4 and 1.4 kb), 4: 
StuI/SpeI (expected bands: 2.8, 1.9, 0.86 and 0.2 kb); (C) restriction digests of the selected positive 
clone containing the mCherry-FL, verified by sequencing. From left to right: Lane 1: BamHI/XhoI 
(expected bands: 5.6 and 3.8 kb), 2: HindIII/NheI (expected bands: 5.3, 3.6 and 0.7 kb), 3: MscI 
(expected bands: 4.8, 2.8, 1.2 and 0.7 kb), 4: HindIII/XhoI (expected bands: 5.0, 4.3 and 0.3 kb). 
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5.4.4 mCherry- cMyBP-C can be successfully co-expressed with RyR2 in 
HEK293 cells  
Immunofluorescence analysis was first conducted to confirm that the recombinant 
mCherry and mCherry-FL cMyBP-C proteins can be co-expressed with RyR2 within 
the same cell and correctly localised in vivo. Secondary Alexa Fluor 488 Ab labelling 
enabled estimation of transfection efficiency of RyR2, whereas direct excitation of 
mCherry fluorescent protein allowed to assess the mCherry alone and mCherry-
tagged cMyBP-C expression. All proteins were expressed to levels clearly 
distinguishable from the background (Figure 5.4 and 5.5; Appendix, Figure 8.3 and 
8.4) and yielded similar transfection efficiencies for both conditions (A: RyR2 + 
mCherry-FL cMyBP-C; B: RyR2 + mCherry) with Effectene transfection reagent 
(~20%/~25%, for both A and B, as illustrated in Figure 5.6), values almost identical 
to previous HA-FL cMyBP-C + RyR2 co-transfection results obtained with Turbofect 
reagent (see Section 3.4.4). Further, in similar manner to aforementioned 
transfection reagent, a high number of co-transfected cells was obtained for both (A) 
and (B), labelled green (for RyR2) and red (for mCherry or mCherry-FL cMyBP-C), 
calculated to be ~70% of all transfected cells for both conditions. As demonstrated in 
Figures 5.4 and 5.5, RyR2 (green) signals could be detected throughout the ER of 
the transfected HEK293 cells in both conditions (A1, B1, C1) in line with previous 
observations described in Chapter 3. Notably, the mCherry-FL cMyBP-C (red) signal 
was found to be distributed throughout the cytoplasm (Figure 5.4, A2, B2, C2) and 
readily detected in the region spanning from bottom side of the nucleus to the areas 
of the cell surface in direct contact with the coverslip (A4. B4, C4, dashed box), 
which failed to be observed in our RyR2 + cMyBP-C HA-FL co-localisation study in 
HEK293 cells (see Section 3.4.5). On the other hand, the monomeric mCherry 
protein displayed very low cytoplasmic expression pattern, with the majority of the 
signal localized in the nucleus (Figure 5.5). 
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Figure 5.2 2D (x-y) slice representation of the immunofluorescence images of RyR2 and cMyBP-C mCherry-FL localisation within the co-transfected HEK293. 
Shown are typical fields of view of three individual cells (A-C), taken in the middle of z-axis direction. (1) detection of RyR2 with Ab 1093 and Alexa Fluor 488 
(green), (2) detection of mCherry-FL with direct laser He/Ne 594 excitation (red), (3) overlay images and (4-6) the corresponding orthogonal sections (z axis). 
Dashed box indicates region where previously red signal (cMyBP-C) could not be detected. Yellow colour shows RyR2 and cMyBP-C pixel overlap, and is 
indicative of co-localisation. 
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Figure 5.3 2D (x-y) slice representation of the immunofluorescence images of RyR2 and mCherry localisation within the co-transfected HEK293. Shown are 
typical fields of view of three individual cells (A-C), taken in the middle of z-axis direction. (1) detection of RyR2 with Ab 1093 and Alexa Fluor 488 (green), (2) 
detection of mCherry with direct laser He/Ne 594 excitation (red), (3) corresponding overlay images and (4-6) the orthogonal sections (z axis). 
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5.4.5 The mCherry tag does not affect the recombinant human cMyBP-
C:RyR2 interaction 
In order to verify whether fusion of cMyBP-C with a mCherry fluorescent protein 
would affect RyR2:cMyBP-C binding, parallel co-IP experiments were conducted of 
HEK293 homogenates from either RyR2 + mCherry-FL cMyBP-C or RyR2 + HA-FL 
cMyBP-C co-transfected cells. Figure 5.7 shows representative blot together with a 
summary of densitometric analysis. Statistical analysis using paired, 2-tailed 
Student’s t-test for specific co-precipitated cMyBP-C protein and negative control 
(non-specific binding) detected positive interaction for each tested pair, while 
comparison of relative binding ability (the specific binding subtracted of non-specific 
binding) of mCherry-FL cMyBP-C + RyR2 to that of HA-FL cMyBP-C + RyR2 did not 
display any statistical differences (calculated using the same test). In general, 
mCherry-FL fusion protein was expressed at considerably higher levels than HA-FL 
cMyBP-C (see Appendix, Figure 8.5), but this appeared to not enhance the RyR2 
binding, as demonstrated in Figure 5.7 B. 
Figure 5.6 Comparable transfection efficiencies of HEK293 cell populations co-expressing RyR2 
(A and B) with either cMyBP-C mCherry-FL (A) or mCherry only (B), counted with LEICA software. 
Percentage of transfection efficiencies were normalized towards total number of cells present in 
selected field of view (used as 100%). Data are shown as mean ±SD, n=3 populations, in average, 
n=24 and n=37 cells in each field of view were analysed, for condition A and B, respectively. 
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Figure 5.7 Representative blot of Co-IP and WB results illustrating recombinant RyR2 interaction with 
one of the two cMyBP-C constructs, either mCherry- or HA-tagged, and cumulative densitometric 
analysis (A). RyR2 was immunoprecipitated with Ab1093 from CHAPS-solubilised HEK293 
homogenate (2 mg per IP lane) and the presence of associated cMyBP-C was analysed with Ab C-t. 
The loading controls represent 1/200th and 1/10th of the processed sample for (top panel) and (lower 
panel), respectively. Bands corresponding to cMyBP-C (mCherry-tagged, ~169 kDa; HA-tagged, 
~150 kDa; black arrows) and RyR2 subunit (~560 kDa, red arrows) are shown; (B) Densitometry 
analysis of mCherry-FL + RyR2 and HA-FL + RyR2 binding from parallel co-IP assays of HEK293 
homogenates. Percentage of relative specific binding (the specific binding subtracted of the non-
specific binding) corrected for the difference in expression levels are presented relative to lysate input 
(1/200th of the processed sample). Data are shown as mean ±SD,, n=3 for each condition, processed 
in parallel. * statistical significance calculated using paired, 2-tailed Student’s t-test for specific co-
precipitated protein and negative control (non-specific binding). 
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5.4.6 Detected decreased calcium oscillations frequency is indicative of 
inhibitory role of cMyBP-C on RyR2 function 
Representative traces of SCR events from RyR2 only-expressing HEK293 cells at 
1.3 mM extracellular Ca2+ and in the presence of either mCherry alone or mCherry- 
FL cMyBP-C are demonstrated in Figure 5.8. Notably, only RyR2 expressing cells 
were responsive to 10mM caffeine (C-E), with the portion of cell population exhibiting 
spontaneous SCR events (F). On the other hand, the RyR2 untransfected cells, but 
expressing either mCherry-FL or mCherry, neither displayed SCR events nor 
responded to caffeine (A and B), in agreement with (Jiang et al. 2002). To assess the 
effects mCherry-FL cMyBP-C co-expression has on the Ca2+ handling dynamics of 
RyR2 channels, the properties of the SCR-events were examined and compared to 
both RyR2 only expressing cells as well as to RyR2 + mCherry co-expressing cells, 
to verify whether any observed changes are not due to mCherry tag presence. 
Namely, the following cellular calcium handling parameters were examined: the 
amplitude, duration, rate up/down of each individual Ca2+ transient, the time between 
Ca2+ transients (inter-SCR duration), the number of Ca2+ transients observed 
(frequency/number of events), and ER Ca2+ store content (see Section 5.3.5).  
As illustrated in Figure 5.8, mCherry-FL cMyBP-C + RyR2 co-expressing HEK293 
cells displayed markedly lower frequency of SCR-events (E), compared with those 
observed in cells expressing mCherry + RyR2 (D) or RyR2 alone (C). Presented as a 
series of bar graphs in Figure 5.9, the kinetic parameters of these three different cell 
populations were compared. The details of the statistical analysis can be found in the 
Appendix, Table 8.6. When compared to RyR2 alone, the presence of mCherry-FL 
cMyBP-C caused a significant increase in the mean duration of each Ca2+ transient 
(Figure 5.9, B) and also of inter-SCR duration (E) as well as decrease in the rate of 
Ca2+ decay (D), thereby overall decreasing the number of oscillations (G) and thus 
their frequency (F). However, in our experimental conditions, cumulative data 
indicated that the observed decrease in the rate of Ca2+ decay and corresponding 
increase in mean Ca2+ transient SCR duration was due to the mCherry protein (RyR2 
alone versus RyR2 + mCherry). Hence the effects directly attributable to cMyBP-C 
were the decrease in the frequency/number of events and parallel increase in inter-
SCR duration (statistically significant when compared to both RyR2 only and RyR2 + 
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mCherry, calculated using Kruskal-Wallis test with Dunn's multiple comparisons test). 
Notably, both the amplitude (A) and the ER Ca2+ store content (H) (measured by the 
Ca2+ transient amplitude induced by 10 mM caffeine application) appeared similar in 
all conditions tested (no statistical difference), which highlights that the observed 
changes are not due to perturbations in Ca2+ load, but specifically because of 
decrease of RyR2 channel open probability because of interaction with cMyBP-C. In 
contrast, all the remaining SCR parameters in HEK293 cells co-expressing RyR2 and 
mCherry appeared similar to cells expressing RyR2 only (apart from mean duration 
and the rate of Ca2+ decay), where no significant differences between the two could 
be detected. 
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Figure 5.8 Representative traces of spontaneous Ca2+ release events from HEK293 cells expressing (A) 
mCherry-FL cMyBP-C only, (B) mCherry only, (C) RyR2 only, (D) RyR2 + mCherry and (E) RyR2 + mCherry-
FL cMyBP-C, measured by Fluo-3 at  1.3 mM extracellular Ca2+.(F) Percentage of the portion of cells 
displaying spontaneous Ca2+.release counted with LEICA software. Percentage of transfection efficiencies 
were normalized towards total number of cells present in selected field of view (used as 100%). Data are 
shown as mean ±SD, n=3 populations, in average, n≥27 cells in each field of view were analysed, for each 
condition A-E. 
. 
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Figure 5.9 Summary of spontaneous Ca2+ release events examination using single cell Ca2+ imaging. Data are normalized for RyR2 + mCherry and shown 
as mean ±SD. Samples: RyR2 + mCherry-FL (cMyBP-C) n=70, RyR2 only n=73, and RyR2 + mCherry n=33, from ≥8 independent experiments; * statistical 
significance at p<0.05 calculated using one-way ANOVA with Bonferroni's multiple comparisons test, # statistical significance at p<0.05 calculated using 
Kruskal-Wallis test with Dunn's multiple comparisons test. 
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5.4.7 Tested RyR2 mutations seem to have no effect on RyR2:cMyBP-C 
interaction 
In order to test whether cMyBP-C interaction with RyR2 could be affected by disease-
causing point mutations in RyR2 N-terminus, four new BT4L constructs were used: 
BT4LS166C (where serine 166 was replaced by cysteine), BT4LR179Q (where arginine 
179 was replaced by glutamine), BT4LR420Q (where arginine 420 was replaced by 
glutamine) and BT4LL433P (where leucine 433 was replaced by proline). Each c-Myc 
tagged mutant plasmid was co-expressed in HEK293 with HA-tagged cMyBP-C CT, 
and protein interaction was assessed by co-IP as before. Densitometry-based 
analysis was performed as described in Section 4.2.2 to quantitatively evaluate the 
impact of each mutation on the amount of recovered co-precipitated BT4L mutant 
following HA-cMyBP-C immunoprecipitation. Figure 5.10 A-B shows representative 
blots of obtained co-IP results. All tested constructs scored as positive with cMyBP-C 
CT when compared to their respective non-specific binding, calculated using 
unpaired, 2-tailed Student’s t-test (C). However, no statistically significant difference 
between cMyBP-C CT interaction with either of the four mutant BT4L fragments was 
observed (calculated using one-way ANOVA with Bonferroni's post-test, see 
Appendix, Table 8.5). Obtained results indicate that cMyBP-C:RyR2 binding is not 
affected by the four tested RyR2-linked mutations. 
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Figure 5.10 Representative results of a series of BT4L mutated c-Myc- tagged RyR fragments co-IP 
with HA-tagged cMyBP-C CT constructs, together with cumulative densitometric analysis.(A-B)) 
cMyBP-C was immunoprecipitated with HA Ab from CHAPS-solubilised HEK293 cell lysate (2 mg) 
and normal, non-immune rabbit IgG was used as negative control. Co-IP samples were loaded on two 
separate SDS-PAGE gels (1/10th and 9/10th split, lower and upper panel, respectively) and analysed 
by immunoblotting with Ab HA (HA WB for CT, lower panels) and Ab c-Myc (c-Myc WB for BT4L 
mutant of interest, upper panels). A cell lysate aliquot was loaded on the gels to verify expression in 
HEK293; in c-Myc WB, 1/200th of the volume processed in co-IP samples; in HA WB 1/100th of the 
volume processed in co-IP samples. All fragments are indicated as follows: BT4L mutant of interest, 
red arrows; cMyBP-C CT, violet arrows. 12% reducing SDS-PAGE gels were used for c-Myc WB and 
12% gels for all HA WB. Black arrows show Ab heavy chains. (C) Densitometry analysis of mutated 
RyR2 BT4L constructs binding with cMyBP-C CT truncated fragment using co-IP assay from HEK 293 
homogenates. Results corrected for the difference in expression levels and non-specific binding are 
presented relative to each respectable lysate input.  Data are shown as mean ±SD, n≥4; * statistical 
significance at p<0.05 calculated using unpaired, 2-tailed Student’s t-test. 
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5.5 Discussion 
 
5.5.1 Decreased cellular calcium oscillation frequency is indicative of 
inhibitory role of cMyBP-C on RyR2 function  
The principal goal of this study was to investigate the possible functional effect/s that 
the cMyBP-C protein could exert on recombinant RyR2 channel. Our reasoning was 
that since each domain of RyR2 NTD governs different aspect of channel activity, 
with NTD subdomain A (residues 1-217) proposed to be involved in Ca2+ release 
termination and subdomain B (residues 218-409) being involved in stabilizing the 
closed state of the channel (Liu et al. 2015), it could be possible for cMyBP-C to 
affect channel function because its RyR2 binding region appears to be contained 
within those subdomains (residues 1-346, see Chapter 4). Another possible impact 
on RyR2 by cMyBP-C could be an influence on the N-terminal to central region 
conformational change of the channel, as a second part of the region important for 
cMyBP-C binding was contained within the SPRY1/P1 domains (mapped RyR2 
residues 654-906). Therefore, quantitative [3H]ryanodine binding was used to assess 
the cytosolic Ca2+ sensitivity of RyR2 with or without cMyBP-C co-expression. To 
directly compare the data, a two-part optimisation step was performed, to ensure that 
approximately equivalent RyR2 levels were present in the two different HEK293 cell 
populations co-transfected either HA empty vector of HA-FL cMyBP-C: assessment 
of RyR2 protein levels by densitometric analysis of Western blot signals (Figure 5.1 
A-B), and second assessment of the total number of fully open RyR2 channels using 
[3H]ryanodine binding under maximum activation conditions (100 µM Ca2+ and 10 
mM caffeine, (C)).  
When fitting the four parameter logistic model, the EC50 is defined as the 
concentration of agonist that provokes a response halfway between the baseline 
(Bottom) and maximum response (Top), while the Hill slope indicates measure of the 
curve steepness (Motulsky and Christopopulos 2003). The Hill equation is commonly 
used to quantify the degree of cooperativity in ligand binding, which in this case 
would be a measure of the RyR2 activation at various Ca2+ concentrations under 
equilibrium [3H]ryanodine binding to RyR2, in the absence/presence of cMyBP-C. As 
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demonstrated in Figure 5.2 B and Table 5.2, neither EC50 nor Hill slope were 
explicitly different between the two experimental conditions (both curves displayed 
comparable 95% confidence intervals for those parameters), but RyR2 + HA-FL 
cMyBP-C curve top was evidently lower when compared to RyR2 + HA (0.95 ±0.08 
RyR2 + HA only versus 0.76±0.06 RyR2 + HA-FL cMyBP-C, (± representing 95% 
confidence intervals; Table 5.2). However, while data presented in Figure 5.2, where 
the RyR2 + HA-FL cMyBP-C Ca2+ activation yielded clearly visible trend in decreased 
activation at Ca2+ concentrations >500 nM (but with statistical difference being 
reached only for 1 µM Ca2+ point), the general large error bar overlaps at each of 
Ca2+ point between two conditions questioned the certainty regarding the observed 
cMyBP-C effect on RyR2. Such variability might be linked to use of HEK293 
homogenates as testing material, which despite similar total protein content can 
display heterogeneous RyR2 and/or cMyBP-C protein distribution even within same 
sample. The rationale behind the use of cell homogenates as opposed to 
microsomes was based on the fact that the majority of the cMyBP-C remains in the 
HEK293 cytosol when co-expressed with RyR2 (Chapter 3). Thus, there was a 
possibility that the reduced cMyBP-C levels (compared to when cMyBP-C is co-
expressed with RyR2) in the microsomal fraction might be too low to mediate any 
functional effects. 
Since ryanodine binds to a RyR conformation associated with an open state of the 
channel (Sutko et al. 1997), it is possible that cMyBP-C may weakly affect the Ca2+ 
sensitivity of RyR2 opening at micromolar Ca2+ levels, which due to considerable 
variability of the assay (as indicated by the large error bars seen in the graphs) did 
not reflect in the change of EC50. Another possible explanation is that cMyBP-C 
influenced the association/dissociation rate of Ca2+ and/or [3H]ryanodine itself, 
however it is highly unlikely as the mapped cMyBP-C binding site does not appear to 
be positioned in or near the pore-forming region of the RyR2 channel, within which 
the residues deemed critical for ryanodine binding are situated (Chen et al. 2002). 
The possible influence of cMyBP-C on ryanodine dissociation could be tested using 
reversible ryanodine analog, ryanodol (Sigalas et al. 2009), which could help to 
determine if indeed cMyBP-C presence affect the RyR2 open probability or simply 
disrupt the ryanodine:RyR2 binding. Notably, as the contaminant free Ca2+ of used 
solutions was not measured, the total free Ca2+ concentrations may not reflect the 
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desired amounts tested in our experimental conditions, and could add to the 
aforementioned variability of the assay. Since the results from the [3H]ryanodine 
binding were rather inconclusive, single cell Ca2+ imaging was used as a second 
functional assay, in order to detect the effects of cMyBP-C protein presence on 
RyR2, while co-expressed in HEK293 cells. 
Prior to single cell analysis, new cMyBP-C fusion construct was made, tagged with 
red fluorescent mCherry protein to allow in vivo real-time monitoring of spontaneously 
oscillating cells (indicative of RyR2 expression) and concomitant selection of cells co-
expressing cMyBP-C. We made use of the fact that mCherry is a monomeric red 
fluorescent protein with an excitation/emission optimum of 587/610 nm (Shaner et al. 
2004), which does not overlap with that of the green fluorescent Ca2+ indicator Fluo-3 
(506/526 nm of Ca2+ bound form). The possible influence of the new tag on cMyBP-C 
interaction with RyR2 was verified using the co-IP assay, and was found to display no 
statistically significant difference between the binding of RyR2 + mCherry- FL 
cMyBP-C and RyR2 + HA-FL cMyBP-C (Graph 5.5). Moreover, as presented in 
Figure 5.4, mCherry-FL cMyBP-C fusion retained the previously reported cytosolic 
expression in HEK293 cells (see Section 3.4.2), implying that the mCherry tag at the 
N-terminal end of cMyBP-C does not cause any detectable alteration in cMyBP-C 
protein trafficking, further highlighted by the clearly distinguishable mCherry pattern 
of expression (mainly nuclear with weak cytoplasmic expression, Figure 5.5). 
Notably, similar localisation of mCherry protein in HEK293 cells has been observed 
previously (Kashir et al. 2011; Auslander et al. 2014).  
To monitor cytosolic Ca2+ transients, HEK293 cells transfected with RyR2 only, or co-
transfected with RyR2 + mCherry or RyR2 + mCherry-FL cMyBP-C were loaded with 
Fluo-3 and were maintained in 1.3 mM extracellular Ca2+. As expected, cells from all 
three conditions readily displayed recombinant RyR2-driven spontaneous Ca2+ 
transients (Jiang et al. 2002), with a few, statistically significant differences (Figure 
5.9). Surprisingly, both cells co-expressing RyR2 and either of mCherry constructs 
(the fluorescent protein only or as cMyBP-C fusion) displayed higher mean duration 
and therefore prolonged Ca2+ transients compared with RyR2 only. Thus, higher Ca2+ 
transient duration is accounted by the mCherry protein tag, and not cMyBP-C. 
Importantly, Ca2+ transients had substantially decreased frequency/number of events 
and thus displayed parallel increase in inter-SCR duration in RyR2 + mCherry-FL 
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cMyBP-C co-expressing cells, compared to both controls (RyR2 only and RyR2 + 
mCherry). These data demonstrate that cMyBP-C decreases the propensity of RyR2 
for spontaneous Ca2+ release when co-expressed in HEK293 cells. Interestingly, we 
have not observed any statistically significant differences in spontaneous Ca2+ 
transient activation (Pohlmann et al. 2007) nor decay time as reported by (Song et al. 
2003; Brickson et al. 2007; Pohlmann et al. 2007) in mouse models of cMyBP-C 
abrogation, implying that the observed effects could be due to compensatory 
remodelling events and not directly linked to cMyBP-C absence, or perhaps simply 
demonstrate the limitations of our recombinant RyR2 HEK293 SCR model.  
It is important to note that the observed effect was not influenced by changes in ER 
Ca2+ content, since it is known that increased amount of available Ca2+ in the stores 
correspondingly results in an increase the opening of RyR2 by SOICR (Jiang et al. 
2005). The ER load tested with 10 mM caffeine application in all three conditions was 
shown to be comparable, without any detectable changes in amplitude of observed 
SCR (Figure 5.9, A and H).  However, as caffeine application is an indirect 
measurement of ER load due to ER Ca2+-ATPase activity and pumping Ca2+ back 
into ER after caffeine induced-RyR2-mediated release (Berridge et al. 2003), a more 
direct approach to study the amount of the Ca2+ contained within ER stores would be 
a simultaneous treatment of caffeine together with thapsigargin, a known inhibitor of 
the ER Ca2+-ATPase (Thastrup et al. 1990). If possible, the future experiments 
should include measurement of both cytosolic Ca2+ and ER Ca2+ load to establish 
their influence on the obtained results. 
 
5.5.2 Tested S166C, R176Q, R420Q and L433P N-terminal RyR2 
mutations have no effect on RyR2:cMyBP-C interaction  
To quantitatively evaluate the possible impact of each disease-linked RyR2 mutation 
on RyR2:cMyBP-C interaction, the amount of recovered co-precipitated mutant BT4L 
following HA-cMyBP-C immunoprecipitation, densitometry-based analysis was 
performed (Figure 5.10). Unfortunately, none of the assessed interactions scored for 
a statistically significant difference in the cMyBP-C C-terminal fragment (CT) binding 
propensities between the four mutants and the WT RyR2 N-terminal fragment 
(BT4L), implying that, at least in terms of the tested mutations, RyR2 binding with 
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cMyBP-C in not affected. However, the functional impact of these mutations cannot 
be dismissed, and thus the contribution of cMyBP-C towards the pathological 
conditions needs to be assessed by functional assay, i.e. expression of RyR2 mutant 
channels in our HEK293 SCR model in the presence of cMyBP-C or by [3H]ryanodine 
binding. Further studies should help to unravel whether and how cMyBP-C:RyR2 
association can be involved in channel dysfunction and aberrant intracellular Ca2+ 
release, thus affecting cardiac contraction/relaxation. 
 
5.5.3 Conclusions 
The single cell Ca2+ imaging investigations suggest that cMyBP-C has an inhibitory 
effect on frequency of spontaneous calcium oscillation, indicative of potential 
inhibitory role of cMyBP-C on RyR2 function. Further, when assessed by co-IP, the 
relative binding ability of cMyBP-C and RyR2 appears unaffected by four different 
RyR2 single point mutation variants, known to be causative of RyR2-linked 
pathological conditions, namely DCM, CPVT and ARVD phenotypes. 
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6 Summary of findings and conclusions 
 
Human RyR2 channel present in the SR membrane of cardiac myocytes plays a 
critical role in ECC by mediating SR calcium release, whereas aberrant regulation of 
the channel is implicated in cardiac arrhythmias as well as cardiomyopathy. On the 
other hand, cMyBP-C is a predominantly sarcomeric modular protein anchored to the 
thick filament through its C-terminal region, while the N-terminal region of cMyBP-C is 
thought to regulate myocardial contractility by modifying actin-myosin cross-bridge 
cycling. In the work presented here, we provide several lines of evidence indicating 
cMyBP-C as a new RyR2 binding partner, which could constitute a novel aspect of 
SR Ca2+ release regulation by a sarcomere component.  
Firstly, co-immunoprecipitation data presented in Chapter 3 indicate that the 
detected interaction between RyR2 and cMyBP-C can be applicable to large 
mammalian species as well as to recombinant human proteins, with RyR2 N-
terminus and cMyBP-C C-terminus being responsible for the binding. Secondly, in 
Chapter 4, by using the two complementary techniques, namely co-IP and Y2H, we 
showed that RyR2 residues 1-167, 175-346 (corresponding to subdomain A and B of 
RyR2 NTD) and 654-906 (domain SPRY1 and P1) are important determinants for the 
binding with cMyBP-C. Further cMyBP-C binding region co-IP mapping studies 
indicated that cMyBP-C residues 820-972 and 1061-1274 are involved in the 
interaction with RyR2, with cMyBP-C Fn domain/s proposed to be directly 
responsible for the binding. Additionally, we found that the corresponding N-terminus 
region (RyR2 1-906 amino acids) of mammalian isoforms RyR1 can also interact with 
MyBP-C, which could indicate that the detected association can be relevant in the 
regulation of ECC coupling not only in cardiac, but also in skeletal muscle. Finally, in 
Chapter 5 we pursued the possible functional significance of RyR2:cMyBP-C 
interaction. The results from single cell Ca2+ imaging implied that cMyBP-C 
interaction with RyR2 may have an inhibitory effect on Ca2+ release channel function, 
with cMyBP-C binding diminishing RyR2 channel activity. Lastly, cMyBP-C:RyR2 
binding was shown to not be affected by four different RyR2 single point mutation 
variants (S166C, R176Q, R420Q and L433P), associated with different channel 
pathological phenotypes. However, as the influence of those mutations on cMyBP-C 
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binding to the intact RyR2 channel (as opposed to the use of mutant fragments) 
cannot be dismissed, more studies are needed to understand what role cMyBP-C 
plays in channel dysfunction. As such, expression of mutant channels in our HEK293 
SCR model and assessment of spontaneous Ca2+ release events would provide 
more insights on potential role of cMyBP-C in those conditions.  
Proper cardiac activation-relaxation kinetics is of a paramount importance for healthy 
circulation, as in between the two beats heart muscle needs to relax to allow for 
proper ventricular filling. Contrary to the thought that relaxation is a mere passive 
process that simply follows contraction, the interplay between three main events can 
limit the rate of relaxation, namely rate of intracellular calcium decline, the rate of 
thin-filament de-activation and the rate of cross-bridge cycling (Biesiadecki et al. 
2014). Each of these processes is directly regulated by a plethora of molecular 
events, and impairment of a single event can result in incomplete filling of ventricles 
upon initiation of the next systole, causing a diminished volume at the beginning of 
the cycle. Thus, even if the contractile activation appears to be similar to the healthy 
heart, slowed relaxation would lead to reduced cardiac output, and if left untreated, 
the impaired balance of systolic/diastolic heart function would lead to development of 
heart failure (Bers 2008; Fearnley et al. 2011).  
As discussed in Chapter 1 an increase in systolic Ca2+ is achieved by Ca2+ influx 
through LTCC and following RyR2-mediated efflux from SR, the main process of 
CICR. The rate at which the Ca2+ transient declines is an important factor that 
contributes to the cardiomyocyte relaxation and it is mainly modulated by coordinated 
action of SERCA and NCX (Bers 2002). For human heart (and other large mammal 
species such as dog, guinea pig and rabbit), the apparent contribution is ~70% by 
SERCA and ~28% by NCX (in the forward mode), respectively, while mouse and rat 
display a ratio of ~92% and ~7%, respectively (Fearnley et al. 2011). This 
corresponds to a varied number of myocyte Ca2+ pumps in each of species (i.e. the 
expression of SERCA is higher in mouse/rat than in rabbit/dog), with pathological 
conditions known to cause the apparent shifts in the contribution of the two routes of 
cytosolic Ca2+ removal, i.e. reduction in SERCA expression and increase in NCX 
expression as reported in human and rabbit heart failure, with 50%:50% change in 
contribution to the Ca2+ transient decline (Piacentino et al. 2003). Since SERCA has 
a much greater Ca2+ transport efficiency that NCX, those protein changes result in a 
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general slower Ca2+ transient decay. Notably, during advanced heart failure, in which 
SR Ca2+ release is low and cytoplasmic Na+ levels are elevated, the NCX outward 
mode can contribute towards Ca2+ influx throughout most of the AP (Weber et al. 
2003). Further, the possible SR Ca2+ leak through the RyR2, which normally is 
minimal but could be substantial in pathological conditions (Marx et al. 2000; 
Kubalova et al. 2005), can also add to the impaired relaxation (Bers 2014).  
Calcium release from SR is also mediated via inositol 1, 4, 5-trisphosphate receptors 
(IP3R), which despite only ~30% identity in primary sequence with RyRs, they 
display substantial structural homology and surprisingly high conservation of 
structure-function relationship (Seo et al. 2012). IP3Rs are activated by inositol 1, 4, 
5 triphosphate (IP3) produced by phospholipase C in response to the stimulation of G 
protein-coupled receptors or tyrosine kinase receptors located at the plasma 
membrane (Patterson et al. 2004). The binding of IP3 increases the sensitivity of the 
receptor to Ca2+ and triggers Ca2+ release from the SR further stimulating the 
channel, that can induce additional SR Ca release via RyR2s (via local CICR)(Bers 
2014). This IP3R-dependent Ca2+ efflux is plays an important role in the modulation 
of ECC in atrial tissue, where IP3Rs are more highly expressed than in ventricular 
myocytes (Li et al. 2005). In the latter, IP3R are relatively localized at the nuclear 
envelope, but nevertheless it has been shown that the IP3R-mediated SR Ca2+ leak 
(with a RyR boost) can both contribute to arrhythmogenic events in atrial myocytes 
as well as ventricular hypertrophic gene program activation (Wu et al. 2006; 
Ljubojevic et al. 2014). The release of Ca2+  from SR has also been suggested to be 
coupled to the activation of the two-pore channels (TPC) located on acidic organelles 
such as lysosomes (Macgregor et al. 2007). It has been proposed that TPCs respond 
to NAADP (nicotinic acid dinucleotide phosphate) by releasing Ca2+ from acidic 
stores, leading to the local increase in Ca2+ concentration (Collins et al. 2011). This is 
thought to contribute to the stimulation of RyR and IP3R, triggering larger Ca2+ 
release events, possibly also influencing to the SR-Ca2+ leak as enhanced Ca2+  
loading of the SR has been observed following NAADP release (Collins et al. 2011; 
Aston et al. 2017).  
Ca2+ binding to Tn/Tm complex is essential to the initiation of sarcomere contraction, 
and although Ca2+ itself does not directly regulate actin:myosin association, it acts as 
a signalling molecule through binding to the thin filament regulatory protein TnC. This 
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interaction maintains the activated state of the thin filament, where TnI is bound to 
TnC-Ca2+ to favour a Tm conformation enhancing actin-exposing myosin binding 
sites. As long as the thin filament is active, the cross-bridges will freely cycle and 
muscle will contract. While the rate of cytosolic Ca2+ decline is an important and 
initiating event in myocardial relaxation (the Ca2+ transient must decay prior to start of 
contractile force dissipation), the removal of Ca2+ from TnC and subsequent 
deactivation of the thin filament, which inhibits the acto-myosin cross-bridge 
formation, are the two crucial processes that allow efficient diastolic ventricular filling 
(Fearnley et al. 2011; Eisner et al. 2013). This dissociation weakens TnI:TnC binding 
to favour TnI inhibitory binding to actin, with additional changes in TnT and Tm further 
contributing to steric block of cross-bridge formation, with the Ca2+ dissociation rate 
directly increased or decreased by Tn and Tm isoform switching, post-translational 
modifications and mutations implicated in pathological conditions (Biesiadecki et al. 
2014).   
Notably, (Previs et al. 2015) have recently demonstrated that cMyBP-C Ig domains 
C0-C3 are also involved in Tm binding in a phosphorylation-dependent manner and 
activation of cross-bridge cycling. The same group also proposed that cMyBP-C acts 
as tunable mechanism element of healthy heart within the thick filament that, 
synergistically with Ca2+, shifts Tm from blocked to closed position at low Ca2+ levels, 
thus correcting the non-uniformity in calcium activation by directly sensitizing the 
contractile apparatus to Ca2+ and counterbalancing the RyR2-released SR calcium 
gradient. Further, both the follow-up study by (Previs et al. 2016) and a report by an 
independent group (Colson et al. 2016) have suggested that phosphorylation of 
cMyBP-C may result in the formation of a calcium-binding motif within the M-domain, 
which could provide previously overlooked, additional level of sarcomere regulation 
by cMyBP-C. In this way, it could be possible for cMyBP-C phosphorylation-mediated 
cardiomyocyte activation to be antagonistically overridden by high Ca2+ levels, and 
have similar to MI-driven effect on heart function (Sadayappan et al. 2006; 
Sadayappan et al. 2009) by inducing cMyBP-C dephosphorylation and following 
release from the sarcomere, thus ultimately contributing to diminished contractile 
force.  
In the heart, following acute MI, the deprivation of oxygen and nutrient supply results 
in a series of abrupt biochemical and metabolic changes. The absence of oxygen 
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switches cell metabolism to anaerobic respiration, resulting in a drop of intracellular 
pH (to <7.0) (Hausenloy and Yellon 2013). This induces NCX to extrude H+ and 
results in intracellular Na+ overload, which in turn switches the reverse NCX mode to 
extrude Na+ and leads to intracellular Ca2+ overload and cardiomyocyte hyper 
contractility (Avkiran and Marber 2002). During reperfusion, the electron transport 
chain is reactivated, generating reactive oxygen species, and mediating dysfunction 
of the SR, which further contributes to the intracellular Ca2+ overload, oxidative 
damage to DNA, diminished cardiomyocyte contracture and necrosis (Hausenloy and 
Yellon 2013). Notably, since it has been shown that the MI-driven dephosphorylated 
cMyBP-C could be released from the sarcomere, with detectable levels of full-length 
cMyBP-C in the cytosol (Decker et al. 2012; Kuster et al. 2014; Baker et al. 2015), it 
is tempting to hypothesize that elevated Ca2+ levels (to which enhanced/prolonged 
RyR2 channels opening contribute), might have direct effect on cMyBP-C. Thus both 
cMyBP-C dephosphorylation and high cytosolic Ca2+ levels could directly induce 
cMyBP-C release, either as full-length cMyBP-C and/or its proteolytic fragments, 
allowing for the translocation of cMyBP-C from the thick filament to cytosol and/or 
SR. This would enable for cMyBP-C to bind to RyR2 N-terminus and induce its 
proposed by us inhibitory effect on RyR2, i.e. to diminish the frequency of RyR2 
openings, as indicated by our Ca2+ imaging data (Chapter 5), and thus ultimately 
contribute to lowering the cytosolic Ca2+ concertation and conferring to the already 
established cardioprotective role of cMyBP-C during MI (Sadayappan et al. 2006; 
Sadayappan et al. 2009). Therefore, at least under pathophysiological conditions, 
cMyBP-C could act as a negative feedback mechanism on RyR2- SR Ca2+ release, 
comprising a novel retrograde sarcomeric control of RyR2 Ca2+ release. It is 
important to note that the proposed mechanism might not be operational in healthy 
hearts, where Ca2+ concertation is well regulated and stay within the physiological 
levels, but instead plays a role in aforementioned post-MI recovery and/or during 
prolonged β-AR stimulation, where Ca2+ homeostasis is perturbed (Section 1.1.2).   
Our study raises the possibility that the perturbation of Ca2+ homeostasis due to 
disrupted cMyBP:RyR2 interactions may constitute a novel pathogenic mechanism 
for the development of heart failure. Future studies should help to unravel the role of 
RyR2 and cMyBP-C association in cardiac physiology and disease. 
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7 Future work 
 
The identified RyR2:cMyBP-C association provides novel insights into the putative 
regulation of RyR2 function by the sarcomeric component cMyBP-C, however the 
understanding of how this mechanism may be applicable to healthy/diseased heart is 
lacking. The work presented here determined the RyR2:cMyBP-C interaction 
biochemically from both native tissue and also a recombinant cell model, which in the 
case of the latter may be lacking the cardiac-specific proteins present in the intact, 
live cardiomyocyte. This is a clear disadvantage in respect to the extrapolation of this 
data to the crowded cellular milieu, where the interplay of many factors are known to 
affect muscle contraction (Bers 2008; Fearnley et al. 2011; Eisner et al. 2013).  
The valuable information regarding the possible translocation of cMyBP-C due to MI 
and high-Ca2+ levels (Decker et al. 2012; Kuster et al. 2014) could be verified by 
immunocytochemistry co-localisation experiments on primary animal cardiomyocytes, 
preferably using next-generation fluorescence super-resolution microscopy, allowing 
to study biological structures with details approaching molecular structure sizes 
(Godin et al. 2014).  For example, a model of in vivo simulated ischemia on adult 
primary rodent cardiomyocytes could be used, achieved by metabolic blockade with 
high potassium content performed on already isolated cells (Baker et al. 2015) to 
assess early stages of cMyBP-C dissociation. However, as our results point that the 
cMyBP-C and RyR2 appear to form protein complexes in higher mammals (Chapter 
3), co-localisation experiments on cardiomyocytes obtained from ischemic pig hearts 
following coronary artery ligation should also be considered (Tarvinder et al. 2017). 
That would allow to compare the co-distribution of RyR2 and cMyBP-C and its 
proteolytic fragments in healthy and pathophysiological conditions, and evaluate if 
cMyBP-C dislocation from the sarcomere results in potential association with RyR2. 
Notably, the described experiments could also help to determine the reciprocal 
significance of cMyBP-C:RyR2 binding, where the calpain-cleaved RyR2 N-terminal 
fragment (which is slightly bigger than our recombinant BT4L construct) could 
dissociate from SR junctions (Fauconnier et al. 2013) and exert a possible functional 
impact on sarcomere contraction via C-zone located cMyBP-C. 
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Cell Ca2+ homeostasis is tightly regulated by the interplay of many factors, i.e. SR/ER 
Ca2+ re-uptake and cytoplasmic Ca2+ removal (Bers 2008), it is crucial to determine 
whether the observed diminished frequency of spontaneous Ca2+ release events 
(Chapter 5) is attributable specifically due to cMyBP-C:RyR2 interaction and whether 
it can be recapitulated in intact cardiomyocytes. As such, RyR2 Ca2+ release at the 
single cell level can be studied by fluorimetric Ca2+ imaging, which will allow to further 
assess the channel function with RyR2 in its native conformation and subcellular 
context. For example, the endogenous cMyBP-C levels in isolated rodent and/or 
porcine cardiomyocytes could be downregulated using adenovirus-mediated delivery 
of short hairpin RNA (Rinne et al. 2009) to generate the cMyBP-C-KO model cells. 
The RT-PCR and WB analysis could be used to confirm reduced transcript and 
protein levels, respectively, with possibility for obtained model to mimic either the 
cMyBP-C KO or KI heart and display reported changes in the Ca2+ transients (Song 
et al. 2003; Brickson et al. 2007; Pohlmann et al. 2007). If our hypothesis that 
cMyBP-C influences RyR2 SR Ca2+ release is true, we should be able to normalise 
affected Ca2+ transients by addition of purified recombinant full-length cMyBP-C 
protein and/or C6-C7 and C8-C9 protein fragments. The fluorescently tagged full-
length protein and peptides can be introduced into the isolated model cMyBP-C KO 
living cardiomyocytes using the microinjection technique (Golebiewska and Scarlata 
2011). The detailed analysis of intracellular Ca2+ mobilisation characteristic of resting 
and stimulated cells by caffeine and isoproterenol (George et al. 2003a; George et al. 
2006) could be directly compared to the results obtained from our HEK293 SCR 
model. Further, protein expression of RyR2, NCX, SERCA, phospholamban and 
phospholamban phosphorylation status can also be verified, to see if their 
involvement in Ca2+ handling is affected by diminished and reconstituted cMyBP-C 
levels.  
To assess the direct effect of cMyBP-C on RyR2 at molecular level, single channel 
recording could be used. The stable cMyBP-C-expressing HEK293 cell line could be 
generated, and further transiently transfected using Ca2+ phosphate precipitation to 
allow for co-expression of recombinant human RyR2 (Handhle et al. 2016). RyR2 
only and RyR2 + cMyBP-C HEK293 enriched microsomal fractions would be 
prepared by differential centrifugation (Mason et al. 2012), with protein assessed by 
WB analysis to ensure that cMyBP-C is retained during RyR2 purification. After 
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incorporation into the planar lipid bilayers, the channel behavior could be tested by 
single channel electrophysiological recordings under a range of free calcium 
concentrations to verify if the RyR2:cMyBP-C binding is Ca2+-dependent (Sitsapesan 
and Williams 1994; Mason et al. 2012). The detailed analysis of open probability, 
gating kinetics, channel conductance and ion-handling properties of individual RyR2 
channels under voltage-clamp conditions would provide detailed information on the 
possible mechanisms underlying altered channel function in the presence of cMyBP-
C.  
The aforementioned studies could help to determine the significance of the novel 
interaction between the sarcomeric component cMyBP-C and SR Ca2+ release 
channel RyR2, thus enhancing our understanding of the possible involvement of 
sarcomere retrograde regulation of Ca2+ signaling. In the longer term, the obtained 
findings also open up completely new and exciting avenues for further research and 
therapeutic applications.
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8 Appendix 
  
Figure 8.1 N-terminal and C-terminal cMyBP-C coding sequence are well conserved between 
different isoform of cMyBP-C. Shown are multiple protein alignment with coordinates 
corresponding to human cMyBP-C (upper panel) amino acids 1-165 and (lower panel) residues 
944-1123). Human cMyBP-C coding sequence [Homo sapiens] (GenBank: CAA58882.1) was 
compared to coding sequences of cMyBP-C from 5 animal species : pig [Sus scrofa] (NCBI 
Reference Sequence: XP_013849807.1); rat [Rattus norvegicus](NCBI Reference Sequence: 
NP_001099960.1); mouse [Mus musculus](NCBI Reference Sequence: NP_032679.2); guinea 
pig [Cavia porcellus](NCBI Reference Sequence: XP_003465195.2); and rabbt [Oryctolagus 
cuniculus] NCBI Reference Sequence: XP_008270674.1t). Multiple protein alignment was 
produced using Clustal Omega software accessed via the European Bioinformatics Institute 
(http://www.ebi.ac.uk/). Legend: an asterisk (*) indicates positions which have a single, fully 
conserved residue; a colon (:) indicates conservation between groups of strongly similar 
properties, whereas a period (.) shows weak conservation. 
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Figure 8.2 Imaging of RyR2 co-expression with cMyBP-C HA-FL in co-transfected HEK293 cell 
populations (A-C) three fields of form three independent experiments are shown; panels depict  
green (RyR2) signal detection, red (cMyBP-C) signal detection and (brightfield) corresponding 
brightfield image.  
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Table 8.1 GraphPad results for Kruskal Wallis test with Dunn's multiple comparisons for BT4L + 
NT/CT/FL co-IP results 
Kruskal-Wallis test 
 
P value <0.0001 
Exact or approximate p value? Approximate 
P value summary **** 
Do the medians vary signif. (P < 
0.05)? 
Yes 
Number of groups 6 
Kruskal-Wallis statistic 32.62 
 
Dunn's multiple 
comparisons test 
Mean 
rank diff. 
Significant? Summary 
CT + BT4L VS. CT + BT7 23.81 Yes ** 
CT + BT4L VS. NT + BT4L 13.97 No ns 
CT + BT4L VS. NT + BT7 27.21 Yes *** 
CT + BT4L VS. FL + BT4L 1.397 No ns 
CT + BT4L VS. FL + BT7 15.71 No ns 
CT + BT7 VS. NT + BT4L -9.843 No ns 
CT + BT7 VS. NT + BT7 3.4 No ns 
CT + BT7 VS. FL + BT4L -22.41 Yes ** 
CT + BT7 VS. FL + BT7 -8.1 No ns 
NT + BT4L VS. NT + BT7 13.24 No ns 
NT + BT4L VS. FL + BT4L -12.57 No ns 
NT + BT4L VS. FL + BT7 1.743 No ns 
NT + BT7 VS. FL + BT4L -25.81 Yes ** 
NT + BT7 VS. FL + BT7 -11.5 No ns 
FL + BT4L VS. FL + BT7 14.31 No ns 
 
Table 8.2 GraphPad results for Kruskal Wallis test with Dunn's multiple comparisons for BT mapping 
Kruskal-Wallis test 
 
P value <0.0001 
Exact or approximate P value? Approximate 
P value summary **** 
Do the medians vary signif. (P < 
0.05)? 
Yes 
Number of groups 11 
Kruskal-Wallis statistic 44.03 
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Dunn's multiple 
comparisons test 
Mean 
rank diff. 
Significant? Summary 
BT4L VS. BT7 45.98 Yes ** 
BT4L VS. BT4 23.28 No ns 
BT4L VS. BT4A 36.78 Yes ** 
BT4L VS. BT4B 38.49 Yes ** 
BT4L VS. BT4C 47.98 Yes *** 
BT4L VS. BT4D 23.49 No ns 
BT4L VS. BT4BL 38.49 Yes ** 
BT4L VS. BT4DL 12.28 No ns 
BT4L VS. BT4EL 28.63 No ns 
BT4L VS. BT4L DELTA89 4.178 No ns 
BT7 VS. BT4 -22.7 No ns 
BT7 VS. BT4A -9.2 No ns 
BT7 VS. BT4B -7.486 No ns 
BT7 VS. BT4C 2 No ns 
BT7 VS. BT4D -22.49 No ns 
BT7 VS. BT4BL -7.486 No ns 
BT7 VS. BT4DL -33.7 No ns 
BT7 VS. BT4EL -17.34 No ns 
BT7 VS. BT4L DELTA89 -41.8 Yes * 
BT4 VS. BT4A 13.5 No ns 
BT4 VS. BT4B 15.21 No ns 
BT4 VS. BT4C 24.7 No ns 
BT4 VS. BT4D 0.2143 No ns 
BT4 VS. BT4BL 15.21 No ns 
BT4 VS. BT4DL -11 No ns 
BT4 VS. BT4EL 5.357 No ns 
BT4 VS. BT4L DELTA89 -19.1 No ns 
BT4A VS. BT4B 1.714 No ns 
BT4A VS. BT4C 11.2 No ns 
BT4A VS. BT4D -13.29 No ns 
BT4A VS. BT4BL 1.714 No ns 
BT4A VS. BT4DL -24.5 No ns 
BT4A VS. BT4EL -8.143 No ns 
BT4A VS. BT4L DELTA89 -32.6 No ns 
BT4B VS. BT4C 9.486 No ns 
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BT4B VS. BT4D -15 No ns 
BT4B VS. BT4BL 0 No ns 
BT4B VS. BT4DL -26.21 No ns 
BT4B VS. BT4EL -9.857 No ns 
BT4B VS. BT4L DELTA89 -34.31 No ns 
BT4C VS. BT4D -24.49 No ns 
BT4C VS. BT4BL -9.486 No ns 
BT4C VS. BT4DL -35.7 No ns 
BT4C VS. BT4EL -19.34 No ns 
BT4C VS. BT4L DELTA89 -43.8 Yes * 
BT4D VS. BT4BL 15 No ns 
BT4D VS. BT4DL -11.21 No ns 
BT4D VS. BT4EL 5.143 No ns 
BT4D VS. BT4L DELTA89 -19.31 No ns 
BT4BL VS. BT4DL -26.21 No ns 
BT4BL VS. BT4EL -9.857 No ns 
BT4BL VS. BT4L DELTA89 -34.31 No ns 
BT4DL VS. BT4EL 16.36 No ns 
BT4DL VS. BT4L DELTA89 -8.1 No ns 
BT4EL VS. BT4L DELTA89 -24.46 No ns 
 
Table 8.3 GraphPad results for one-way ANOVA with Bonferroni's multiple comparisons test for BT4L 
RyR1 and RyR3 co-IP.  
ANOVA summary 
 
F 1.464 
P value 0.2626 
P value summary ns 
Significant diff. among means (P < 
0.05)? 
No 
R square 0.1633 
 
Bonferroni's multiple comparisons test Mean 
Diff. 
95.00% CI of 
diff. 
Significant? Summary 
BT4L + CT VS. BT4L RYR1 + CT -9.189 -77.66 to 59.28 No ns 
BT4L + CT VS. BT4L RYR3 + CT -49.68 -130 to 30.61 No ns 
BT4L RYR1 + CT VS. BT4L RYR3 + CT -40.49 -120.8 to 39.8 No ns 
 
  Appendix 
190 
 
Table 8.4 GraphPad results for Kruskal Wallis test with Dunn's multiple comparisons test for cMyBP-C 
mapping and GraphPad results for one-way ANOVA with Bonferroni's multiple comparisons test for 
BT4L binding with CT, C8-C9 and C9-C10. 
Kruskal-Wallis test 
P value <0.0001 
Exact or approximate P value? Approximate 
P value summary **** 
Do the medians vary signif. (P < 
0.05)? 
Yes 
Number of groups 11 
Kruskal-Wallis statistic 53 
 
Dunn's multiple 
comparisons test 
Mean 
rank diff. 
Significant? Summary 
CT VS. C6-C8 -14,11 No ns 
CT VS. C8-C10 6,472 No ns 
CT VS. FC6-C7 -2,444 No ns 
CT VS. C6-C7 -11,53 No ns 
CT VS. FC6 32,91 Yes * 
CT VS. C7 33,78 Yes * 
CT VS. C8 34,35 Yes * 
CT VS. C9 33,72 Yes * 
CT VS. C8-C9 22,47 No ns 
CT VS. C9-C10 0,4722 No ns 
C6-C8 VS. C8-C10 20,58 No ns 
C6-C8 VS. FC6-C7 11,67 No ns 
C6-C8 VS. C6-C7 2,583 No ns 
C6-C8 VS. FC6 47,02 Yes * 
C6-C8 VS. C7 47,9 Yes * 
C6-C8 VS. C8 48,46 Yes * 
C6-C8 VS. C9 47,83 Yes * 
C6-C8 VS. C8-C9 36,58 No ns 
C6-C8 VS. C9-C10 14,58 No ns 
C8-C10 VS. FC6-C7 -8,917 No ns 
C8-C10 VS. C6-C7 -18 No ns 
C8-C10 VS. FC6 26,44 No ns 
C8-C10 VS. C7 27,31 No ns 
C8-C10 VS. C8 27,88 No ns 
C8-C10 VS. C9 27,25 No ns 
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C8-C10 VS. C8-C9 16 No ns 
C8-C10 VS. C9-C10 -6 No ns 
FC6-C7 VS. C6-C7 -9,083 No ns 
FC6-C7 VS. FC6 35,35 No ns 
FC6-C7 VS. C7 36,23 No ns 
FC6-C7 VS. C8 36,79 No ns 
FC6-C7 VS. C9 36,17 No ns 
FC6-C7 VS. C8-C9 24,92 No ns 
FC6-C7 VS. C9-C10 2,917 No ns 
C6-C7 VS. FC6 44,44 Yes * 
C6-C7 VS. C7 45,31 Yes ** 
C6-C7 VS. C8 45,88 Yes ** 
C6-C7 VS. C9 45,25 Yes * 
C6-C7 VS. C8-C9 34 No ns 
C6-C7 VS. C9-C10 12 No ns 
FC6 VS. C7 0,875 No ns 
FC6 VS. C8 1,438 No ns 
FC6 VS. C9 0,8125 No ns 
FC6 VS. C8-C9 -10,44 No ns 
FC6 VS. C9-C10 -32,44 No ns 
C7 VS. C8 0,5625 No ns 
C7 VS. C9 -0,0625 No ns 
C7 VS. C8-C9 -11,31 No ns 
C7 VS. C9-C10 -33,31 No ns 
C8 VS. C9 -0,625 No ns 
C8 VS. C8-C9 -11,88 No ns 
C8 VS. C9-C10 -33,88 No ns 
C9 VS. C8-C9 -11,25 No ns 
C9 VS. C9-C10 -33,25 No ns 
C8-C9 VS. C9-C10 -22 No ns 
 
 
ANOVA summary 
F 13.05 
P value 0.0004 
P value summary *** 
Significant diff. among means (P < 
0.05)? 
Yes 
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R square 0.62 
 
Bonferroni's 
multiple 
comparisons test 
Mean Diff. 95.00% CI of diff. Significant? Summary 
CT VS. C8-C9 99.72 43.13 to 156.3 Yes *** 
CT VS. C9-C10 -4.886 -69.42 to 59.65 No ns 
C8-C9 VS. C9-C10 -104.6 -173.9 to -35.29 Yes ** 
 
Table 8.5 GraphPad results for one-way ANOVA with Bonferroni's multiple comparisons test for RyR2 
mutant BT4L binding (S166C, R176Q, R420Q or L433P) with cMyBP-C CT or FL. 
ANOVA summary 
F 1.235 
P value 0.3054 
P value summary ns 
Significant diff. among means (P < 
0.05)? 
No 
R square 0.2359 
 
Bonferroni's multiple comparisons test Mean 
Diff. 
95.00% CI of 
diff. 
Significant? Summary 
BT4L + CT vs. BT4L S166C + CT -
0.7062 
-114 to 112.6 No ns 
BT4L + CT vs. BT4L R176Q + CT -34.07 -147.4 to 79.27 No ns 
BT4L + CT vs. BT4L R420Q + CT -3.937 -117.3 to 109.4 No ns 
BT4L + CT vs. BT4L L433P + CT -9.825 -123.2 to 103.5 No ns 
BT4L S166C + CT vs. BT4L R176Q + CT -33.36 -161.2 to 94.5 No ns 
BT4L S166C + CT vs. BT4L R420Q + CT -3.231 -131.1 to 124.6 No ns 
BT4L S166C + CT vs. BT4L L433P + CT -9.119 -137 to 118.7 No ns 
BT4L R176Q + CT vs. BT4L R420Q + CT 30.13 -97.73 to 158 No ns 
BT4L R176Q + CT vs. BT4L L433P + CT 24.24 -103.6 to 152.1 No ns 
BT4L R420Q + CT vs. BT4L L433P + CT -5.888 -133.7 to 122 No ns 
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Figure 8.3 Imaging of RyR2 co-expression with cMyBP-C mCherry-FL in co-transfected HEK293 cell 
populations (A-C) three representative fields of form three independent experiments are shown;  
panels show green (RyR2) signal detection, (2) red (cMyBP-C) signal detection and (brightfield) 
corresponding brightfield image. 
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Figure 8.4 Imaging of RyR2 co-expression with mCherry in co-transfected HEK293 cell populations 
(A-C) three representative fields of form three independent experiments are shown; panels show  
green (RyR2) signal detection, red (mCherry) signal detection and (brightfield) corresponding 
brightfield image. 
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Table 8.6 GraphPad results for single cell Ca2+ imaging with either one-way ANOVA with Bonferroni's 
multiple comparisons or Kruskal Wallis test with Dunn's multiple comparisons test for RyR2 versus 
RyR2 + mCherry-FL cMyBP-C versus RyR2 + mCherry parameters: (A) amplitude, (B) mean duration, 
(C) rate of Ca2+ release, (D) rate of Ca2+ decay, (E) inter-SCR duration, (F) frequency, (G) number of 
events, (H) ER Ca2+ store load 
ANOVA summary (A) 
Amplitude 
F 0,4066 
P value 0,6666 
P value summary ns 
Significant diff. among 
means (P < 0.05)? 
No 
R square 0,004678 
 
Bonferroni's multiple comparisons test Mean Diff. 95.00% CI of 
diff. 
Significant? Summary 
RyR2 + mCherry-FL amplitude vs. 
RyR2 amplitude 
-0,09436 -0.4773 to 
0.2886 
No ns 
RyR2 + mCherry-FL amplitude vs. 
RyR2 + mCherry amplitude 
0,07565 -0.4078 to 
0.5591 
No ns 
Figure 8.5 Blot displaying mCherry-FL and HA-FL expression in CHAP-solubilised HEK293 lysates, 
detected using cMyBP-C C-t Ab. Loaded 1/200 of amount processes in co-IP samples per lane, each 
being separate biological replicate used in co-IP analysis (Section 5.4.6). 
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RyR2 amplitude vs. RyR2 + mCherry-
FL amplitude 
0,17 -0.3102 to 
0.6502 
No ns 
  
Kruskal-Wallis test (B) 
Mean 
duration 
P value <0.0001 
Exact or approximate P 
value? 
Approximate 
P value summary **** 
Do the medians vary 
signif. (P < 0.05)? 
Yes 
Number of groups 3 
Kruskal-Wallis statistic 23,12 
 
Dunn's multiple comparisons test Mean rank diff. Significant? Summary 
RyR2 + mCherry-FL mean duration vs. RyR2 
mean duration 
38,88 Yes **** 
RyR2 + mCherry-FL mean duration vs. RyR2 + 
mCherry mean duration 
6,128 No ns 
RyR2 mean duration vs. RyR2 + mCherry mean 
duration 
-32,75 Yes ** 
 
ANOVA summary (C) 
Rate of 
Ca2+ 
release 
F 0,3184 
P value 0,7277 
P value summary ns 
Significant diff. among 
means (P < 0.05)? 
No 
R square 0,003667 
 
Bonferroni's multiple comparisons test Mean 
Diff. 
95.00% 
CI of diff. 
Significant
? 
Summary 
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RyR2 + mCherry-FL mean rate up vs. RyR2 
mean rate up 
-0,04055 -0.1909 
to 0.1098 
No ns 
RyR2 + mCherry-FL mean rate up vs. RyR2 + 
mCherry mean rate up 
0,01232 -0.1774 
to 0.2021 
No ns 
RyR2 mean rate up vs. RyR2 + mCherry mean 
rate up 
0,05287 -0.1356 
to 0.2414 
No ns 
 
ANOVA summary (D) 
Rate of 
Ca2+ 
decay 
F 6,661 
P value 0,0016 
P value summary ** 
Significant diff. among 
means (P < 0.05)? 
Yes 
R square 0,0715 
 
Bonferroni's multiple comparisons test Mean 
Diff. 
95.00% CI 
of diff. 
Significant
? 
Summary 
RyR2 + mCherry-FL mean rate down vs. Ryr2 
mean rate down 
-0,0655 -0.1119 to -
0.01915 
Yes ** 
RyR2 + mCherry-FL mean rate down vs. RyR2 
+ mCherry mean rate down 
-0,00499 -0.0635 to 
0.05351 
No ns 
RyR2 mean rate down vs. RyR2 + mCherry 
mean rate down 
0,06051 0.002388 to 
0.1186 
Yes * 
 
ANOVA summary (E) 
Inter-
SCR 
duration 
F 5,177 
P value 0,0067 
P value summary ** 
Significant diff. among 
means (P < 0.05)? 
Yes 
R square 0,06498 
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Bonferroni's multiple comparisons test Mean 
Diff. 
95.00% 
CI of diff. 
Significant? Summary 
RyR2 + mCherry-FL mean intr scr dur vs. RyR2 
mean intr scr dur 
7,742 0.02083 
to 15.46 
Yes * 
RyR2 + mCherry-FL mean intr scr dur vs. RyR2 + 
mCherry mean intr soc dur 
11,84 2.198 to 
21.49 
Yes * 
RyR2 mean intr scr dur vs. RyR2 + mCherry 
mean intr scr dur 
4,102 -5.182 to 
13.39 
No ns 
 
Kruskal-Wallis test (F) 
Frequency 
P value 0,0031 
Exact or approximate P 
value? 
Approximate 
P value summary ** 
Do the medians vary 
signif. (P < 0.05)? 
Yes 
Number of groups 3 
Kruskal-Wallis statistic 11,52 
 
Dunn's multiple comparisons test Mean rank diff. Significant? Summary 
RyR2 + mCherry-FL frequency vs. RyR2 
frequency 
-27,1 Yes ** 
RyR2 + mCherry-FL frequency vs. RyR2 + 
mCherry frequency 
-25,54 No ns 
RyR2 frequency vs. RyR2 + mCherry frequency 1,553 No ns 
 
Kruskal-Wallis test (G) 
Number of 
events 
P value 0,0124 
Exact or approximate P 
value? 
Approximate 
P value summary * 
Do the medians vary 
signif. (P < 0.05)? 
Yes 
Number of groups 3 
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Kruskal-Wallis statistic 8,773 
 
Dunn's multiple comparisons test Mean rank diff. Significant? Summary 
RyR2 + mCherry-FL no of events vs. RyR2 no of 
events 
-21,3 Yes * 
RyR2 + mCherry-FL no of events vs. RyR2 + 
mCherry no of events 
-26,14 Yes * 
RyR2 no of events vs. RyR2 + mCherry no of 
events 
-4,847 No ns 
 
Kruskal-Wallis test (H) 
ER store 
content 
P value 0,2923 
Exact or approximate P 
value? 
Approximate 
P value summary ns 
Do the medians vary 
signif. (P < 0.05)? 
No 
Number of groups 3 
Kruskal-Wallis statistic 2,46 
 
Dunn's multiple comparisons 
test 
Mean 
rank 
diff. 
Significant? Summary 
PC caffeine response vs. 
caffeine response 
-8,187 No ns 
PC caffeine response vs. mc 
caffeine response 
8,363 No ns 
caffeine response vs. mc 
caffeine response 
16,55 No ns 
 
 
   
200 
 
Figure 8.6 Summary of raw data (all outliers included) of spontaneous Ca2+ release events examination using single cell Ca2+ imaging. Data are normalized 
for RyR2 + mCherry and shown as mean ±SD.. Samples: RyR2 + mCherry-FL (cMyBP-C) n=83, RyR2 only n=94, and RyR2 + mCherry n=37, from ≥8 
independent experiments; * statistical significance at p<0.05 calculated using one-way ANOVA with Bonferroni's multiple comparisons test, # statistical 
significance at p<0.05 calculated using Kruskal-Wallis test with Dunn's multiple comparisons test. 
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Figure 8.7 Summary of raw data (all outliers included) and post-outlier removed data (as in Figure 
5.2,A) as assessed in [3H]ryanodine binding assay over a range of free Ca2+ concentrations. (A) 
raw data,  (B) post-outlier removed data, both presented relative to maximum binding obtained for 
the RyR2 (+HA) at 100μmol Ca2+ and shown as mean ±SEM, * statistical significance at p<0.05 
calculated using unpaired, 2-tailed Student’s t-test, n≥15 for each Ca2+ concertation point.  
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